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Ena/VASP proteins have emerged as key regulators of the actin cytoskeleton during 
cell migration. They are conserved from flies to mammals, where they consist of three 
family members: Mena, VASP and Evl. All three proteins localise to sites of cell 
adhesion and the leading edge of migrating cells, where they play an important role in 
regulating actin polymerization. Ena/VASP proteins consist of three domains, EVH1 
and EVH2 domains, which are separated by a proline rich region.  The EVH1 domain 
mediates the intra-cellular targeting of Ena/VASP proteins by interacting with FPPPP 
motifs found in proteins such as Zyxin and lamellipodin.  The demonstration that Tes, 
which lacks an FPPPP motif binds to the EVH1 domain of Mena but not VASP and Evl 
via its LIM3 domain, indicates that EVH1 domains can also bind non-FPPPP containing 
proteins.  My PhD project focused on using biochemical approaches to identify 
additional non-classical binding partners of the EVH1 domains of Ena/VASP proteins 
and elucidating their roles during cell migration.  I have found that the WAVE complex, 
which activates Arp2/3 complex-dependent actin nucleation, binds directly to the EVH1 
domain of Ena/VASP proteins and that this interaction was mediated by Abi.  I 
identified the EVH1 binding site in both human and Drosophila Abi.  By expressing Abi 
mutants deficient in EVH1 binding I was able to demonstrate that Ena/VASP proteins 
stabilize the WAVE complex the tip of lamellipodia in both Rat-2 cells as well as 
Drosophila S2 and S2R+ cells.  Moreover, collaborative studies showed VASP could 
activate the WAVE complex in vitro and enhance the effect of Rac on activating the 
WAVE complex. My work has shown that Ena/VASP proteins are directly coupled to 
the WAVE complex, suggesting that they may regulate actin dynamics at the plasma 
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Chapter 1. Introduction 
1.1 Cell migration is essential for life 
Cell migration is a fundamental cellular process that is important for the function and 
survival of all eukaryotes.  In single-celled eukaryotes such as Dictyostelium, the ability 
to migrate enables them to take the advantage of sources of energy over a wider 
spatial environment.  This reduces the level of competition for resources in a 
population of individuals (Lauffenburger et al., 1982).  In higher eukaryotes such as 
humans, cell migration is required for the normal function of basic cellular processes 
throughout our whole life span.  During development, cell movement is required to 
create the overall structure of the human body.  During gastrulation, for instance, a 
tubular body plan where a central gut surrounded by three germ layers that are known 
as the ectoderm, mesoderm, and the endoderm, is formed by a highly coordinated and 
directed movement of a large number of cells (Narasimha and Leptin, 2000).  Following 
gastrulation, neural crest cells, which are derived from ectoderm, travel long distances 
from the neural tube to different sites throughout the embryo to form the nervous 
system (Bronner-Fraser, 1994). In the adult, cell migration is essential for the 
functioning of the immune system, tissue repair and wound healing.  For example, 
leukocytes leave the bloodstream by crossing the endothelial barrier to reach the 
affected tissue to defend against foreign invaders and hence serve as a critical part in 
the innate immune response (Muller, 2011).   
 
Unfortunately, cell migration is not only essential for life, it also plays pathogenic roles 
in a variety of human diseases including osteoporosis, mental retardation, chronic 
inflammatory disease and tumour metastasis (Ridley et al., 2003, Insall and Machesky, 
2009).  Therefore, understanding the molecular basis underling cell migration will not 
only expand our knowledge of this fundamental cellular process, but may also help us 
to develop effective therapeutics to treat diseases such as tumour metastasis.   
 
1.2 An overview of cell migration 
1.2.1 The classic migration cycle  
Michael Abercrombie conceptualised single cell migration in vitro as a cyclic process 
(Abercrombie, 1980).  The migration cycle is a four-step process, involving cell 
protrusion, adhesion, contraction and retraction (Figure 1.1). 
 17 
 
In response to external environmental stimuli, a cell first becomes polarised to form 
distinct anterior and posterior regions in the direction of migration (Lauffenburger and 
Horwitz, 1996).  This results in the re-organisation of the cell shape and leads to the 
formation of extended protrusions at the anterior of the cell.  The protrusions which can 
be wide, flat-like lamellipodia or elongated, spike-like filopodia, or both are induced by 
actin polymerisation (Ridley, 2011).  In the second step, attachments (termed focal 
contacts) between the newly formed protrusions and the substrate are formed.  These 
sites of contact are stabilised by integrin-based adhesion complexes, which directly 
connect the cell actin cytoskeleton to the substrate (Friedland et al., 2009).  Following 
the formation of focal contacts, the intracellular actomyosin network induces the cell 
body to contract (Chhabra and Higgs, 2007).  This serves to pull the cell body forward 
towards the extended protrusions.  In the final step, the anchoring between the 
posterior of the cell and the substrate is weakened by the disruption of integrin-
cytoskeleton interactions via the cleavage of focal adhesion proteins and integrins by 
calpains, a family of proteases (Franco and Huttenlocher, 2005).  This cleavage allows 
the retraction of the posterior of the cells into the cell body (Figure 1.1).  
 
The four steps described above are closely coordinated to ensure that cells are able to 
migrate in a directed fashion.  Although different cell types are thought to undergo 
similar steps during cell migration, their morphologies can vary remarkably.  For 
example, little cell shape change is observed during the gliding migration of 
keratocytes compared with fibroblasts that exhibit distinct alterations in cell morphology 




Figure 1.1 The classical migration cycle. 
Model of the four steps involved in the migration of a single cell over a substratum.  
The cell produces actin-based protrusions to extend into new areas of the substrate, 
where focal adhesions are formed.  The rear of the cell then undergoes contraction to 
move the cell body forward and release focal contacts with the substrate.  The same 
cycle can be repeated, moving the cell forward in a stepwise fashion.  Green arrows 
indicate the direction of movement.  The newly formed actin filaments at the leading 
edge are highlighted in red.  Taken from (Alberts et al., 2007).  Copyright 2008 from 
Molecular Biology of the Cell by Alberts et al.  Reproduced by permission of Garland 
Science/Taylor & Francis Books, Inc. 
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1.2.2 Cell migration in vivo 
The classical migration cycle that was originally classified based on the morphology of 
cell migrating in vitro is in two dimensions (2D).  In the in vivo three dimensional (3D) 
environment, however, different mechanisms and cell morphologies, which reflect their 
interactions with the surrounding tissue environments, are observed (Figure 1.2).   
 
Fibroblasts and neural crest cells often induce rearrangements of fibrin or collagen in 
the extracellular matrix (ECM) and use a so-called mesenchymal mode to migrate in 
3D (Grinnell, 2008, Tucker, 2004).  In contrast, macrophages and some stem cells 
undergo amoeboid-like migrations by forming bleb-like membrane protrusions at the 
leading edge in 3D (Blaser et al., 2006, Yoshida and Soldati, 2006).  Moreover, 
leukocytes and Dictyostelium also undergo amoeboid migrations, although the 
migratory process is achieved by forming pseudopodial-like protrusions at the leading 
edge rather than blebs.  Those cells that undergo amoeboid like migrations do not form 
focal adhesions and migrate at a relatively high speed in either 2D or 3D (Yoshida and 
Soldati, 2006, Lammermann et al., 2008).   
 
Cells not only migrate individually, they can also move in a collective fashion (Figure 
1.2).  Groups of migrating cells that are attached to each other to form sheets, strands, 
tubes and cluster-like structures, have been observed in vivo (Friedl and Wolf, 2010, 
Sahai, 2005).  During Drosophila oogenesis, for example, a group of six to eight motile 
cells, named border cells move in a collective fashion from the anterior to the posterior 
inside the egg chamber to form the micropyle organ (Aman and Piotrowski, 2010).  
Migration of the lateral line primordium in zebrafish is another example of collective cell 
migration.  During this migratory process, a cluster of about 100 epithelial-like cells 
move directionally from the anterior head to the posterior of the animal, during which 
some cells remain at regular spaced intervals to go on to develop into mechano-
sensory organs (Weijer, 2009, Friedl and Gilmour, 2009).  
 
It was originally thought that each cell type prefers to use a specific “default” migration 
mode, such as amoeboid (leukocytes), mesenchymal (stromal cells) or collective 
migration (epithelial cells) (Friedl, 2004).  However, the migratory behaviour of a cell 
can be influenced by a combination of extra- and intracellular parameters, including 
cell-cell contact, interactions with the ECM, cytoskeletal polarity, the ability to contract, 
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protrude and proteolyse the ECM as well as the properties and architecture of the ECM 
itself.  Depending on these multiple parameters, cells can change the nature of their 
migration mode to adapt themselves to fit the surrounding environment (Friedl and 
Wolf, 2010).  The mesenchymal-to-amoeboid and collective-to-individual transitions are 
the best studied examples of alterations in cell migration modes during development 
(Friedl and Wolf, 2010).   Moreover, cancer cells are able to alter their migration modes 
to promote invasion and metastasis, as they are capable of switching their shape and 
type of migration depending on the context of their surrounding environment (Wolf et 





Figure 1.2 Modes of cell migration in vivo. 
A cartoon illustrating the morphologies of cells in different modes of cell migration in 
vivo.  Cells can migrate individually and collectively.  A single cell can undergo either 
amoeboid-like or mesenchymal migrations.  Grey arrows indicate the direction of cell 
migration.  Brown lines indicate the ECM.  Taken from (Friedl and Wolf, 2010) with 
permission.   
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1.3 Actin cytoskeleton  
1.3.1 The biochemistry and dynamics of Actin 
Actin, which is one of the most abundant proteins of any eukaryotic cell, is central to 
providing the driving force behind cell migration.  There are three actin isoforms in 
vertebrates.  They are the α-, β- and γ-isoforms. α-actin is only found in muscle tissues, 
where it cooperates with myosin to produce force and cause muscle contraction.  By 
contrast, β-actin and γ-actin, which are the major components of the actin cytoskeleton, 
can be found in most cell types (Dominguez and Holmes, 2011).  Actin (G-actin) is a 
globular protein with a molecular mass of 42 kDa that interacts with either ATP or ADP-
Pi (Pollard and Borisy, 2003).  Interestingly, G-actin is also capable of spontaneously 
self-assembling into a polymeric filament (F-actin) (Figure 1.3).  
 
The process of actin polymerisation occurs in three major steps (dos Remedios et al., 
2003) (Figure 1.4A).  Firstly, two G-actin monomers associate with each other to form a 
dimer, which is inherently unstable and likely to dissociate to monomers.  If however, 
the dimer binds another G-actin, it forms a trimer, which is much more stable than the 
dimer.  This trimer is the nucleus for actin filament assembly, a situation, in which actin 
polymerisation is more likely than depolymerisation.  The formation of trimers is 
therefore the rate-limiting step for actin polymerisation and filament assembly.  Once 
the trimer has been formed, the actin filament rapidly elongates by the addition of actin 
monomers, if the concentration of G-actin is above the critical concentration (see 
below). 
 
The arrangement of G-actin subunits in the actin filament is key for the structural and 
biochemical polarity of F-actin (Rafelski and Theriot, 2004).  The structural polarity of 
F-actin is revealed when the filaments are decorated with the actin-binding domain of 
myosin (Figure 1.4B).  Based on their appearance, the opposite ends of the filament 
are called the “barbed” and the “pointed” end respectively (Pollard and Borisy, 2003).  
The asymmetric structure of F-actin leads to a fast growing barbed and a slower 
growing pointed end through the specific interactions of G-actin at each end (Rafelski 
and Theriot, 2004).  Monomeric G-actin can attach to both ends of F-actin, however, 
the required amount of free G-actin for addition at the pointed end is seven times 
higher than that for the addition at the barbed end (Wegner and Isenberg, 1983).  This 
difference explains the unidirectional growth of the actin filament with a consistent flux 
of G-actin subunits from the fast growing barbed end to the slow growing pointed end 
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(dos Remedios et al., 2003).  Given that the attachment of G-actin to the two ends of F-
actin is dependent on the concentration of free actin monomer, the filament growth rate 
at the two ends of actin filament varies dramatically with the concentration of G-actin 
(Guo et al., 2010). The concentration of free G-actin, when a dynamic eqilibrium 
between growth and shrinkage of actin filaments Is reached (no change in net polymer 
length), is referred to as the critical concentration (Cc) (Guo et al., 2010).  Thus, actin 
filaments undergo polymerisation above the Cc, depolymerise below the Cc and 
maintain a constant length at the Cc (Sept and McCammon, 2001) (Figure 1.4C).  
 
In vitro, actin filament dynamics are inherently regulated by the structural asymmetry of 
the filament.  The activities of actin assembly and disassembly are also temporally 
regulated by hydrolysis of the nucleotide that is bound to the actin monomer (Rafelski 
and Theriot, 2004) (Figure 1.4D).  Nucleotides, which bind actin are able to achieve 
three different nucleotide states corresponding to adenosine triphosphate (ATP), 
adenosine diphosphate (ADP) and adenosine inorganic phosphate (ADP-Pi) (Korn et 
al., 1987).  Free G-actin preferentially binds ATP to form ATP-G-actin.  Soon after the 
interaction between ATP-G-actin and the barbed end of the actin filament, there is a 
conversion of the ATP to ADP-Pi.  The resulting ADP-Pi-G-actin in the filament is a 
long-lived intermediate and present in the newly assembled actin filaments.  Inorganic 
phosphate (Pi) is slowly released over time.  This leads to the formation of ADP-F-
actin, which induces a physical alteration of the actin filament, which promotes the 
dissociation of ADP-actin monomers from ends of the filaments.  This process is called 
actin depolymerisation, which is not as simple as the opposite of actin polymerisation 
due to the irreversible property of ATP hydrolysis (dos Remedios et al., 2003).  Once 
ADP-G-actin dissociates from the actin filament, it is rapidly converted to ATP-G-actin 
by the action of profilin (Perelroizen et al., 1995, Pantaloni and Carlier, 1993, Vinson et 
al., 1998).  
 
The structural polarity of F-actin together with the irreversible nature of nucleotide 
hydrolysis regulates actin dynamics spatially and temporally.   In addition to the 
observations on actin dynamics in vitro, a number of studies have shown that similar 
dynamic actin assembly and disassembly also occurs in vivo (Wang, 1985, Symons 
and Mitchison, 1991, Theriot and Mitchison, 1991, Waterman-Storer et al., 1998, Lai et 






Figure 1.3 Structures of G- and F-actin. 
A. Crystal structure of G-actin, which was derived from a complex with profilin (2BTF).  
Sub-domains are labelled D1-D4.  Sub-domain 1 and 2 form the outer domain, 
whereas sub-domain 3 and 4 form the inner domain.  B. The helical structure of F-actin 
that was derived from cryo-electron microscopy (3MFP), in which the structure of G-
actin has been fitted.  The filament is arranged on a single helix, which consists of five 
G-actin subunits.  Different colours indicate different G-actin subunits in the filament.  A 
and B were generated using the MacPyMOL Molecular Graphics System, Version 
0.99, DeLano Scientific LLC, 2006.  
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1.3.2 Actin-dependent cell motility 
In 1978, actin was first hypothesized to provide the force for cell migration as the fast 
growing barbed ends of F-actin always pointed towards the direction of membrane 
protrusions in electron micrographs (Small and Celis, 1978, Small et al., 1978).  
Subsequent studies supported this hypothesis and demonstrated that microinjected 
fluorescently labelled G-actin only incorporated into the actin network of lamellipodia 
(Glacy, 1983, Wang, 1985).  Moreover, isolated lamellipodia of keratocytes are able to 
migrate independently from rest of the cellular components, suggesting the self-
organising property of actin alone is capable of driving cell motility (Verkhovsky et al., 
1999). 
 
Direct evidence that actin is key for cell migration is based on the experiments using 
drugs that strongly inhibit actin polymerisation.  Cytochalasin D, which is produced by 
Helminthosporium, inhibits actin polymerisation by binding G-actin and the barbed 
ends of actin filaments (Cooper, 1987).  Following treatment with Cytochalasin D, 
inhibition of actin filament elongation is observed both in vitro and in vivo.  This leads to 
the termination of protrusions at the leading edge of migrating cells (Sampath and 
Pollard, 1991, Forscher and Smith, 1988).  The observations from these experiments 
also strongly supported the idea that the driving force for protrusion during cell 
migration is provided by actin polymerisation.      
 
In addition, evidence also comes from a number of bacterial pathogens such as 
Shigella flexneri and Listeria monocytogenes, which can undergo actin-based motility 
(Pantaloni et al., 2001).  Following infection, inside the cytoplasm of the host cell, 
Listeria develops a comet tail, which is made of an oriented, cross-linked network of 
actin filaments with their barbed ends facing the bacterium (Tilney and Portnoy, 1989).  
Fluorescently labelled G-actin was only incorporated into the actin tail near the 
bacterial surface (Sanger et al., 1992). This suggests a role of actin in providing a 
driving force for motility of Listeria. Furthermore, the rate of actin polymerisation is 
found to be the same as the speed of Listeria movement inside the host cell (Theriot et 
al., 1992).  The resulting actin tail not only allows the bacteria to move inside the host 
cytoplasm, it also plays an important role in the spread of infection (Robbins et al., 
1999, Cameron et al., 2000).   
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Taken together, actin-dependent cell motility is responsible for the formation of cellular 
protrusions as well as the life cycle of some bacterial pathogens.  The underlying 
mechanism of generating force via actin filament assembly to drive membrane 
protrusions of the motile cells can be described using the “elastic Brownian ratchet” 
model.  The model suggests that actin monomers are added to the barbed end of the 
actin filament during thermal fluctuations of the plasma membrane in order to allow 




Figure 1.4 The dynamics of actin. 
A. The process of spontaneous actin polymerisation.  Actin dimers are much more 
unstable than actin trimers.  Following the formation of trimer, rapid polymerisation and 
elongation of actin filament occurs.  Numbers represents the rate constants for adding 
and removing G-actin. Arrows indicate the fluxes of actin monomers.  B. An electron 
micrograph showing an actin filament decorated with the actin binding domain of 
myosin.  The end, which displays the arrowhead appearance, is termed “pointed end”.  
The opposite end is termed the “barbed end”.  Taken from (Pollard and Borisy, 2003) 
with permission of Elsevier.  C. A cartoon showing that the growth and shrinkage of 
actin filaments is dependent on the free G-actin concentration.  Arrows indicate the 
fluxes of actin monomers.  D. A cartoon illustrating that ATP hydrolysis cycle during 
actin filament polymerisation (treadmilling).  ATP bound G-actin polymerises at the 
barbed end of actin filaments, whereas ADP-G-actin dissociates from the pointed end.  
G-actin monomers are recycled for addition at the barbed end by profilin mediated 
exchange of ADP to ATP.  
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1.3.3 In vivo actin-based membrane protrusions  
In vivo, individual actin filaments are organised into complex macromolecular 
structures such as web-like structures (networks) and bundles (Insall and Machesky, 
2009).  These macromolecular actin-based assembles are key in driving membrane 
protrusions during cell migration.  Several distinct actin-based membrane protrusions 
have been described, including lamellipodia, filopodia, and invadopodia (Figure 1.5).  
 
Lamellipodia, which consist of a two-dimensional cross-linked actin meshwork, have a 
thin sheet-like structure. They were the first described protrusions at the leading edge 
of migrating cells (Abercrombie et al., 1970).  It is thought that lamellipodia generate 
the force needed to pull the cell forward during migration (Small et al., 2002).   
Lamellipodia have been observed in a variety of motile cells, including keratocytes in 
zebrafish and in epidermal and neural crest cells in both Xenopus and zebrafish 
(Weijer, 2009, Keren et al., 2008).   
 
Filopodia, contain parallel bundled actin filaments and form finger-like protrusions.  
These protrusive structures can be observed either within the lamellipodia where they 
are termed microspikes or can be derived from lamellipodia in which case they are 
called filopodia (Chhabra and Higgs, 2007).  Filopodia have been observed in most cell 
types, including fibroblasts and nerve growth cones, where they act as directional 
sensors during cell migration (Zheng et al., 1996, Faix and Rottner, 2006).  
 
Cells use both lamellipodia and filopodia during migration in 2D. However, in order to 
move in 3D, such as during leukocyte transmigration and cancer cell invasion, cells 
form actin-rich matrix-degrading protrusions that are termed invadopodia (Chen, 1989).  
The main function of invadopodia is to degrade ECM to facilitate cell invasion 
(Buccione et al., 2009).  These 3D protrusions have been observed in a wide range of 
cancer cell lines including breast and colon cancer cell lines (Linder et al., 2010) 
 
Each of these protrusive structures contributes to cell migration in both 2D and 3D 
environments.  Their functions correlate with their morphologies, which are highly 





Figure 1.5 Actin-based membrane protrusions.  
Schematic representation showing a migrating cell that possesses distinct plasma 
membrane protrusions.  The actin filaments (red) are organised into different structures 
to provide force to generate these protrusive structures.  Adapted from (Ladwein and 
Rottner, 2008) with permission of Elsevier.  
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1.3.4 Actin binding proteins (ABPs) 
The assembly and organisation of actin filaments in vivo is regulated by the interaction 
with a large number of actin binding proteins (ABPs) (Figure 1.6).  Actin binding 
proteins are part of the actin cytoskeleton.  Some ABPs only interact with G-actin (e.g. 
thymosin) or F-actin (e.g. α-actinin), whereas some ABPs interact with both G-actin 
and F-actin (e.g. gelsolin).  The function of each ABP in modulating the actin 
cytoskeleton is different.  Some ABPs accelerate the disassembly of actin filaments 
(e.g. cofilin), whereas others prevent the assembly of actin filaments (e.g. capping 
protein).  ABPs also modulate the organisation of F-actin by cross-linking (e.g. filamin), 
bundling (e.g. fascin) or attaching the filaments to membranes (e.g. spectrin).    
 
Given that the average cell contains more than 100 different ABPs, I will only focus on 
a number of ABPs that are involved in stimulating the formation of new actin filaments 
through nucleation.  These actin nucleators are the most relevant ABPs for the topic of 
this thesis. 
 
Although actin can self-assemble by initially forming an actin trimer, this spontaneous 
nucleation is kinetically unfavourable due to the low stability of the proceeding actin 
dimer (Goley and Welch, 2006). De novo actin filament nucleation is the most 
important activity enhancing actin polymerisation to generate force for cell migration 
(Pollard and Borisy, 2003).  The nucleators, which are responsible for spontaneous 
formation of new actin filaments, are classified into three groups.  They are the Arp2/3 
complex, Spire and formins (Figure 1.7).   
 
Formins and Spire have both been found to nucleate unbranched parallel actin 
filaments (Goley and Welch, 2006).  Formins are very diverse and have a relatively 
high molecular weight of between 120-220 kDa but share two distinct formin homology-
1 (FH1) and forming homology-2 (FH2) domains in their C termini (Chesarone et al., 
2010).  The FH2 domain alone is capable of mediating actin nucleation through a direct 
interaction with actin (Pruyne et al., 2002).  However, the dimerisation of the FH2 
domain is thought to be crucial to stimulate actin filament assembly (Moseley et al., 
2004, Xu et al., 2004).  Spire was initially identified as an actin nucleator in Drosophila 
(Quinlan et al., 2005).  The same study also showed that the tandem WASP-homology-
2 (WH2) domains together with an extra G-actin binding linker of Spire are essential to 
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stimulate actin filament nucleation.  Moreover, Spire is found to directly bind and affect 
the activity of formin in actin filament nucleation, suggesting that Spire may cooperate 
with formins to regulate un-branched actin filament growth (Quinlan et al., 2007).  
 
In contrast to formin and Spire, the Arp2/3 complex, which has been most extensively 
studied, is responsible for generating Y-shaped branched actin networks (Campellone 
and Welch, 2010, Insall and Machesky, 2009, Mullins et al., 1998). The initiation of 
nascent daughter actin filaments on the side of an existing mother actin filament by the 
Arp2/3 complex has been visualised in vitro (Amann and Pollard, 2001b, Bailly et al., 
2001, Rouiller et al., 2008).  The resulting branched actin filament networks form the 
fundamental basis of many membrane protrusions such as lamellipodia and 
invadopodia (Ridley, 2011).  
 
However, the branched nature of actin filaments has been questioned.  It was 
suggested that the observations of the Y-shaped branches in lamellipodia are due to a 
fixation artefact, and the actin filaments in lamellipodia are not branched (Koestler et 
al., 2008, Urban et al., 2010).  The data in these studies is controversial and further 





Figure 1.6 Actin binding proteins that regulate the dynamics and organisation of 
actin cytoskeleton. 
Schematic representation of the activity of selected ABPs.  More than a hundred 
different ABPs have been identified so far, although it is likely that many other ABPs 
that are essential have not been discovered yet. Taken from (Alberts et al., 2007).  
Copyright 2008 from Molecular Biology of the Cell by Alberts et al.  Reproduced by 




Figure 1.7 Paths to actin nucleation. 
Actin is able to self-assemble, although this spontaneous nucleation is kinetically 
unfavourable, as it requires the formation of a stable trimer.  Three classes of actin 
nucleators are found to promote actin nucleation.  They are the Arp2/3 complex, Spire 
and formins.  The Arp2/3 complex is able to generate branched actin networks, 
whereas Spire and formins are found to promote the nucleation of un-branched parallel 
actin filaments.  The Arp2/3 complex can mimic an actin dimer and acts as a template 
for the formation of a nascent filament from an existing mother filament.  Spire binds 
actin filaments and acts as a scaffold for actin polymerisation.  In contrast to the Arp2/3 
complex and Spire, which can dissociate from a growing actin filament after actin 
nucleation, Formins bind the barbed end of actin filaments and remain associated with 
the growing barbed end during actin polymerisation.  Actin is depicted in red, actin 
nucleators are shown in blue.  Taken from (Goley and Welch, 2006) with the 
permission of Nature Pulishing Group.   
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1.4 The Arp2/3 complex 
1.4.1 Subunits and branching ability 
The actin-related protein 2 (Arp2) was first identified as an actin-like protein in yeast 
and Drosophila (Lees-Miller et al., 1992, Schwob and Martin, 1992, Fyrberg and 
Fyrberg, 1993).  The intact Arp2/3 complex was first isolated from Acanthamoeba 
castellanii extracts using a profilin affinity column (Machesky et al., 1994).  This 
biochemical analysis revealed that the complex comprises seven stably associated 
subunits: Arp2, Arp3 and five smaller subunits.  The five smaller subunits were 
originally named based on their molecular weight, but are now referred to as actin-
related protein complex-1 (ARPC1), ARPC2, ARPC3, ARPC4 and ARPC5 respectively 
(Goley and Welch, 2006).  Following the purification of the Arp2/3 complex from A. 
castellanii, the whole complex was successfully identified and isolated from other 
organisms such as yeast, Xenopus and human (Welch et al., 1997, Winter et al., 1997, 
Ma et al., 1998).  
 
The nucleating and branching properties make the Arp2/3 complex a unique regulator 
of the actin cytoskeleton. The Arp2/3 complex has been shown to act as a template for 
the nucleation of Y-shaped branched actin filaments both in vitro and in vivo (Blanchoin 
et al., 2000, Pantaloni et al., 2000, Mullins et al., 1998, Bailly et al., 2001, Amann and 
Pollard, 2001b, Amann and Pollard, 2001a, Svitkina et al., 1997, Svitkina and Borisy, 
1999).  Two models were initially proposed to describe the underlying mechanism of 
actin branch formation by the Arp2/3 complex.  In the barbed end branching model, it is 
suggested that the Arp2/3 complex binds the barbed end of a pre-existing filament to 
allow the elongation of the mother filament into two nascent daughter filaments 
(Pantaloni et al., 2000).  By contrast, the side branching model suggests that the 
Arp2/3 complex binds to the side of a mother filament to initiate the nucleation of a new 
daughter filament that grows away from the mother filament (Rouiller et al., 2008, 
Blanchoin et al., 2000).  The latter model is strongly supported by structural 
observations and is therefore the favoured model.  
 
1.4.2 Structure of the branch junction 
The crystal structure of the Arp2/3 complex was solved in either the presence or 
absence of bound nucleotide (Robinson et al., 2001, Nolen et al., 2004, Nolen and 
Pollard, 2007).  The Arp2/3 complex structure observed in the crystal is thought to be 
 35 
the inactive state due to the spatial arrangements of Arp2 and Arp3 within the complex. 
Arp2 and Arp3 are thought to act as a heterodimer to mimic an actin dimer in order to 
initiate actin nucleation.  However, according to the crystal structure, Arp2 and Arp3 
are not closely linked to each other and are therefore unlikely to form a nucleating 
trimeric complex with G-actin.  Thus, it hypothesised that the Arp2/3 complex 
undergoes a conformational change when it is activated (Robinson et al., 2001) (Figure 
1.8A).  However, in the absence of a high-resolution structure of the activated Arp2/3 
complex, the integration of the complex into actin filaments is a matter of speculation 
(Pollard, 2007). 
 
Given a high-resolution structure of the activated Arp2/3 complex is currently 
unavailable, the conformation of the Arp2/3 complex at Y-braches has been examined 
using a combination of homology modelling and 3D reconstitution after electron 
tomography (Rouiller et al., 2008, Beltzner and Pollard, 2004) (Figure 1.8B).  Based on 
these approaches, it is thought that Arp2 and Arp3 are responsible for binding directly 
to the first two subunits in the daughter filament as they are highly conserved and 
similar to actin.  By contrast, ARPC2 and ARPC4 are essential for mediating the direct 
interaction between the complex and the existing mother actin filament.  Using 
mutagenesis, a recent study defined key residues of the ARPC2 and ARPC4 subunits 
within the Arp2/3 complex that play a central role in F-actin binding, actin nucleation as 





Figure 1.8 The structure of the Arp2/3 complex.  
A. Model of Arp2/3 complex activation.  Ribbon diagrams of the inactive complex (left) 
and the proposed active complex (right).  Subunits of the Arp2/3 complex are labelled.  
It is hypothesised that Arp2 and Arp3 are brought into contact through shifting Arp2, 
ARPC1, ARPC4 and ARPC5.  Taken from (Robinson et al., 2001) with permission of 
The American Association of the Advancement of Science.  B. The electron 
micrograph shows the Arp2/3 complex and the morphology of a Y-branched actin 
filament.  The model on the right shows the subunits of the Arp2/3 complex bind the 
existing mother filament and the newly formed daughter filament.  Although all 7 
subunits of the Arp2/3 complex contribute to binding of the mother filament, Arp2 and 
Arp3 act as the first two subunits of the daughter filament.  Taken from (Campellone 
and Welch, 2010) with permission of Nature Publishing Group.   
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1.4.3 Activation of the Arp2/3 complex 
The structure of the Arp2/3 complex showed that Arp2 and Arp3 are not in close 
proximity suggesting that an inactive form of the complex had been purified and 
crystallised (Robinson et al., 2001, Nolen et al., 2004, Nolen and Pollard, 2007).  
Furthermore, in vitro experiments revealed that the purified Arp2/3 complex by itself 
was not very efficient at initiating actin polymerisation (Mullins et al., 1998, Welch et al., 
1998, Machesky and Insall, 1998).  Based on these observations, it was clear that 
additional factors are required to achieve a fully activated and functional Arp2/3 
complex in vivo.  Although the structure representing the active state of the Arp2/3 
complex has not yet been solved, a number of aspects concerning Arp2/3 complex 
activation have started to emerge. 
 
1.4.3.1 Activation by ATP 
ATP has been found to regulate the activity of the Arp2/3 complex (Goley and Welch, 
2006).  Evidence for this comes from the crystal structure of ATP bound Arp2/3 
complex and fluorescence resonance energy transfer (FRET) experiments (Nolen et 
al., 2004, Goley et al., 2004).  These studies demonstrated that binding of ATP to Arp2 
and Arp3 leads to conformational changes in the Arp2/3 complex, suggesting an 
important role for the nucleotide in activating the complex.  Interestingly, despite the 
fact that both Arp2 and Arp3 can interact with ATP, only ATP hydrolysis on Arp2 has 
been observed (Le Clainche et al., 2003, Dayel et al., 2001, Martin et al., 2006). ATP 
hydrolysis by Arp2 and/or Arp3 was originally thought to be important for the activation 
of the Arp2/3 complex, as it is capable of nucleating actin filaments when it interacts 
with ADP or a non-hydrolysable ATP analogue (Dayel et al., 2001).  However, a 
subsequent study showed that an Arp2 mutant in yeast that cannot undergo nucleotide 
hydrolysis did not lead to defects in Arp2/3 complex dependent actin filament 
nucleation.  This led the authors to suggest the role of nucleotide hydrolysis is to 
facilitate de-branching rather than branching of the “dendritic” actin networks that are 
created by the Arp2/3 complex (Martin et al., 2006).  Similar to actin, ATP hydrolysis 
may regulate the activity of the Arp2/3 complex temporally, for example, Y-branch 
disassembly and recycling of the Arp2/3 complex (Goley and Welch, 2006).  Thus, the 
interplay between nucleotide hydrolysis and the Arp2/3 complex dependent actin 
nucleation remains to be determined. 
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1.4.3.2 Activation of the Arp2/3 complex by nucleating promoting 
factors (NPFs) 
In addition to nucleotide binding and hydrolysis, the activation of the Arp2/3 complex is 
regulated by a number of nucleating promoting factors (NPFs). Depending on the 
mechanisms and efficiencies of the NPFs in activating the Arp2/3 complex, they have 
been grouped into two classes (Goley and Welch, 2006) (Figure 1.9).  
 
The VCA domain, which is only found in class I NFPs, is thought to be the key for 
Arp2/3 complex activation (Campellone and Welch, 2010, Goley and Welch, 2006).  
The VCA domain is divided into different regions based on the specific function of the 
individual region in activating the Arp2/3 complex.  These are a verprolin-homology (V) 
region, which is also called the WASP-homology-2 (WH2 or W) domain, and is 
responsible for interacting with monomeric G-actin (Chereau et al., 2005); a central 
cofilin-homology region, which is also called the connecting (C) region, that shares 
sequence similarity with the V region and can also bind G-actin (Boczkowska et al., 
2008, Irobi et al., 2004); and finally a C-terminal acidic (A) region.  The C and A regions 
together bind and regulate the conformation of the Arp2/3 complex to activate its actin 
nucleating activity (Marchand et al., 2001, Panchal et al., 2003, Goley et al., 2004, 
Martin et al., 2005, Rodal et al., 2005).   
 
Cross-linking studies have shown that the VCA domain interacts with multiple subunits 
of the Arp2/3 complex, including Arp2, Arp3, ARPC1, ARPC3 and ARPC5 (Kreishman-
Deitrick et al., 2005, Weaver et al., 2002, Zalevsky et al., 2001a, Kelly et al., 2006, 
Zalevsky et al., 2001b).  However, the detailed mechanism of Arp2/3 complex 
activation upon its binding to the VCA domain remains to be determined.  One working 
hypothesis suggests that the A region mediates the initial contact with the Arp2/3 
complex and the C region causes a conformational change within the Arp2/3 complex 
to bring Arp2 and Arp3 close to each other (Goley and Welch, 2006).  The closely 
positioned Arp2 and Arp3 together with a G-actin that is presented by the V region of 
the VCA domain form a trimer.  The Arp2/3 complex is therefore activated and the 
assembly of the daughter actin filament is initiated (Goley and Welch, 2006).   
 
A recent study however showed two VCA domains and two actin monomers are 
required for maximal Arp2/3 complex activation (Padrick et al., 2011).  This study 
identified two distinct VCA binding sites on the Arp2 and Arp3 subunits of the Arp2/3 
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complex.  Upon binding, each VCA brings one G-actin to the Arp2/3 complex.  The 
same study also showed the two VCA binding sites play different roles during Arp2/3 
complex activation.  It appears that delivery of actin to the VCA binding site on Arp3 is 
more important for Arp2/3 complex activation although the binding of actin to the VCA 
bound to Arp2 is also required.  This study is consistent with previous work from the 
same group that demonstrated that dimerised VCA domains have higher affinities than 
single VCA domains for the Arp2/3 complex and are better at activating it (Padrick et 
al., 2008).  Furthermore, previous biochemical observations also showed that Arp2 and 
Arp3 are possible acceptors for the first actin monomer that is delivered by the VCA 
domain (Marchand et al., 2001, Kreishman-Deitrick et al., 2005, Beltzner and Pollard, 
2004, Boczkowska et al., 2008).  Moreover, another recent study confirmed that the 
Arp2/3 complex is able to interact with two VCA domains (Ti et al., 2011).  The same 
group also showed that the binding affinities of the VCA domain for the two sites on the 
Arp2/3 complex are very different.  It has been observed that binding of the VCA 
domain to the high affinity site on the Arp2/3 complex inhibits the interaction between 
the complex and F-actin.  In contrast, the VCA domain binds to the other site on the 
Arp2/3 complex with much higher affinity when the Arp2/3 complex is associated with 
F-actin (Ti et al., 2011).  Together, these data indicate that the mechanism of maximal 
Arp2/3 complex activation involves more than one VCA domain.  However, how the 
VCA domain influences the formation of Y-shaped actin branches by binding to 
different sites on the Arp2/3 complex remains to be determined.  
 
Additionally, the binding of ATP or ADP to Arp2 and Arp3 can increase the affinity of 
the VCA domain for the Arp2/3 complex, although ATP is more efficient (Dayel et al., 
2001, Goley et al., 2004, Le Clainche et al., 2003).  Interestingly, it has also been 
shown that the binding affinity of ATP to both Arp2 and Arp3 increases when the VCA 
domain interacts with the Arp2/3 complex (Le Clainche et al., 2003, Dayel et al., 2001).  
However, it is still not clear how the Arp2/3 complex is activated by the VCA domain, 
and whether the one VCA domain, one G-actin or the two VCA domains, two actins 
model is correct.  Further biochemical and biological studies are necessary to fully 
understand the significance of the dynamic interactions between the VCA domain, G-
actin and the Arp2/3 complex in initiating actin nucleation.  
 
In contrast to class I NPFs, class II NPFs only contain a related acidic region at their N 
terminus.  This acidic region is responsible for binding the Arp2/3 complex 
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(Campellone and Welch, 2010).  However, class II NPFs lack the G-actin binding 
region.  Instead, they have an F-actin binding region, which is responsible for filament 
binding and activating the Arp2/3 complex (Campellone and Welch, 2010).  Class II 
NPFs are less potent activators of the Arp2/3 complex when compared to class I NPFs.  
It has been suggested that class II NPFs function as stabilisers of the newly formed Y-
branch following the activation of the Arp2/3 complex by class I NPFs (Goley and 
Welch, 2006).  Examples of class II NPFs include cortactin and coronin (Campellone 
and Welch, 2010).  Cortactin-knockout cells display modest defects in membrane 
ruffling and motility (Lai et al., 2009).  In contrast, depletion of Coronin 1B affects 
barbed end distribution as well as actin filament organisation at the leading edge (Cai 
et al., 2007).  These studies strongly suggest cortactin and coronin 1 B are essential in 
regulating actin polymerisation possibly by modulating the activity of the Arp2/3 
complex. 
 
Class I NPF will be discussed in more detail in the next section, as they are more 
relevant to my thesis.  
 
 
Figure 1.9 Classification Arp2/3 complex NPFs. 
NPFs can be divided into two classes.  All mammalian class I NPFs consist of variable 
N-terminal regions and a conserved C-terminal VCA domain. The VCA domain, which 
binds both G-actin and the Arp2/3 complex, is essential for Arp2/3 complex activation.  
Class I NPFs are also used by microbial pathogens to induce actin polymerisation.  
ActA from Listeria and RickA from Rickettsia are examples of these microbial NPFs.  In 
contrast to class I NPFs, class II NPFs, which lack the VCA domain, bind and activate 
the Arp2/3 complex via an N-terminal acidic region.  In addition, class II NPFs do not 
interact with G-actin, although they are able to interact with F-actin.  Regions of NPFs 
that are responsible for interacting with actin and the Arp2/3 complex are shown in 
grey.  Taken from (Campellone and Welch, 2010) with the permission of Nature 
Publishing Group.   
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1.5 Class I Nucleating Promoting Factors (NPFs) 
ActA from Listeria monocytogenes was the first class I NPF to be identified that can 
activate the Arp2/3 complex in vitro (Welch et al., 1998).  Since then, a number of 
conserved class I NPFs have been found in metazoans and will be discussed in detail 
in the following section (Figure 1.9). 
 
1.5.1 WASP and N-WASP  
Wiskott-Aldrich Syndrome protein (WASP) and neuronal Wiskott-Aldrich syndrome 
protein (N-WASP) are the best-characterised class I NPFs.  WASP and N-WASP are 
conserved from fungi to human (Campellone and Welch, 2010, Veltman and Insall, 
2010).  In contrast to N-WASP, which is ubiquitously expressed, WASP is only found in 
haematopoietic cells (Molina et al., 1992).  In mice, mutations in WASP lead to 
immunodeficiencies (Molina et al., 1992), whereas deletion of N-WASP is embryonic 
lethal (Snapper et al., 2001).   
 
WASP and N-WASP proteins share about 50% amino acid sequence identity and have 
a similar domain organisation (Takenawa and Suetsugu, 2007).  Both proteins 
comprise an N-terminal WASP homology (WH1) domain, which has a similar fold 
compared to the EVH1 domain of Ena/VASP proteins (Prehoda et al., 1999, Peterson 
and Volkman, 2009).  This WH1 domain is followed by a basic region (B), a Cdc42 and 
Rac interactive binding region (CRIB), auto-inhibitory motifs (AI), a proline-rich domain 
(PRD) and a VCA domain (Chapter 1.4.3).  The CRIB and AI motifs together are 
referred to as the GTPase binding domain (GBD).  Although WASP and N-WASP have 
a similar domain organisation, their C-terminal VCA domain differs.  The N-VASP VCA 
domain contains two V regions compared with one in WASP (Figure 1.9) 
 
Each region/domain of WASP and N-WASP interacts with different proteins, some of 
which regulate their activities (Campellone and Welch, 2010).  In their inactive state, 
the VCA domain is masked due to its interaction with the GBD region (Kim et al., 
2000).  In this auto-inhibited state, the VCA cannot bind or activate the Arp2/3 complex 
(Kim et al., 2000).  Moreover, WASP interacting protein (WIP), which binds the WH1 
domain of WASP and N-WASP, is also thought to stabilise the inactive conformation of 
the two proteins (Anton et al., 2007).  This auto-inhibitory interaction can be released 
by a variety of signalling pathways that are activated at the plasma membrane in 
response to extracellular stimuli and transfered to intracellular factors that bind the 
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GBD or the PRD of WASP/N-WASP (Campellone and Welch, 2010, Moreau et al., 
2000, Carlier et al., 2000).  For instance, competitive binding of Cdc42 to the GBD 
causes a conformational change in WASP/N-WASP that leads to the unmasking of the 
VCA domain (Kim et al., 2000, Prehoda et al., 2000).  Src homology 3 (SH3) containing 
proteins have been found to activate N-WASP by interacting with the PRD.  These 
proteins include non-catalytic kinase 1 (Nck1), Nck2 (Tomasevic et al., 2007, Rivera et 
al., 2009), transducer of Cdc42-dependent actin assembly 1 (TOCA1) (Ho et al., 2004, 
Takano et al., 2008) and the Abelson interacting protein 1 (Abi1) (Innocenti et al., 
2005).  Additionally, phosphorylation of the GBD is thought to not only stabilise the 
activated WASP/N-WASP but also to enhance the effects of SH2 domain containing 
proteins on activating WASP/N-WASP family proteins (Torres and Rosen, 2006, Cory 
et al., 2002, Cory et al., 2003, Blundell et al., 2009, Danson et al., 2007, Pocha and 
Cory, 2009). 
 
Cells lacking functional N-WASP exhibit defects in the Arp2/3-dependent membrane 
protrusions, such as impaired dorsal membrane ruffling (Legg et al., 2007), filopodia 
formation (Snapper et al., 2001, Bu et al., 2009) and membrane invagination (Tsujita et 
al., 2006).  A number of studies have also shown that N-WASP contributes to 
endocytosis (Innocenti et al., 2005, Bu et al., 2009, Tsujita et al., 2006, Benesch et al., 
2005).   
 
1.5.2 WAVE1, WAVE2 and WAVE3 
Similarly to WASP and N-WASP, the WASP-family verprolin-homologous protein 
(WAVE; also referred to as suppressor of cyclic AMP repressor (SCAR)) is also 
conserved in metazoans (Veltman and Insall, 2010).  In mammals, there are 3 WAVE 
isoforms that are referred to as WAVE 1-3 (Veltman and Insall, 2010).  All three 
mammalian WAVE isoforms are expressed in many cell types, although they are 
especially enriched in brain tissue.  In general, WAVE1 and WAVE2 are expressed 
more widely than WAVE3 (Campellone and Welch, 2010).  In mice, depletion of 
WAVE1 leads to sensorimotor defects, abnormal behaviour and reduced viability (Dahl 
et al., 2003, Soderling et al., 2003).  In contrast, knockout of WAVE2 is embryonic 
lethal and results in abnormalities in angiogenesis, in heart and brain development 
(Yan et al., 2003, Yamazaki et al., 2003).   
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WAVE1 has about 49% sequence identity compared to WAVE2 and WAVE3, with the 
C-terminal VCA domain being the most conserved region in all three mammalian 
isoforms (Suetsugu et al., 1999, Veltman and Insall, 2010). WAVE family proteins 
consist of an N-terminal SCAR homology domain (SHD) and a basic domain (B) but 
lack the GBD that is found in WASP and N-WASP (Figure 1.9).  Moreover, the PRD of 
WAVE family proteins, which is next to the C-terminal VCA domain, differs from the 
PRD of WASP/N-WASP (Figure 1.9).  The SHD, which is very distinct from the WH1 
domain of WASP/N-WASP, interacts with HSPC300, Abi1, NCK-associated protein 1 
(Nap1) and Rac-associated 1 (SRA1; also called PIR121) to form a pentameric 
complex known as the WAVE complex (Gautreau et al., 2004, Echarri et al., 2004, 
Innocenti et al., 2004, Leng et al., 2005).  Interestingly, depletion of a single component 
of the WAVE complex significantly reduces the expression of the other subunits in 
addition to disrupting the stability of the complex itself (Steffen et al., 2004, Innocenti et 
al., 2004, Rogers et al., 2003, Dubielecka et al., 2011, Kunda et al., 2003).  Due to the 
relevance of the WAVE complex to my study, I will discuss the details of the WAVE 
complex, such as its cellular function, activation and regulation in section 1.6. 
 
1.5.3 WASH  
WASP and Scar homolog (WASH) is a novel class I NFPs that has been identified 
recently by comparative and phylogenetic analyses (Linardopoulou et al., 2007).  
WASH is found in many animals and plants, but not yeast (Rottner et al., 2010).  In 
Drosophila, washout (WASH ortholog in Drosophila) mutant flies display defects in 
pupal morphology, suggesting that WASH is important during early development 
(Linardopoulou et al., 2007).  
 
As observed in WASP and WAVE, WASH has a modular domain organization (Figure 
1.9).  In addition to the C-terminal VCA domain, WASH contains a unique N-terminal 
WASH homology domain (WAHD, also called WAHD1), which is followed by the 
tubulin-binding region (TBR; also called WAHD2) (Campellone and Welch, 2010).  A 
proline rich region is also present in WASH, although it is significantly smaller than 
those found in WASP and WAVE (Figure 1.9).   
 
As seen with WAVE family proteins, WASH seems to function as part of a complex in 
cells (Campellone and Welch, 2010).  These WASH-associated proteins are FAM21, 
Srumpellin, SWIP (Srumpellin and WASH-interacting protein) and Ccdc53 (coiled-coil 
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domain-containing protein 53) (Derivery et al., 2009b, Gomez and Billadeau, 2009). 
Exactly how the WASH-associated complex and the individual components contribute 
to the assembly and stability of the complex remain to be determined (Campellone and 
Welch, 2010).  However, it has been shown that the WASH-mediated Arp2/3 activity 
regulates the shape of the membranes of the early and recycling endosomes.  This 
influences recycling of endosomes to the plasma membrane and the trafficking of 
endosomes to the trans-Golgi network (Derivery et al., 2009b, Gomez and Billadeau, 
2009, Duleh and Welch, 2010).  A recent study also demonstrated a role for WASH in 
promoting actin polymerization on mature lysosomes in Dictyostelium (Carnell et al., 
2011).  The same study also showed that binding of these newly formed actin filaments 
on mature lysosomes to the Vacuolar-type H+-ATPase (V-ATPase) is mediated by 
WASH.  Observations in Drosophila suggest that WASH is also able to bundle and 
crosslink actin filaments and microtubules in response to Rho1 signalling (Liu et al., 
2009a).  Therefore, WASH not only interacts with actin and the Arp2/3 complex, but 
can also associate with the microtubule cytoskeleton. WASH may act as a connector to 
link the actin and microtubule cytoskeletons together. 
 
1.5.4 WHAMM  
In addition to WASH, another member of NPF I family: WASP homolog associated with 
actin, membranes, and microtubules (WHAMM) is also found to associate with both the 
actin and microtubule cytoskeletons (Campellone et al., 2008, Rottner et al., 2010). 
 
WHAMM was identified during a bioinformatics search of the human proteins that have 
a VCA motif (Campellone et al., 2008).  WHAMM is ubiquitously expressed in 
vertebrates (Campellone et al., 2008).  Using in vitro actin-pyrene assays, the same 
study also demonstrated that like N-WASP there are two V regions in the VCA domain 
of WHAMM and that this VVCA domain is able to stimulate the actin nucleation activity 
of the Arp2/3 complex.  However, the ability of WHAMM to promote Arp2/3 dependent 
actin nucleation is less potent than N-WASP.  Furthermore it has been reported that 
the activity of the VVCA domain alone is equal to the activity of the full length WHAMM, 
suggesting that the protein is not auto-inhibited (Campellone et al., 2008).  However, 
this study was done with pure WHAMM, which might also exist as part of a larger 
complex that is tightly regulated.  
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In addition to the C-terminal VVCA domain, WHAMM processes a WHAMM 
membrane-interacting domain (WMD) at its N-terminus, which has little or no sequence 
homology to any known protein (Campellone and Welch, 2010).  The WMD localises 
WHAMM to the cis-Golgi and tubulovesicular membranes.  WHAMM has been found to 
interact with actin and microtubules and function in ER to Golgi transport (Campellone 
et al., 2008).  The WMD is followed by a central coiled-coil (CC) region and a small 
proline rich region (Figure 1.9).  The binding partners of WHAMM are currently 
unknown (Campellone and Welch, 2010).  Moreover, it is not clear if WHAMM is part of 
a multi-protein complex like WAVE and WASH (Rottner et al., 2010).   Further studies 
are required to identify proteins that interact with WHAMM to uncover how the activity 
of WHAMM is regulated. 
 
1.5.5 JMY   
Junction mediating and regulatory protein (JMY), which is closely related to WHAMM, 
is the latest class I NFP to be identified (Campellone and Welch, 2010).  Like WHAMM, 
JMY is confined to vertebrates and is expressed in most mammalian tissues and cell 
types (Rottner et al., 2010).  JMY was originally identified as a cofactor of the 
transcriptional regulators p300 and p53 (Shikama et al., 1999).  JMY was believed to 
only function with p53 until a recent study demonstrated that JMY has Arp2/3 complex 
dependent actin nucleation activity (Zuchero et al., 2009).   
 
In addition to a unique N-terminal (N) and a central CC region, which is similar to 
WHAMM, JMY has an unusual C-terminal VCA domain (Figure 1.9).  The C-terminal 
domain of JMY comprises three V regions and an extra linker sequence that separates 
the second and third V region (Figure 1.9).  Notably, this non-classical VVLVCA 
domain of JMY can also promote spontaneous actin nucleation in the absence of the 
Arp2/3 complex (Zuchero et al., 2009).  However, the resulting actin networks are 
unbranched and similar to those induced by formins and spire (Chapter 1.3.4).  
Moreover, the activity of full-length JMY has not yet been determined.  Further studies 
are required to address whether the Arp2/3 complex and the actin nucleating activities 
of JMY are coordinated or if one is more dominant than the other (Campellone and 
Welch, 2010).  
 
In the cell, JMY is able to shuttle between the nucleus and plasma membrane (Zuchero 
et al., 2009).  JMY is enriched in the cell nucleus, where its localisation is correlated 
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with DNA damage (Coutts et al., 2009).  During cell migration, JMY localises to the 
lamellipodia, where its presence or absence affects the speed of cell migration 
(Zuchero et al., 2009).  
 
1.6 The WAVE complex 
The WAVE1 complex was first purified from bovine brain (Li et al., 2002).  Subsequent 
studies showed that WAVE2 and WAVE3 are also able to associate with the same four 
subunits as WAVE1 (Innocenti et al., 2004, Gautreau et al., 2004, Suetsugu et al., 
2006, Stovold et al., 2005).  Although all three WAVE complexes share the same four 
subunits, they have been found to localise differentially in neuronal growth cones 
(Nozumi et al., 2003).  Moreover, WAVE1-deficient fibroblasts exhibit defects in dorsal 
ruffling and ECM-degrading MMP-dependent 3D migration, whereas defects in 
peripheral membrane ruffling at the leading edge were observed in WAVE2-deficient 
fibroblasts (Suetsugu et al., 2003).  These results suggest that each of the WAVE 
complexes plays a different role in regulating membrane protrusions during cell 
migration.  However, a later study observed the normal production of dorsal ruffles in 
cells lacking WAVE1 as well as in cells that have reduced levels of WAVE2, whereas 
cells lacking N-WASP exhibited defects in dorsal ruffles (Legg et al., 2007).  It suggests 
that N-WASP rather than WAVE is essential for Arp2/3-mediated dorsal ruffle 
formation.   
 
1.6.1 Subunits and structural organisation 
The WAVE complex comprises WAVE (68kDa), Abi (55kDa), Nap1 (125kDa), PIR121 
(140kDa) and the small HSPC300 (9kDa).  All five components of the WAVE complex 
are evolutionarily conserved (Veltman and Insall, 2010) (Table 1.1). Based on the 
molecular weight of the individual subunits, a 1:1:1:1 stoichiometry of the WAVE1 
complex components is predicted (Eden et al., 2002).  By testing all pairwise 
combinations between the different subunits in a reconstitution system, the molecular 
architecture of the WAVE complex was predicted to be a stack of HSPC300, WAVE, 
Abi, Nap1 and PIR121 from top to the bottom (Gautreau et al., 2004).  The same study 
also found that Nap1 and Abi are the most critical components of the WAVE complex 
by examining the binding ability of the other subunits when one particular subunit is 
excluded.  Moreover, using in vitro pull down assays, it has been shown that the 
interaction between WAVE and Abi involves the N-terminal regions of both proteins 
(Innocenti et al., 2004).  This study also showed Nap1 and PIR121 can be purified as a 
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subcomplex and that the binding of this subcomplex to WAVE is dependent on Abi.  
These results pointed to Abi being the most key component for mediating WAVE 
complex formation.  A subsequent study successfully reconstituted the Nap1:PIR121 
heterodimer and the WAVE:Abi:HSPC300 heterotrimer in vitro using the recombinant 
proteins (Ismail et al., 2009).  Based on the observations from these biochemical 
studies, a model for the molecular organisation of the WAVE complex was proposed 
(Figure 1.10A).  The interaction between Abi and Nap1 is at the core of the complex.  
On one side of the core, WAVE interacts with Abi and HSPC300 to form a trimer.  On 
the other side of the core, Nap1 binds PIR121 to form a dimer (Derivery and Gautreau, 
2010).   
 
Table 1.1 WAVE complex homologs and nomenclature in various species  
Different isoforms of the proteins are spaced by “,”.  Different names of the same 
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More recently, the structure of the WAVE complex has been solved (Chen et al., 2010).  
Consistent with previous suggestions, the structure of the WAVE complex can be 
described as two subcomplexes: a Nap1:PIR121 dimer and a WAVE:Abi:HSPC300 
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trimer (Figure 1.10B).  Nap1 and PIR121 form homologous structures and bind to each 
other extensively to form an elongated pseudo-symmetric dimer.  This elongated 
structure is thought to act as a platform for the rest of the complex.  In contrast to 
Nap1, which only binds Abi, all three subunits in the WAVE:Abi:HSPC300 subcomplex 
were found to interact directly with the N-terminal region of PIR121.  However, the 
most extensive contact between the two subcomplexes is made by HSPC300, which 
interacts with WAVE, Abi and PIR121, along its full length.  Notably, HSPC300 is the 
only subunit of the WAVE complex that can either exist as a component of the complex 
or as an isolated HSPC300 trimer in an abundant cytosolic pool (Derivery et al., 2008).  
Given the ability of trimeric HSPC300 to associate with newly synthesised subunits to 
generate a functional WAVE complex, it has been suggested that the free HSPC300 
trimer acts as the precursor for the assembly of the WAVE complex (Derivery et al., 
2008).  A more recent study showed the HSPC300 trimer is formed by the interaction 
of coiled-coil regions in its C-terminus (Linkner et al., 2011).  The crystal structure of 
this parallel triple coiled-coil bundle in HSPC300 trimer is similar to the heterotrimeric 
α-helix bundle that is observed in the WAVE:Abi:HSPC300 subcomplex (Chen et al., 
2010).  HSPC300 therefore appears to be the key subunit mediating the interaction 
between Nap1:PIR121 and WAVE:Abi:HSPC300 subcomplexes during WAVE 





Figure 1.10 Structure of the WAVE complex. 
A. The cartoon illustrates the proposed organisation of the WAVE complex.  The 
WAVE complex can be sub-divided into the WAVE:Abi:HSPC300 and Nap1:PIR121 
subcomplexes.  B. The structure of the WAVE complex.  Top and bottom structures 
are related by a 180° rotation around a horizontal axis.  Different colours, which are the 
same as in A, indicate the subunits of the WAVE complex.  Dashed lines indicate the 
poly-proline regions of WAVE, which are absent in the structure as they are disordered.   
B was taken from (Chen et al., 2010) with permission of Nature Publishing Group.  
 
1.6.2 Regulation of the WAVE complex 
Initial reports suggested that WAVE complex had a basal activity to activate the actin 
nucleating capacity of the Arp2/3 complex when it was first purified from bovine brain 
(Li et al., 2002).  However, subsequent studies revealed the WAVE complex is inactive 
using affinity purified WAVE complex from mammalian cell lines or reconstituted 
recombinant protein complexes from different expression systems (Derivery et al., 
2009a, Ismail et al., 2009).  Notably, the study using the reconstituted WAVE complex 
suggested that inhibition of its activity is mediated by an interaction between the VCA 
domain of WAVE and the Nap1:PIR121 subcomplex (Ismail et al., 2009) (Figure 
1.11A).  The structure has now shown that the WAVE complex is inhibited through the 
direct interaction between the C-terminus of WAVE and PIR121 (Chen et al., 2010) 
(Figure 1.11B).  Based on their structural and mutagenic analyses, Chen et al 
demonstrated that binding of PIR121 to the VCA domain and the adjacent intervening 
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loops (meander region) of WAVE leads to sequestration of VCA and inhibition of the 
activity of the WAVE complex towards the Arp2/3 complex (Chen et al., 2010).    
 
 
Figure 1.11 WAVE complex regulation.  
A. A model for WAVE complex activation.  Under resting conditions, the WAVE 
complex is auto-inhibited by an intermolecular interaction between the VCA domain 
and the Nap1:PIR121 subcomplex.  Activation of the WAVE complex leads to a 
conformational change within the complex.  This results in the exposure of the VCA 
domain, which subsequently interacts with G-actin and the Arp2/3 complex to initiate 
actin nucleation.  B. A close up of the structure of the inhibited WAVE complex.  The C 
terminus of WAVE, which contains a meander region (black dashed line) and the VCA 
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region, binds directly to PIR121 (green).  B was taken from (Chen et al., 2010) with 
permission of Nature Publishing Group.   
1.6.2.1 Activation of the WAVE complex by Rac 
The best-established activator of the WAVE complex is the small GTPase Rac 
(Derivery and Gautreau, 2010).  Depletion of Abi, Nap1 or PIR121 using RNAi 
significantly abrogates the formation of Rac dependent lamellipodial protrusions 
(Innocenti et al., 2004, Steffen et al., 2004).  This suggests that Rac plays an essential 
role in regulating actin-based cell protrusion by activating the WAVE complex.  Using 
pyrene actin assays, subsequent studies demonstrated that Rac is able to active the 
reconstituted WAVE complex in vitro without disrupting the integrity of the complex 
(Chen et al., 2010, Ismail et al., 2009, Lebensohn and Kirschner, 2009).  The data from 
these in vitro biochemical experiments resolved the conflicts in literature that 
suggested the WAVE complex is disassembled upon addition of active Rac (Eden et 
al., 2002).  Given that WAVE lacks an obvious GBD, it is thought that binding of Rac-
GTP to the complex is dependent on PIR121, as it possesses an N-terminal GBD 
(Kobayashi et al., 1998).  Indeed, in vitro binding assays revealed that a series of 
PIR121 mutations severely disrupted the interaction between the WAVE complex and 
Rac (Chen et al., 2010).  The same study also showed that deleting the VCA region 
from WAVE increases the affinity of the complex for Rac.  This suggests that Rac 
competes with the VCA region of WAVE for interacting with PIR121 in the complex, 
and that this subsequently leads to activation of the complex (Chen et al., 2010).  The 
recruitment of Rac to the WAVE complex is also thought to be mediated by IRSp53.  
IRSp53, which was originally identified as an insulin receptor substrate, was 
subsequently demonstrated to interact directly with Rac-GTP as well as WAVE (Miki et 
al., 2000).  Moreover, IRSp53 RNAi-treated cells exhibit defects in the recruitment and 
activation of the WAVE complex, leading to decreased lamellipodia formation 
(Takahashi and Suzuki, 2010, Suetsugu et al., 2006).  However, the mechanism by 
which IRSp53 contributes to Rac mediated activation of the WAVE complex remains to 
be determined.    
 
1.6.2.2 Activation by membrane clustering 
In addition to activation by Rac, the activity of the WAVE complex is also regulated 
through membrane localisation/clustering (Derivery and Gautreau, 2010).  IRSp53 not 
only acts as a bridge to mediate the interaction between Rac and WAVE, but it appears 
to play an important role in clustering the WAVE complex at the plasma membrane 
(Derivery and Gautreau, 2010).  IRSp53 possesses a Bin-Amphiphysin-Rvs (BAR) 
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domain, which is responsible for interacting with Rac as well as phosphatidylinositol 
(4,5)-bisphosphate (PIP2) at the plasma membrane (Mattila et al., 2007).  Cells lacking 
IRSp53 display defects in the recruitment and activation of the WAVE complex 
(Takahashi and Suzuki, 2010, Suetsugu et al., 2006).   It thus appears that IRSp53 is a 
central player in recruiting the WAVE complex to the plasma membrane, prior to WAVE 
complex activation.  Furthermore, Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), 
which is the product of phosphatidylinositol 3-kinase (PI3K), is found to bind directly 
and recruits WAVE at the plasma membrane (Oikawa et al., 2004).  However, a recent 
study argued that the interaction between the WAVE complex and PIP3 is not direct 
but is dependent on IRSp53 (Takahashi and Suzuki, 2010).  Further studies are 
required to fully understand how the WAVE complex is regulated through its clustering 
at the plasma membrane.  In particular, the function and relative contribution of various 
proteins and lipids at the plasma membrane in mediating the activity of the WAVE 
complex remains to be established.  
 
1.6.2.3 Activation by phosphorylation 
Finally, phosphorylation is also emerging as the key mechanism to regulate the activity 
of the WAVE complex. Tyr150 of WAVE2  (Tyr151 in WAVE1 and WAVE3), which is 
conserved from plants to humans, can be phosphorylated by Abelson tyrosine (Abl) 
kinase (Chen et al., 2010).  The phosphorylation of WAVE by Abl kinase is key for 
WAVE complex dependent actin polymerisation and lamellipodia formation (Sossey-
Alaoui et al., 2007, Stuart et al., 2006, Leng et al., 2005).  The structure of the WAVE 
complex revealed that Tyr151 localises within the “meander region” at the C terminus 
of WAVE, which interacts with PIR121 (Chen et al., 2010).  WAVE complex containing 
a Y151E mutation exhibited high activity in vitro and in vivo, suggesting 
phosphorylation of Try151 destabilised the inhibited WAVE complex to exposure the 
VCA region and activate the Arp2/3 complex (Chen et al., 2010).  In addition, Src and 
Cdk5 can phosphorylate Tyr125 and Thr138 in WAVE respectively (Miyamoto et al., 
2008, Ardern et al., 2006).  As with Tyr151, the location of both Tyr125 and Thr138 are 
within the “meander region”, suggesting that phosphorylation of these sites will also 
help activate the WAVE complex (Chen et al., 2010).  Furthermore, Casein Kinase 2 
and MAP kinases phosphorylate multiple residues within the VCA domain of WAVE 
(Pocha and Cory, 2009, Mendoza et al., 2011).  Phosphorylation of these residues also 
activates the WAVE complex in vivo (Pocha and Cory, 2009, Mendoza et al., 2011).  
All the residues that can be phosphorylated by a variety of different protein kinases are 
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found within the “meander region” of WAVE, which plays an important role in regulating 
the activity of the WAVE complex.  Therefore, in addition to the effects of both Rac and 
membrane clustering, phosphorylation provides an extra layer of regulation of the 
WAVE complex (Derivery and Gautreau, 2010).  
 
1.6.3 Abl interactor (Abi) 
The WAVE component Abi is conserved throughout evolution (Veltman and Insall, 
2010) (Table 1.1).  Three Abi isoforms exist in mammals including Abi1, Abi2 and Abi3, 
whereas only one Abi isoform is found in Drosophila as well as in Dictyostelium (Huang 
et al., 2007, Pollitt and Insall, 2008, Hirao et al., 2006).  Mammalian Abi1 and Abi2, 
which share the greatest amino acid sequence similarity, were first identified using a 
yeast two-hybrid screen for potential new binding partners of c-Abl (Shi et al., 1995, 
Dai and Pendergast, 1995).  Mammalian Abi3 (also called NESH), which was identified 
later when trying to clone p53/73 exon domains, has similar domain organisation to 
Abi1 and Abi2 but only has amino acid sequence similarity with Abi1 and Abi2 at its N-
terminus (Ichigotani et al., 2002, Miyazaki et al., 2000).  
 
All three mammalian Abi isoforms can be incorporated into the WAVE complex (Hirao 
et al., 2006), although the specific function of each isoform in regulating WAVE 
complex dependent actin dynamics is currently unknown.  However, a recent study 
using embryonic fibroblasts isolated from a conditional Abi1 knockout mouse showed 
that loss of Abi1 leads to severe defects in cell motility and that increasing Abi2 
expression levels is not sufficient to fully compensate for the loss of Abi1 (Dubielecka 
et al., 2011).  This study for the first time demonstrated that Abi isoforms are not 
equivalent in their ability to stabilise and/or regulate the WAVE complex. 
 
All mammalian Abi isofoms consist of a N-terminal coil-coiled region, which is followed 
by several proline rich motifs and a SH3 domain at the very C terminus.  Using these 
domains, Abi can associate with a variety of proteins and participates in different 
multiprotein complexes to regulate the actin cytoskeleton.  Excluding WAVE complex 
components, the best-characterized binding partner of Abi is Abl (Juang and Hoffmann, 
1999, Dai and Pendergast, 1995, Shi et al., 1995).  Phosphorylation of Abi by Abl has 
been observed in Drosophila S2 cells and is thought to be essential for lamellipodia 
formation (Huang et al., 2007).  Abi is also capable of interacting with Eps8 and Sos1 
to form a trimer, which plays a role in regulating Rho family GTPases (Scita et al., 
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1999).  The modulation of Rho family GTPases by the Abi:Eps8:Sos1 complex is 
required for downstream actin polymerisation (Scita et al., 1999).  Another study, which 
showed a direct interaction between Abi and Rac, suggested that this interaction 
enables Abi to positively regulate cell spreading as well as macropinocytosis in a Rac-
dependent manner (Dubielecka et al., 2010).  Like PIR121, Abi may be another 
component of the WAVE complex that is capable of bringing Rac to the complex, 
leading to the activation of the complex.   
 
Finally, a yeast two-hybrid screen identified Mena as a new binding partner of Abi (Tani 
et al., 2003).  A subsequent study, using a combination of biochemical approaches and 
mass spectrometry identified VASP as another binding partner of Abi (Dittrich et al., 
2010).  Both Mena and VASP are members of the Ena/VASP family of proteins, which 
have emerged as key players in regulating the actin cytoskeleton during cell migration 
(Bear and Gertler, 2009).        
 
1.7 Ena/VASP proteins 
Ena/VASP proteins are highly conserved throughout evolution.  They localise to the 
cell leading edge and focal adhesions, where they play a pivotal role in regulating the 
actin cytoskeleton during cell migration (Krause et al., 2003).  Drosophila Enabled 
(Ena), which was discovered as a dominant suppressor of Drosophila Abl (dAbl) is one 
of the founding member of the Ena/VASP family of proteins (Gertler et al., 1990).  
Mena, which is the mammalian ortholog of Ena was subsequently identified (Gertler et 
al., 1996).  Vasodilator-stimulated phosphoprotein (VASP), which is another 
mammalian Ena/VASP protein, was originally identified as a substrate of cyclic 
nucleotide-dependent kinases such as cAMP and cGMP in platelets (Haffner et al., 
1995, Halbrugge and Walter, 1989, Waldmann et al., 1987).  In addition to Mena and 
VASP, mammals have a third Ena/VASP protein called Enabled/vasodilator-stimulated 
phosphoprotein-like protein (Evl) (Gertler et al., 1996).  Evl was identified as an 
expressed sequence tag with homology to Ena and VASP.  Unc-34 and Dictyostelium 
VASP (DdVASP) are the only members of Ena/VASP proteins in C. elegans and 
Dictyostelium.  
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1.7.1 Ena/VASP domain organisation and binding partners 
The domain organisation is highly conserved among all members of Ena/VASP family 
proteins (Krause et al., 2003).  Ena/VASP proteins possess N-terminal Ena/VASP 
homology 1 (EVH1) domain and a C-terminal Ena/VASP homology 2 (EVH2) domain 
that are separated by a proline rich region (Figure 1.12).  Each of these domains has 
specific binding partners that regulate different aspects of Ena/VASP proteins, namely 
their localisation, activity and role in controlling the actin cytoskeleton (Krause et al., 




Figure 1.12 Domain organisation of Ena/VASP proteins. 
Ena/VASP proteins are highly conserved with the N-terminal EVH1 domain (green) and 
the C-terminal EVH2 domain (blue) that are separated by a proline rich region (pink).  
The EVH1 domain is the targeting domain, which drives the intracellular localisation of 
Ena/VASP proteins.  The proline rich region, which harbours binding sites for profilin 
and a variety of proteins containing either WW or SH3 domains, is thought to be 
required for regulating the activity of Ena/VASP proteins.  The EVH2 domain harbours 
a G-actin binding motif (GAB) (yellow), and F-actin binding motifs (FAB) (orange).  The 
EVH2 domain is the functional domain of Ena/VASP proteins, which is essential for 
their ability to regulate the actin cytoskeleton.  Ena/VASP proteins can undergo 
tetramerisation through the coiled coil region at the C terminus (red).   
 
1.7.2 EVH1 domain 
Structural studies reveal that the EVH1 domain belongs to the Pleckstrin homology 
(PH) domain-like superfamily (Ball et al., 2000, Barzik et al., 2001, Beneken et al., 
2000, Fedorov et al., 1999, Prehoda et al., 1999).  Members of the PH domain 
superfamily share the PH fold, which consists of two perpendicular β-sheets followed 
by an α-helix at the C terminus (Peterson and Volkman, 2009).  PH domains interact 
with a variety of ligands including inositol lipids, phosphotyrosines and proline rich 
sequences (Rebecchi and Scarlata, 1998).  The EVH1 domain, however, recognises 
proline rich sequences through its ligand-binding groove assembled by β-strands 1, 2, 
6 and 7 (Peterson and Volkman, 2009, Fedorov et al., 1999, Prehoda et al., 1999).  
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The EVH1 domain interacts with left-handed polyproline type II rich sequences in a 
similar fashion to WW or SH3 domains (Prehoda et al., 1999, Fedorov et al., 1999, Ball 
et al., 2000, Carl et al., 1999, Niebuhr et al., 1997, Peterson et al., 2007, Zarrinpar et 
al., 2003).  The residues flanking the core polyproline type II helix of the ligand define 
the specificity of interacting with WW, SH3 or EVH1 domains (Krause et al., 2003).  
Unlike WW and SH3 domains, the EVH1 domain of Ena/VASP proteins only 
recognises the ligands containing proline rich sequences with the consensus sequence 
(F/W/Y/L)PPPPX(D/E)(D/E) abbreviated to FPPPP motif (Niebuhr et al., 1997, Ball et 
al., 2000, Carl et al., 1999, Renfranz and Beckerle, 2002, Peterson and Volkman, 
2009).  EVH1-like domains have also been found in other protein families such as 
WASP/N-WASP, Homer/Vesl and some Sprouty-related proteins (SPRED) (Peterson 
and Volkman, 2009).  Although the EVH1 domains of these proteins have strong 
sequence and structural homology to the EVH1 domains of Ena/VASP proteins, their 
binding specificities differ.  For example, the EVH1 domain of the Homer/Vesl protein 
family only interact with ligands that have a PPxxF motif (x representing any amino 
acid) (Beneken et al., 2000, Barzik et al., 2001), whereas a sequence motif in WIP 
(ISDLPPPEPYVQ) is found to be responsible for binding the EVH1 domain of WASP 
(Zettl and Way, 2002, Peterson et al., 2007, Volkman et al., 2002).   
 
The EVH1 domain is responsible for the intra-cellular targeting of Ena/VASP proteins 
through its interaction with a variety of FPPPP motif containing proteins (Ball et al., 
2000, Niebuhr et al., 1997, Krause et al., 2003).  For example, the localisation of 
Ena/VASP proteins to focal adhesions is mediated by an interaction with the FPPPP 
containing protein Zyxin (Drees et al., 2000, Garvalov et al., 2003, Hoffman et al., 
2006).  In contrast, MRL proteins such as lamellipodin, MIG-10 and RIAM, which also 
contain multiple FPPPP motifs, recruit Ena/VASP proteins to the leading edge of a 
migrating cell (Krause et al., 2004, Michael et al., 2010, Lafuente et al., 2004, Quinn et 
al., 2006).  During neural development, Semaphorin 6A-1, another FPPPP containing 
protein, is thought to recruit Ena/VASP proteins to the plasma membrane by binding 
their EVH1 domains.  The interaction between Semaphorin 6A-1 and Ena/VASP 
proteins is pivotal in axon guidance (Klostermann et al., 2000).  Furthermore, ActA 
from the intracellular bacterial pathogen Listeria, which contains multiple FPPPP 
motifs, can also recruit Ena/VASP proteins to the bacterial surface by binding directly 
to the EVH1 domains (Niebuhr et al., 1997).  This interaction enhances the ability of 
Listeria to induce actin polymerization to promote their motility inside the host cell 
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(Cameron et al., 2000, Auerbuch et al., 2003, Geese et al., 2002).  Other FPPPP 
containing proteins that bind directly to the EVH1 domain of Ena/VASP proteins include 
roundabout (Robo) (Bashaw et al., 2000), Fyn-binding (Fyb)/SLP-76 associated protein 
(SLAP) (Krause et al., 2000) and Palladin (Mykkanen et al., 2001).  
 
1.7.2.1 Proline rich region 
The central proline rich region is the most divergent portion of Ena/VASP proteins.  It 
has been suggested that Ena/VASP proteins interact with different proteins via their 
proline rich regions in order to be regulated by many different signalling pathways 
(Krause et al., 2003).  The proline rich region of Ena/VASP proteins contains numerous 
binding sites for proteins containing either SH3 or WW domains (Krause et al., 2003).  
Given the sequence diversity of this proline rich region, binding specificity for proteins 
that have SH3 or WW domains to this region is variable among Ena/VASP family 
proteins.  For example, the SH3 domain of Abl and the WW domain of FE65 bind the 
proline rich region of both Mena and Evl, whereas the SH3-containing protein Neural 
Src (N-Src) can only interact with Evl (Lambrechts et al., 2000, Gertler et al., 1996, 
Ermekova et al., 1997).  In addition to SH3 and WW-containing proteins, the proline 
rich region of all Ena/VASP proteins can interact with profilin (Krause et al., 2003).  
Profilin I and II can bind to the proline rich region of VASP, although the binding affinity 
of profilin I for VASP is much lower than that of profilin II (Jonckheere et al., 1999). 
 
Profilin, which is one of the most important ABPs, as it plays an essential role in 
regulating actin dynamics (Bugyi and Carlier, 2010).  Profilin binds G-actin and has a 
higher affinity for ATP-G-actin than for ADP-G-actin (Perelroizen et al., 1995, Pantaloni 
and Carlier, 1993).  Profilin is therefore able to sequester actin monomers to prevent 
their spontaneous nucleation since profilin bound G-actin can only promote actin 
polymerisation by being added on to the barbed end of growing actin filaments (Bear 
and Gertler, 2009, Bugyi and Carlier, 2010).  Moreover, upon binding to G-actin, profilin 
also has the ability to convert the bound ADP to ATP (Vinson et al., 1998). This 
nucleotide exchange provides a constant pool of ATP-G-actin in order to facilitate 
efficient actin assembly.  
 
1.7.2.2 EVH2 domain 
The C-terminal EVH2 domain has been described as the functional domain (Bachmann 
et al., 1999).  The EVH2 domain contains three sub-domains: an N-terminal G-actin 
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binding (GAB) site followed by a F-actin binding (FAB) site and a coiled-coil motif at the 
extreme C terminus.  GAB and FAB sites are responsible for interacting with 
monomeric and filamentous actin respectively (Bachmann et al., 1999, Gertler et al., 
1996).  The GAB site has strong sequence homologies to the WH2 domains found in 
many cytoskeletal proteins, including β-thymosin, N-WASP and Spire (Paunola et al., 
2002, Dominguez, 2007, Dominguez, 2009).  The GAB site is essential for the actin 
nucleating activity of VASP in vitro (Walders-Harbeck et al., 2002).  A subsequent 
study proposed that the GAB site together with the last polyproline segment in the 
proceeding proline rich region serves as a loading region for binding a profilin:G-actin 
complex (Ferron et al., 2007).  Upon binding to Ena/VASP proteins, the actin in the 
profilin:G-actin complex is thought to be able to then bind the barbed end of F-actin 
(Ferron et al., 2007).  In contrast to GAB, FAB is found to bind and bundle F-actin 
(Bachmann et al., 1999, Huttelmaier et al., 1999).  Additionally, the C-terminal coiled-
coil motif within EVH2 domain is required for the tetramerisation of Ena/VASP proteins 
(Bachmann et al., 1999, Zimmermann et al., 2002).  Homo- and hetrotetramerisation of 
Ena/VASP family members has been observed in vivo (Carl et al., 1999, Ahern-Djamali 
et al., 1998).  
 
1.7.3 Ena/VASP-mediated cell migration 
Ena/VASP proteins have been shown to play a pivotal role in the regulation of the actin 
cytoskeleton during cell migration (Krause et al., 2003, Bear and Gertler, 2009).  
However, it is still debated whether Ena/VASP proteins positively or negatively regulate 
cell migration. 
 
In fibroblasts, the overexpression of Ena/VASP proteins reduces the speed of cell 
migration in a dose-dependent manner, whereas the depletion of Ena/VASP proteins 
from focal adhesions and the plasma membrane increases their speed (Bear et al., 
2000).  Furthermore, complementation of Ena/VASP-deficient cells with Mena leads to 
a reduction in migration speed (Bear et al., 2002).  During corticogenesis, neurons 
move radially from the germinal areas of ventricular zone (VZ) outward to form the 
cortical plate (CP) (Rakic, 1978).  Inhibition of Ena/VASP function in neurons within the 
developing neocortex leads to increased neuronal migration towards a more superficial 
location (Goh et al., 2002).  Taken together, these studies support the idea that 
Ena/VASP proteins act as negative regulators of cell motility. 
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The first evidence for the positive role of Ena/VASP proteins in regulating actin-
dependent cell motility came from analysis of actin-based motility of Listeria, which is 
dependent on ActA (Pistor et al., 1995).  Ena/VASP proteins interact with the FPPPP 
motifs in ActA via their N-terminal EVH1 domains (Niebuhr et al., 1997).  Mutation of 
these EVH1 binding motifs in ActA led to a significant decrease in the intracellular 
motility of Listeria, which suggests that Ena/VASP proteins are positive regulators of 
actin-dependent motility (Niebuhr et al., 1997, Smith et al., 1996).   
 
Growing evidence suggests that Ena/VASP proteins play a role to promote tumour 
formation and metastasis (Gertler and Condeelis, 2011).  Mena expression is 
unregulated in invasive tumour cells in rats and mice (Wang et al., 2004, Wang et al., 
2007).  Furthermore, Mena is able to promote cancer cell motility and invasiveness in 
vitro and in vivo (Philippar et al., 2008, Roussos et al., 2011).  VASP is also found to 
contribute to the invasive migration of cancer cells in response to Rac signalling (Han 
et al., 2008).  Overexpression of Evl leads to a significant increase in motility of human 
cancer breast cells (Hu et al., 2008).  These studies suggest that Ena/VASP proteins 
can act as positive regulators of tumour cell invasion and metastasis.  
 
A positive role of Ena/VASP proteins in controlling actin-dependent cell migration is 
also supported by recent studies in Drosophila.  During Drosophila oogenesis, border 
cells migrate from the anterior to the posterior part inside the egg chamber (Montell, 
2003).  Neutralisation of Ena function in border cells leads to a significant decrease in 
their migration speed (Gates et al., 2009).  This suggests that Ena acts as a positive 
regulator to promote cell migration in vivo.  Consistent with this, a new study 
demonstrated that overexpression of Ena increases the rate of haemocyte migration in 
the Drosophila embryo, whereas depletion of Ena from its normal cellular localisation 
decreases the rate of cell migration (Tucker et al., 2011). 
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1.7.4 Molecular functions 
Ena/VASP proteins are capable of regulating actin-dependent cell migration in many 
different types of cells.  Different mechanisms have been provided for how Ena/VASP 
proteins regulate the actin cytoskeleton, such as anti-branching and bundling.  
However, of all the hypothesised models, the strongest evidence exists for the anti-
capping activity of Ena/VASP proteins (Bear and Gertler, 2009).  In this model, 
Ena/VASP proteins bind directly at or near the growing barbed end of actin filaments to 
inhibit the function of capping proteins that terminate filament growth (Figure 1.13).   
 
 
Figure 1.13 Anti-capping activity of Ena/VASP proteins.  
Ena/VASP proteins localise to the plasma membrane through the direct interaction with 
the FPPPP-containing ligands via their N-terminal EVH1 domains (blue).  The coiled 
coil region mediates the tetramerisation of Ena/VASP proteins.  Profilin:G-actin 
complexes are loaded onto the last polyproline segment of Ena/VASP proteins and 
subsequently added to the barbed end of F-actin.  The GAB and FAB motifs within the 
EVH2 domain are responsible for binding to or near the barbed end of F-actin to block 
the binding of capping proteins to the barbed end.  FPPPP-containing ligands, the 
structural components of Ena/VASP proteins, actin and actin binding proteins are 
indicated.  Adapted from (Bear and Gertler, 2009) with permission of Company of 
Biologists Ltd.  
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1.7.4.1 Anti-capping hypothesis 
As its name suggests, capping protein (CP), prevents the addition of G-actin at the 
barbed end of actin filaments by directly interacting with the barbed end (Pollard and 
Borisy, 2003).  CP is therefore able to tightly regulate actin polymerisation at the 
leading edge of migrating cells (Pollard and Borisy, 2003).  
 
The anti-capping activity of Ena/VASP proteins was first described in a study where the 
activity of Ena/VASP proteins was manipulated in fibroblasts (Bear et al., 2002).  
Electron microscopy showed that actin filaments in lamellipodia of migrating cells were 
shorter and more branched when Ena/VASP proteins were depleted from the plasma 
membrane.  In contrast, membrane targeted Mena resulted in longer and less 
branched actin filaments.  Subsequently, a direct interaction between Ena/VASP 
proteins and the barbed end of actin filaments could be verified in vitro (Bear et al., 
2002).  Additionally, in vitro polymerisation assays showed that VASP is able to inhibit 
the capping activity of CP to promote actin filament elongation in a dose-dependent 
manner. Based on these observations, a functional antagonism between CP and 
Ena/VASP protein in regulating actin assembly was proposed (Bear et al., 2002).  The 
anti-capping activity of Ena/VASP proteins was also supported by a subsequent study 
using similar in vitro assays (Barzik et al., 2005).  This analysis demonstrated that the 
GAB and FAB motifs as well as the coiled-coil region are all required for the anti-
capping activity of Ena/VASP proteins (Barzik et al., 2005).  
 
In addition to indirect in vitro pyrene-actin polymerisation assays, total internal 
reflection fluorescence microscopy (TIRF) assays were used to directly study the 
function of Ena/VASP proteins in promoting actin assembly (Pasic et al., 2008, 
Breitsprecher et al., 2008, Breitsprecher et al., 2011, Hansen and Mullins, 2010).  The 
advantage of using TIRF microscopy is that it is possible to monitor the formation of 
individual actin filaments, to obtain more detailed information including their growth 
rate.  Consistent with previous reports, the elongation of individual actin filaments in the 
presence of CP and VASP confirmed the anti-capping activity of Ena/VASP proteins 
(Pasic et al., 2008, Breitsprecher et al., 2008, Breitsprecher et al., 2011, Hansen and 
Mullins, 2010).  Interestingly, one study reported that clustering of VASP on the surface 
of a bead is able to mediate the elongation of actin filaments even in the presence of 
high concentrations of CP that would normally inhibit VASP dependent elongation of 
actin filaments in solution (Breitsprecher et al., 2008).  This study suggests that the 
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clustering of Ena/VASP proteins at cell leading edge is required for their association 
with the barbed end of actin filaments.  However, in order to draw this conclusion, 
future experiments are required to establish the relationship between the density of 
Ena/VASP proteins and their anti-capping activity.  
 
The ability of Ena/VASP proteins to interact directly with the barbed end of actin 
filaments was observed using pyrene and TIRF actin polymerisation assays (Pasic et 
al., 2008, Bear et al., 2002).  A later study using TIRF showed that mutant VASP 
lacking GAB, FAB or both motifs was still able to capture the barbed end of actin 
filaments (Pasic et al., 2008).  This suggests that although both GAB and FAB motifs 
are required for the anti-capping activity of Ena/VASP proteins (Barzik et al., 2005), 
they are dispensable for barbed end binding.  Interestingly, a region at the extreme C-
terminus of EVH2 domain was found to be required for barbed end capture (Pasic et 
al., 2008).  This C-terminal region contains the coiled-coil region that is responsible for 
tetramerisation of Ena/VASP proteins (Zimmermann et al., 2002, Bachmann et al., 
1999).  This suggests that a structural interface that is formed during oligomerisation of 
Ena/VASP proteins is required for interacting with the barbed end of actin filaments 
(Bear and Gertler, 2009).  However, a more recent study reported that Ena/VASP 
proteins lack an intrinsic barbed end capture motif and that G-actin binding is required 
for their interaction with the barbed end of actin filaments (Hansen and Mullins, 2010).  
Future experiments will be required to resolve these differences and delineate the 
mechanism by which Ena/VASP proteins bind the barbed end of actin filaments.    
 
Although the studies above all agree that Ena/VASP proteins have an anti-capping 
activity, there are few issues that remain to be solved.  Firstly, it is not clear whether 
Ena/VASP proteins are potent accelerators of actin filament elongation.  One study 
reported that VASP has only minor effects on the rate of actin filament elongation 
(Pasic et al., 2008), whereas others concluded that it is actually capable of accelerating 
elongation (Breitsprecher et al., 2011, Breitsprecher et al., 2008).  By replacing the 
GAB and FAB motifs within the EVH2 domain of mammalian VASP with those of 
DdVASP, a recent study showed that the rate of actin filament elongation driven by 
Ena/VASP proteins is dependent on saturation of G-actin on the GAB motif 
(Breitsprecher et al., 2011).  This study suggests that Ena/VASP proteins are fully 
saturated with G-actin at high actin concentrations and therefore act as potent filament 
elongators in vivo.  Moreover, different conclusions regarding the effects of profilin on 
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the activity of Ena/VASP proteins were drawn from previous studies.  Some studies 
concluded that Ena/VASP proteins accelerate barbed-end actin filament elongation 
when profilin:actin complexes are present (Barzik et al., 2005, Hansen and Mullins, 
2010, Pasic et al., 2008), whereas the other found no effect of profilin on VASP 
mediated actin assembly (Breitsprecher et al., 2008).  These inconsistencies may in 
part be due to the different techniques used to produce the recombinant Ena/VASP 
proteins and whether the proteins are in solution or immobilised on beads as well as 
the ionic strength of the buffers used in the different assays (Hansen and Mullins, 
2010, Bear and Gertler, 2009).   
 
1.7.4.2 Additional hypotheses 
In addition to their anti-capping activity, other possible roles for Ena/VASP proteins in 
regulating actin cytoskeleton have been proposed.  These additional activities may 
collaborate with anti-capping to regulate actin dynamics synergistically.   
 
For example, an anti-branching activity of Ena/VASP proteins has been observed in 
several studies using both light and electron microscopy (Bear and Gertler, 2009, 
Plastino et al., 2004, Samarin et al., 2003, Skoble et al., 2001).  The strongest 
evidence for this comes from the observation that VASP decreases actin branch 
formation induced by ActA and the Arp2/3 complex in vitro (Skoble et al., 2001).  Given 
CP is not present in these assays, it suggests that the anti-branching activity of 
Ena/VASP proteins is independent of their anti-capping activity.  Moreover, a 
subsequent study established a link between the anti-branching activity and the anti-
capping activity of Ena/VASP proteins in regulating the actin cytoskeleton (Akin and 
Mullins, 2008).  This study showed that the level of G-actin available for polymerisation 
is elevated by increased filament capping, which leads to more Arp2/3 mediated actin 
branching.  This suggests that Ena/VASP proteins decrease actin filament branching 
by blocking the function of CP.  The effects of Ena/VASP proteins on Arp2/3 complex 
mediated actin branching need to be examined using more direct assays such as TIRF 
before a firm mechanistic understanding can be achieved.  
 
Ena/VASP proteins are also involved in bundling (cross-linking) actin filaments in actin 
based membrane protrusions such as filopodia where large numbers of parallel actin 
filaments are present (Schirenbeck et al., 2006).  Unlike other bundling proteins such 
as fascin, which are found along the whole length of filopodia, Ena/VASP proteins are 
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only observed at the distal tips of those actin bundles (Lanier et al., 1999).  The EVH2 
domain of Ena/VASP proteins is essential for their bundling activity suggesting that the 
interaction of F-actin and tetramerisation are both required for their bundling activity 
(Bachmann et al., 1999).  A subsequent study suggested that the actin bundling is 
mediated by the electrostatic interaction between F-actin and Ena/VASP proteins as 
bundle formation is heavily dependent on the salt concentration that was used in the 
assay (Barzik et al., 2005).  
 
No evidence has shown that any of the characterised functions of Ena/VASP proteins 
in regulating actin cytoskeleton is mutually exclusive.  It is therefore likely that 
Ena/VASP proteins coordinate their anti-capping, anti-branching and cross-linking 
activities to act as multifunctional regulators of actin dynamics.  
 
1.7.5 Regulation of Ena/VASP proteins 
It has been shown that all 3 mammalian Ena/VASP proteins are substrates for cAMP- 
and cGMP- induced protein kinases (PKA and PKG) (Gertler et al., 1996, Lambrechts 
et al., 2000, Butt et al., 1994). In vitro biochemical assays demonstrated that 
phosphorylation inhibits the ability of Ena/VASP proteins to promote actin 
polymerisation (Lambrechts et al., 2000, Harbeck et al., 2000).  Subsequently, it was 
shown that the anti-capping and bundling activities of Ena/VASP proteins appear to be 
inhibited when the proteins are phosphorylated (Barzik et al., 2005).  This suggests 
that the ability of Ena/VASP proteins to regulate actin dynamics is likely to be 
controlled by phosphorylation, although exactly how phosphorylation modulates the 
properties of Ena/VASP proteins still remains unclear.  
 
A number of in vitro studies have shown that phosphorylation has an effect on the 
affinities of Ena/VASP proteins for actin and other ligands.  However, opposite effects 
of phosphorylation on the binding of Ena/VASP proteins to actin filaments have also 
been reported.  One group found that phosphorylation of VASP increases its 
interaction with actin filaments (Laurent et al., 1999), whereas another study reported 
that phosphorylation of VASP decreases its association with actin filaments (Harbeck 
et al., 2000).  A more recent study supported the latter conclusion, as the co-
localisation of VASP and actin filaments in smooth muscle cells is inhibited when VASP 
is phosphorylated (Defawe et al., 2010).  The interaction between VASP and G-actin is 
also negatively influenced by phosphorylation (Walders-Harbeck et al., 2002).  Finally, 
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phosphorylation affects the interaction between the central proline rich region of the 
protein and SH3-containing proteins, although the binding of profilin to this region is 
unaffected (Lambrechts et al., 2000).  There is, however, no evidence that 
phosphorylation of Ena/VASP proteins has any effect on binding FPPPP containing 
ligands or tetramerisation (Harbeck et al., 2000).  
 
1.7.5.1 Serine/Threonine Phosphorylation 
In vitro studies have identified three Serine/Threonine phosphorylation sites (Ser157, 
Ser239 and Thr278) in VASP (Gertler et al., 1996, Lambrechts et al., 2000, Waldmann 
et al., 1987).  Mena possesses two phosphorylated residues equivalent to VASP 
Ser157 and Ser239, while Evl only has one phosphorylation site, which corresponds to 
VASP Ser157 (Gertler et al., 1996, Butt et al., 1994, Lambrechts et al., 2000).  In 
addition to PKA and PKG that phosphorylate Ser157 and Ser239 of VASP, AMP-
activated protein kinase (AMPK) was found to phosphorylate VASP on Thr278 (Blume 




Figure 1.14 Serine/Threonine phosphorylation sites in VASP.  
There are three serine/threonine phosphorylation sites in VASP.  They are Ser157, 
Ser239 and Thr278.  Red arrows indicate the locations of these phosphorylation sites 
in VASP.  Ser157 and Ser239 can be phosphorylated by both PKA and PKG.  
However, Ser157 is the primary target for PKA, whereas Ser239 is preferentially 
phosphorylated by PKG.  Thr278 is exclusively phosphorylated by AMPK.  The 
thickness of the black arrows indicates the preferences for each kinase.  
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Phosphorylation of Ena/VASP proteins has been shown to alter actin based cell 
adhesion and migration.  Howe et al 2002 showed that detachment of fibroblasts from 
fibronectin lead to rapid PKA dependent phosphorylation of VASP on Ser157 and 
reattachment of fibroblasts to fibronectin causes the phosphorylation of VASP (Howe et 
al., 2002).  Following cell spreading, VASP becomes phosphorylated again (Howe et 
al., 2002).  Another study demonstrated that a mutant Mena, which cannot be 
phosphorylated on Ser236 (equivalent of VASP Ser157) by PKA/PKG, is unable to 
rescue the normal motility of fibroblasts that lack endogenous Ena/VASP proteins 
(Loureiro et al., 2002).  In contrast, a phosphomimetic Ser236 mutant functions as 
efficient as the wild type protein to fully rescue the motility of MVD7 cells (Loureiro et 
al., 2002).  Taken together, these studies suggest that phosphorylation VASP and 
Mena at their first conserved Serine phosphorylation site adjacent to the proline rich 
region affects the ability of Ena/VASP proteins to regulate actin cytoskeleton (Figure 
1.14).   
 
Subsequent studies showed that phosphorylation of VASP on Ser239 and Thr278 also 
regulates the actin cytoskeleton (Benz et al., 2009).  Using both in vitro and in vivo 
assays Benz et al., showed that phosphorylation of Ser157 leads to translocation of 
VASP to the cell periphery but there were no major effects on actin filament assembly, 
whereas phosphorylation of Ser239 and Thr278 induces a significant increase in actin 
filament assembly (Benz et al., 2009).  Similar results were obtained when the sites 
equivalent to Ser157 in Mena and Evl were phosphorylated (Benz et al., 2009).  This 
study suggests that phosphorylation of VASP on Ser239 and Thr278 enhances actin 
assembly.  However, the results are not consistent with previous work, which 
demonstrated that phosphorylation of VASP on Thr278 by AMPK inhibits actin filament 
assembly (Blume et al., 2007).  It is not clear why these studies have such different 
outcomes.  It is also difficult to compare the results from the two studies because 
different cell types and assays were used.   
 
A number of recent studies also suggest VASP phosphorylation on Ser239 is essential 
in modulating actin based cell motility.  Overexpressed VASP containing a 
phosphomimetic Ser239 mutation leads to significant depletion of VASP at the leading 
edge of migrating epithelial cells (Lindsay et al., 2007).  This leads to a loss of 
lamellipodial protrusions followed by retraction of the leading edge and cell rounding 
(Lindsay et al., 2007).  A subsequent study demonstrated that co-localisation of VASP 
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and F-actin is disrupted by phosphorylation of VASP Ser239, suggesting that binding of 
VASP to F-actin is negatively regulated by phosphorylation of Ser239, which lies within 
the EVH2 domain (Defawe et al., 2010).  The interaction between the EVH2 domain of 
VASP and F-actin is key for the localisations of Ena/VASP proteins at the lamellipodia 
tips (Loureiro et al., 2002).  Phosphorylation of VASP Ser239 may therefore inhibit 
lamellipodia protrusions at the leading edge of migrating cells by interfering VASP 
binding to actin filaments.  VASP Ser239 phosphorylation has also been shown to play 
a role in suppressing cancer cell invasion and metastasis by inhibiting the proteolytic 
function of invadopodia (Zuzga et al., 2011).  
 
1.7.5.2 Tyrosine phosphorylation 
Ena was first identified as a suppressor of Drosophila Abl (dAbl) and was subsequently 
shown to be the substrate of this kinase (Gertler et al., 1995).  Six tyrosine 
phosphorylation sites have been identified in Ena, although mutation of all six sites only 
has a minor effect on the ability of Ena to rescue the phenotype of the ena mutant fly 
(Comer et al., 1998).  Abl has however, been shown to regulate the cellular localisation 
of Ena.  One study observed the amount of Ena at the apical cortex of blastoderm cells 
in the embryo of the abl mutant is much higher than the wild type situation 
(Grevengoed et al., 2003).  Moreover, another study found that Abl RNAi-treated D16-
C3 cells display higher amount of Ena at the tip of filopodia than control cells (Gates et 
al., 2009).  These studies suggests there is a regulatory role for Abl in controlling the 
intracellular localisation of Ena, although it is not clear whether this is mediated by 
phosphorylation of Ena itself.  Given phosphorylation Ena by Abl has been shown to 
disrupt the interaction between Ena and its SH3-containing ligands (Comer et al., 
1998), it is likely that phosphorylation events interfere with the ability of its binding 
partners to tether it to sites of action (Bradley and Koleske, 2009).    
 
The tyrosine phosphorylation sites in Drosophila Ena are not conserved in the 
mammalian Ena/VASP proteins (Krause et al., 2003).  Among all three mammalian 
Ena/VASP isoforms, Mena is the only one that has been found to be a substrate of Abl 
(Krause et al., 2003).  Initially, only a specific neuronal isoform of Mena was shown to 
be phosphorylated by Abl (Gertler et al., 1996).  Subsequently, it was found that 
Tyr296 of two more ubiquitously expressed isoforms of Mena could also be 
phosphorylated by Abl (Tani et al., 2003).  Tyr296 of Mena is not conserved in VASP 
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and Evl, suggesting that at least in mammalian cells, only Mena is a specific substrate 
of Abl.  
 
Our molecular understanding of the definitely regulation of Ena/VASP family proteins 
by phosphorylation is still relatively poor.  Future work is required to address how the 
functions of Ena/VASP proteins in regulating the actin cytoskeleton are regulated by 
this important posttranslational modification.   
 
1.7.6 The non-classical EVH1 interactors 
It was believed that the EVH1 domain of Ena/VASP proteins could only interact with 
FPPPP-containing proteins until the identification of the non-classical EVH1 binding 
partner, Tes (Boeda et al., 2007).  Tes, which is ubiquitously expressed, consists of an 
N-terminal PET domain of unknown function and three tandemly arranged LIM 
domains in its C-terminal half (Garvalov et al., 2003, Coutts et al., 2003) (Figure 
1.15A).  LIM domain is a protein-protein interaction domain.  It consists of two 
contiguous zinc finger domains, which are separated by a hydrophobic linker in the 
middle (Kadrmas and Beckerle, 2004).  The C-terminal half of Tes can interact with a 
variety of cytoskeletal proteins such as Zyxin and Arp7A (Coutts et al., 2003, Boeda et 
al., 2011).  The interaction between the LIM1 domain of Tes and Zyxin is required for 
recruiting Tes to focal adhesions (Garvalov et al., 2003).  Tes is found to be down 
regulated in cancer cell lines and primary tumours (Tatarelli et al., 2000, Tobias et al., 
2001, Drusco et al., 2005, Mueller et al., 2007, Sarti et al., 2005).   Moreover, 
overexpression of Tes inhibits cancer cell growth in nude mice (Sarti et al., 2005).  
Based on these studies, it is proposed that Tes is a tumour suppressor.   
 
Tes was shown to specifically bind the EVH1 domain of Mena but not VASP and Evl 
(Boeda et al., 2007).  In contrast to previous EVH1 binding partners, the interaction 
between Tes and Mena is not mediated by an FPPPP motif.  Instead, the LIM3 domain 
of Tes is responsible for the direct interaction with the EVH1 domain of Mena (Figure 
1.15B).  Tes thus represents the first non-FPPPP containing protein, which can 
specifically interact with a single Ena/VASP family member.  The same study also 
demonstrated that the LIM3 domain of Tes regulates the ability of the EVH1 domain of 
Mena to bind to FPPPP containing ligands such as Zyxin.  Moreover, this study 
showed that Tes negatively regulates cell migration in a Mena dependent manner.  
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Based on these observations, it suggests previously unidentified non-FPPPP 
containing EVH1 binding proteins can potentially regulate Ena/VASP proteins.  
 
In addition, a subsequent study demonstrated that nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 (NFATc2), which lacks a polyproline region, is 
also capable of interacting directly with the EVH1 domain of homeopathic Ena/VASP 
homologue (Homer), although the structure showed that NFATc2 binds to a site that is 
located opposite the FPPPP binding pocket on the EVH1 domain (Huang et al., 2008).   
 
 
Figure 1.15 The non-classical EVH1 binding partner:Tes. 
A. A cartoon of the domain organisation of Tes.  Tes consists of a N-terminal PET 
domain and 3 C-terminal LIM domains.  The LIM3 domain of Tes (black) is responsible 
for interacting with the EVH1 domain of Mena.  B. The structure of the LIM3:EVH1 
complex.  The LIM3 domain is shown in blue and the EVH1 domain of Mena is shown 
in yellow.  The grey spheres indicate the coordinated zinc atoms.  
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1.8 Aim of my thesis 
Given that Tes, which lacks a FPPPP motif, can interact directly with the EVH1 domain 
of Mena, it is highly likely that other unique non-FPPPP containing binding partners 
and potential regulators of Ena/VASP proteins will exist.  My thesis project was to 
identify new EVH1 binding partners that lack FPPPP motifs and elucidate their possible 
roles during cell migration.  Using biochemical approaches, I found that Ena/VASP 
proteins are capable of interacting with the WAVE complex via their EVH1 domain.  My 
subsequent studies verified the direct interaction between Ena/VASP proteins and the 
WAVE complex and examined the physiological importance of this interaction in actin-
mediated cell motility.  
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Chapter 2. Materials and Methods 
2.1 General buffers and culture media 
General buffers and culture media were provided by the in-house central service at 
Cancer Research UK and their recipes are listed below.  Buffers and solutions for 
specific applications are described at the end of the relevant sections.  
 
2.1.1 General Buffers 
Phosphate Buffered Saline A (PBSA) 
8.00 g               NaCl 
0.25 g               KCl 
1.43 g              Na2HPO4  
0.25 g              KH2PO4,  
The reagents were dissolved in distilled water; the pH was adjusted to 7.2 before the 
solution was adjusted to a total volume of 1 L.  The solution was autoclaved.  
 
Tris/EDTA (TE) Buffer, pH 8.0 
1.21 g  Trizma Base  
0.37 g  Ethyldiaminotetraacetic acid disodium salt (EDTA), 
The reagents were dissolved in distilled water; the pH was adjusted to 8.0 with 
hydrochloric acid (HCl) before the solution was adjusted to a total volume of 1 L.  
 
2.1.2 Cell Culture Media 
Trypsin Solution: 0.25% in Tris Saline  
Tris Saline (TS) 
8.00 g  NaCl 
2.00 ml 19% (w/v) KCl solution 
0.10 g  Na2H2PO4 
1.00 g  D-Glucose 
3.00 g  Trizma Base 
1.50 ml 1% (w/v) Phenol red solution 
0.06 g  Penicillin 
0.10 g  Streptomycin 
The Tris Saline reagents were dissolved in distilled water, the pH was adjusted to 7.7 
with HCl and the solution was made to a final volume of 200 ml.  Penicillin (0.06 g) and 
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0.1 g streptomycin were then added to the Tris Saline solution. The trypsin solution 
was prepared by dissolving 2.5 g trypsin (Difco 1:250) in 200 ml of distilled water (pH 
7.7). The Tris Saline and the trypsin solution were mixed and made up to a final 
volume of 1 L with distilled water. The pH was adjusted to 7.7.  The solution was then 
sterilised by filtration through a 0.22 µm filters and stored at -20 ºC until needed. 
 
Versene Solution 
8.00 g  NaCl 
0.20 g  KCl 
1.15 g  Na2HPO4 
0.20 g  KH2PO4, pH 7.2 
0.20 g  EDTA 
1.50 ml            1% (w/v) Phenol red solution 
The reagents were dissolved in distilled water, the pH was adjusted to 7.2 with HCl and 
the solution was made up to 1 L. The solution was autoclaved and stored at room 
temperature until use. 
 
Glutamine Solution 
A 10x stock solution (0.24 M) was prepared by dissolving 35.05 g of L-Glutamine in 1 L 
of distilled water. The solution was sterilised by filtration through a 0.22 µm filter and 
stored at -20 ºC until required. 
 
Minimal Essential Medium (MEM) 
9.68 g  MEM powder  
3.70 g  NaHCO3, 
The reagents were dissolved in 10 litres of distilled water and the pH was adjusted to 
7.0 with CO2. The solution was sterilised by filtration through a 0.22 µm filter and stored 
at room temperature until use. 
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2.1.3 Bacteriological Media 
Luria-Bertani (LB) Medium 
10 g  Bacto-tryptone 
  5 g  Bacto-yeast extract 
10 g  NaCl 
The reagents were dissolved in distilled water, the pH was adjusted to 7.2 with NaOH 
(1 M) and the solution was made up to a total volume of 1 L with water.  The resulting 
solution was autoclaved and stored at room temperature.  
 
LB Agar 
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2.2 Tissue culture 
2.2.1 Culture and Freezing stocks  
All cell lines used in this thesis and their respective culture media are listed in Table 
2.1. 
Table 2.1 Cell lines and media 
Cell 
lines 
Species Medium Glutamine Serum Antibiotics Source 
HeLa Human MEM 2mM 10% 
FCS5 









Pen/Strep7 Way lab 
stock 













Pen/Strep7 Vic Small 
IMBA 












Pen/Strep7 Nic Tapon 
LRI 




Pen/Strep7 Nic Tapon 
LRI 
Notes 
1Dulbecco’s modified eagle medium 4500 mg/dm3 glucose from Sigma (D-6546) 
2Schneider’s Drosophila Medium from Invitrogen (21720-024) 
3Shields and Sang M3 Insect Medium from Sigma (S3652) 
4GlutaMAXTM-1 from Sigma (35050-079) 
5Fetal calf serum, from PAA Laboratories (A15-041) 
6Fetal calf serum, from Sigma (F9665) 
7100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulphate, from 100x stock, 
Invitrogen (15140-122) 
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2.2.1.1 Mammalian cell culture 
Cells were grown in 10 cm plastic tissue culture dishes at 37 ºC in 5% CO2 and 
depending on cell type passaged every 2-3 days when they reached a confluence of 
around 70%. Cells to be passaged were washed once with PBSA and 0.5 ml 0.05% 
trypsine/versene solution was subsequently added. The plate was kept at 37 ºC until all 
the cells had detached. Then 10 ml complete medium was added and the cells were 
plated in a new dish at the required confluence. Cells were then cultured in the 
appropriate complete medium.   
 
To generate frozen stocks, cells from one 10 cm tissue culture dish were trypsinised at 
a confluence of 70%, re-suspended in complete medium and collected by 
centrifugation at 1000 rpm for 5 min at room temperature. Cells were then re-
suspended in 0.5 ml FCS containing 10% DMSO, aliquoted into cryo-vials and 
transferred to -80 ºC freezer.  The cryo-vials containing cells were transferred into 
liquid nitrogen 7 days later. 
 
To recover cells, a cryo-vial of cells stored in liquid nitrogen was resuspended in 10 ml 
complete medium and plated on to a 10 cm dish.  After cells had settled down and 
spread on the bottom of the dish, the DMSO containing medium was substituted with 
10 ml fresh complete medium.   
 
2.2.1.2 Drosophila haemocyte culture 
S2 and S2R+ cells were grown in 160 ml tissue culture flasks at 25 ºC and passaged 
every 7 days at a confluence of 100%.  For passaging S2R+ cells, they were washed 
twice with PBSA and 1 ml of 0.05% trypsine/versene solution was subsequently added. 
The flask was put at 37 ºC for 1 min before being moved to room temperature until all 
the cells detached.  The detached cells were washed once with 10 ml complete 
medium and collected by centrifugation at 1000 rpm for 5 min at room temperature.  
Cells were then resuspended in 10 ml complete medium and plated in to a new flask at 
the required confluence.  S2 cells were passaged by centrifugation at 1000 rpm for 5 
min at room temperature, washed once with PBSA before they were resuspended in 
10 ml complete medium and subsequently transferred to a new flask at the required 
confluence.   
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To generate frozen stocks, S2R+ cells and S2 cells were collected from their flasks by 
trypsinising and resuspending respectively.  Following centrifugation, cells were 
resuspended in 0.5 ml complete medium containing 10% FCS and 10% DMSO, 
aliquoted into cryo-vials and transferred to the -80 ºC freezer.  The vials were 
transferred into liquid nitrogen 7 days later. 
 
To recover cells, a cryo-vial containing either S2R+ or S2 cells stored in liquid nitrogen 
was resuspended in 10 ml complete medium and transferred into a 160 ml flask.  After 
cells settled down and spread on the bottom of the flask, the DMSO containing medium 
was substituted with 10 ml fresh complete medium.   
 
2.2.2 Transfection 
In this thesis, two different transfection protocols were used for overexpressing proteins 
in mammalian or insect cells depending on the assay, the cell type used and the 
transfection efficiency required.  
 
2.2.2.1 Calcium Phosphate 
Tissue culture cells were transfected with a CMV-based (CB6) or an actin promoter 
based (pAC) vector using a calcium phosphate method (De Rivoyre et al., 2006, 
Rietdorf et al., 2001).  This method was used when large-scale transfections were 
required with a relatively low cost compared to lipid based transfection methods.  
Before transfection, cells were seeded and allowed to adhere for 3 hours.  To transfect 
a 10 cm dish, 5 µg DNA was incubated in 0.5 ml CaCl2 solution (0.25 M) for 20 min at 
room temperature.  Following drop-wise addition of 0.5 ml HBS (280 mM NaCl, 10 mM 
KCl, 1.5 mM Na2HPO4, 12 mM glucose, 50 mM HEPES (Gibco), pH 7.05), the mix was 
incubated for another 20 min at room temperature and added to the prepared cells.  
After incubating the cells for 20 hr at 37 ºC with the transfection mix, the medium was 
replaced with fresh complete medium.  Cells were analysed immediately or incubated 
for another 24 h depending on the experiment.  
 
2.2.2.2 Effectene 
Effectene-based transfection (Qiagen) was used to transfect cells when calcium 
phosphate transfection could not be used for certain cell types or when a higher 
transfection efficiency was required.  Cells were plated at 70% confluence in complete 
medium one day before transfection. To transfect a 10 cm dish, 2 µg of DNA was 
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diluted in EC buffer to a final volume of 300 µl.  Enhancer (16 µl) was added and the 
solution was incubated for 5 min at room temperature. Afterwards, 50 µl of Effectene 
was added and the mix was incubated for another 15 min at room temperature.  The 
resulting transfection solution was mixed with 3 ml complete medium and added to the 
cells, which were analysed after 24-48 hr depending on the cell type used and the 
experiment. 
  
2.2.3 RNA interference  
2.2.3.1 Abi siRNA 
siRNAs that specifically target the three different rat Abi isoforms were purchased from 
Dharmacon and Invitrogen (Table 2.2).  The non-targeting oligos containing random 
DNA sequences (Invitrogen) were used as control.  The siRNAs were resuspended in 
siRNA buffer (Dharmacon) at a concentration of 20 µM and were stored in aliquots at -
20 ºC.  For siRNA transfection, 2x105 Rat-2 cells were seeded in 12 well plates in 
antibiotic-free complete medium one day before the transfection.  On the day of 
transfection, 5 µM siRNA solution in RNAase free buffer was prepared. 5 µl of the 5 µM 
siRNA solution was added to 95 µl serum free medium.  In parallel, 100 µl transfection 
reagent was prepared by diluting 0.5 µl DharmaFECT 1 transfection reagent in 99.5 µl 
serum free medium.  The siRNAs were added to the transfection reagent and 
incubated for 20 min at room temperature. Antibiotic-free complete medium (0.8 ml) 
was added to the mixture to obtain a final volume of 1 ml of transfection medium.  
Culture medium in each well was replaced by the prepared transfection medium.  Cells 
were incubated with the transfection medium at their normal growing condition for 24-
48 hr before qRT-PCR analysis. 
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Table 2.2 siRNA oligonucleotides duplexes used to knockdown rat Abi isoforms.  
Rat Abi 
isoform 





































2.2.3.2 Drosophila Abi (dAbi) dsRNA 
2.2.3.2.1 Generation of dsRNA 
Individual DNA fragments for the 3’ untranslated region (3’UTR) of dAbi, the open 
reading frame (ORF) of dAbi were amplified from a Drosophila cDNA library using PCR 
(Chapter 2.3).  The DNA fragment of LacZ (control) was amplified using PCR from a 
LacZ clone that was kindly provided by the Tapon lab at Cancer Research UK.  The 
PCR primers also contain a 5’ T7 RNA polymerase binding site 
(TAATACGACTCACTATAGGG) in front of the gene specific sequence that were 
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designed using E-RNAi (http://www.dkfz.de/signaling/e-rnai3/) (Table 2.3).  The purified 
PCR products were used as templates for single stranded RNA (ssRNA) synthesis as 
described in the manufacturers instructions for the Ambion MEGAscript High yield 
Transcription T7 kit.  The synthesised ssRNAs were incubated with TURBO DNase for 
15 min at 37 °C and their complementary strands were annealed by heating to 70º C 
for 10 min followed by cooling down to 25 ºC at 0.1 ºC per second.   Double stranded 
RNA (dsRNA) products were purified as described in the manufacturers instruction for 
the Ambion MEGAclearTM kit.  Annealing was performed once more after purification.  
The purity of the obtained dsRNA was confirmed using gel electrophoresis.  All purified 
dsRNA products were stored in aliquots at -80 ºC until required.  











For  TAATACGACTCACTATAGGGCGCAAGCCCATCGACTACTC dAbi  
ORF Rev TAATACGACTCACTATAGGGAGTGTCCCGGTATTGCTGAC 
230 
For  TAATACGACTCACTATAGGGGGTCTGTTCCAGTCCTCTGC dAbi 
3’UTR Rev TAATACGACTCACTATAGGGTTAGACTAAATGCGGTTGG 
216 
For  TAATACGACTCACTATAGGGGCCTTCCTGTTTTTGCTCAC LacZ 
 Rev TAATACGACTCACTATAGGGTTGCCGGAAGCTAGAGTAA 
520 
 
2.2.3.2.2 Knockdown of dAbi 
S2R+ and S2 cells were seeded in 24 well plates at a density of 1x105  cells per well in 
0.5 ml complete medium at least 3 hr before performing RNAi knockdown.  After cells 
adhered to the bottom of the dish, 4 µg dsRNA was added into each well.  The plate 
was swirled gently and the cells were allowed to grow at 25 ºC for 3 days.  dAbi 
expression in the cells was assayed by qRT-PCR as well as western blot analysis.  
 
For parallel knockdown of endogenous dAbi and overexpression of dAbi, S2R+ and S2 
cells were treated with dsRNA one day before transfection with effectene based 
approaches. Cells were incubated 25 ºC in complete medium containing dsRNA and 
the transfection mix for another two days before being analysed by western blot, 
immunofluorescence and live cell imaging.  
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2.2.3.3 qRT-PCR 
Knockdown efficiencies of purchased siRNAs and self-made dsRNA were determined 
by qRT-PCR.  mRNAs from siRNA treated Rat-2 or dsRNA treated insect cells were 
extracted and purified using the Qiagen RNeasy Mini kit.  The mRNA concentration in 
each sample was adjusted to 50 ng/µl using RNase-free water as required. For first 
strand cDNA synthesis, 500 ng mRNA, 200 ng random primers (Invitrogen) and 10 mM 
dNTP were mixed and incubated at 70 ºC for 10 min.  Subsequently, First-Strand 
Buffer, 0.1 M DTT and 200 units SuperScipt II Reverse Transcriptase (Invitrogen) were 
added to the reaction mix, which was then incubated at 42 ºC for 45 min.  The reaction 
was terminated by heating to 70 ºC for 15 min.  The qRT-PCR primers as listed in 
Table 2.4 were designed using the Roche Universal ProbeLibrary Assay Design Center 
(https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=uplct_030000).  All qRT-PCR 
primers that can only amplify a single target gene were verified and confirmed using 
melting curve analysis following qRT-PCR.  For each qRT-PCR reaction, 2 µl cDNA 
(approximately 100-500 ng), 200 ng primer mix and 5 µl EXPRESS SYBR Green ERTM 
qRT-PCR SuperMix Universal (Invitrogen) were mixed and adjusted to 10 µl with 
distilled water.  qRT-PCR reactions were set up in MicroAmp Fast Optical 96-Well 
Reaction Plates (Applied Biosystems) and performed/analyzed using the 7500 Fast 
Real-Time PCR System (Applied Biosystems).  The standard cycling program was set 
up as follows. 
 
Holding stage:            50 °C 2 min 
                                   95 °C 10 min 
   ---------------------- 
Cycling stage:             96 °C 15 sec ⎫   
              60 °C 1 min ⎭   40 cycles 
                                   ---------------------- 
Melting curve stage:   95 °C 15 sec 
                                   60 °C 1 min *  
   95 °C 30 sec * 
   60 °C 15 sec 
* Running speed was slowed down between the steps.  
 
For statistical analysis, all data generated from qRT-PCR experiments was normalised 
to an endogenous β-Actin control.  The relative standard curve method was used to 
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quantify mRNA expression of each Abi isoform in Rat-2 cells.  The comparative CT  
method was used to quantify mRNA expression of the RNAi targeted proteins in siRNA 
treated Rat-2 and dsRNA treated S2 and S2R+ cells.   
Table 2.4 Primers designed to perform qRT-PCR.  
Targeted  
Gene 
Oligonucleotide Sequence Size 
(bp) 
For  AATTTCTATTGCCCCCCCTC 20 
Rat Abi1 
Rev GTGGAGTTGGGCTATCAGCA 20 
For  CACCATGGGCACCAAGGTCT 20 
Rat Abi2 
Rev AGCCCAGTCACTCCATTCAT 20 
For  CGCCCTGCTACGGGTGGCCA 20 
Rat Abi3 
Rev GGCTTCCACCTGCCGCAGGG 20 
For  GACATCCGTAAAGACCTCTATGCC 24 
Rat β-Actin 
Rev ATAGAGCCACCAATCCACACAGAG 24 
For  GGGACGCAATATCAACAGGA 20 
dAbi 
Rev TGGTCGTCCGAAGTCTTGAT 20 
For  TGCCTCATCGCCGACATAA 19 
Drosophila β-Actin 
Rev CACGTCACCAGGGCGTAAT 19 
 
2.2.4 Stable Rat-2 cell lines 
2.2.4.1 Lentivirus system 
Stable Rat-2 cell lines were generated using the lentiviral expression vectors, a 
modified pL/L3.7 (Robinson et al., 2001), the HIV-1 based pLVX-Puro and pLVX-IRES-
Hyg from Clontech.  All lentiviral expression vectors containing the gene of interest that 
were used in this thesis are listed in Table 2.5.  For generating lentiviruses encoding 
the protein of interest, 2x106 HEK 293T cells were seeded into each of the 6 cm dishes.  
On the following day, the medium in each dish was replaced with fresh medium 3 hr 
before transfection.  Using the calcium phosphate method, cells were transfected with 
pL/L3.7 vectors containing the gene of interest together with 5 µg of the viral packaging 
vector, RRE (gag-pol plasmid), RER (RNA export protein) and VSVG (Virus envelope).  
Transfected cells were incubated overnight at their normal growing condition.  On the 
third day, the transfection media were replaced with fresh media containing 10 mM 
sodium butyrate (Sigma).  After 8 hr, the media containing sodium butyrate was 
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replaced with 3 ml fresh medium.  On the fourth day, the medium containing the 
packaged lentivirus was passed through a 0.45 µm filter.   
 
For lentivirus infection, Rat-2 cells were seeded into 6 well plates at least 12 hr before 
infection at 50% confluence.  The filtered, 3ml of virus-containing medium from each 
the of the 6 cm dishes was added to each well.  Rat-2 cells were incubated with virus-
containing media for 2 days at their normal growing condition. On day 6, Rat-2 cells 
were washed with PBSA and fresh medium was added.  Cells were then either 
expanded for FACS sorting or treated with drugs for antibiotic selection.  
 
Table 2.5 Lentiviral expression vectors used to generate stable Rat-2 cell lines. 
Vector Used 1st in figure Created by 
pL/L3.7 RFP-APPPP-mito 5.3 X. Chen 
pL/L3.7 RFP-FPPPP-mito 5.3 X. Chen 
pL/L3.7 GFP  5.5 B. Boëda 
pL/L3.7 GFP-Abi 5.5 X. Chen 
pL/L3.7 GFP-Abi mut 5.5 X. Chen 
pLVX-Puro GFP-VASP 5.12 X. Chen 
pLVX-IRES-Hyg Abi-RFP 5.12 X. Chen 
pLVX-IRES-Hyg Abi mut-RFP 5.12 X. Chen 
 
2.2.4.2 Fluorescence activated cell sorting (FACS) 
GFP, RFP or both GFP and RFP-positive Rat-2 cell lines that were generated using 
the lentiviral approaches, were obtained by performing flow cytometry in the FACS 
facility at Cancer Research UK.  The lentivirus-infected cells were trypsinised and 
harvested by centrifugation at 1000 rpm for 5 min at 4 °C.  The cell pellet was 
resuspended in the PBSA containing 1% FCS and passed through a cell strainer to 
remove cell aggregates and debris.  For each cell line created, non-lentivirus-infected 
Rat-2 cells were used as negative controls to set up the gating on the FACS machine.  
For each cell line, cells at 90% confluence from a 15 cm dish were sorted.  Due to the 
problems of over-expressing Abi in cells, FACS sorting of GFP/RFP-tagged Abi 
expressing cells was repeated twice.  Cells were expanded between each sorting.  The 
sorted fluorescence positive cells were expanded and stored in aliquots at -80 °C 
before they were transferred to liquid nitrogen for future use.  
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2.2.4.3 Antibiotic selection 
GFP- and RFP-positive Rat-2 cells, which were generated using the lentiviral 
expression vectors pLVX-Puro and pLVX-IRES-Hygro were selected and expanded 
under antibiotic selection.  A minimum amount of each drug was used in order to keep 
infected cells growing healthy when growing under constant selection pressure.  This 
was determined by performing a drug kill curve by examining the level of Rat-2 survival 
in different concentrations of Puromycin (Sigma), Hygromycin B (Sigma) or both drugs.  
After infection, Rat-2 cells were incubated with the complete medium containing 5 
µg/ml Puromycin and 400 µg/ml Hygromycin B for 1-2 weeks in their normal growing 
condition.  The antibiotic containing medium was changed every 3 days.  Cells were 
not split during the drug selection.  Hygromycin B and Puromycin double resistant cells 
were then expanded.  GFP and RFP-positive antibiotic resistant cells were FACS 
sorted once and expanded again before they were used immediately in the FRAP 
analyses.  
 
2.3 Molecular biology 
2.3.1 General buffers and solutions for molecular biology 
TBE 
89 mM    Tris-HCL pH 7.5 
89 mM    Borate 
  2 mM    EDTA 
 
Ethidium Bromide 
The stock solution was made to 10 mg/ml and was used at 0.5 µg/ml.  
 
10x DNA Loading Buffer 
0.25% (w/v) Bromophenol Blue 
30% (v/v) Glycerol 
 
10x dNTPs (Amersham Pharmacia Biotech) 
2 mM dATP 
2 mM dCTP 
2 mM dGTP 
2 mM dTTP  
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2.3.2 Expression vectors  
In addition to the lentiviral expression vectors that were used to generate Rat-2 stable 
cell lines, six different vectors were used for protein expression.  For expression in 
mammalian cells, the CB6 vector (CMV promoter) (Reckmann et al., 1997) was used, 
for bacteria expression, the pMW172 vector (T7 promoter) (Way et al., 1990) was 
used, for expression in Drosophila haemocytes, the pAC vector (Ac5 promoter) 
(modified pAc5.1/V5-His (Invitrogen) from Tapon lab at Cancer Research UK, 
unpublished), the pAW vector (Ac5 promoter) (modified pAW from Tapon lab at Cancer 
Research UK, unpublished) and the pUAST vector (GAL4-inducible UAS promoter) 
(Brand and Perrimon, 1994) were used and for expression in baculoviruses, the 
pBacPAK vector (Clonetech) from protein expression facility at Cancer Research UK, 
unpublished) were used.  All six vectors contained a tag at the N- or C-termini of the 
proteins of interest.  The tags that were used were green fluorescent protein (GFP) 
(Chalfie et al., 1994), red fluorescent protein (RFP/mCherry) (Campbell et al., 2002, 
Shaner et al., 2004), 6-Histidine (HIS) or glutathione-S-transferase (GST) (Smith and 
Johnson, 1988).  All DNA constructs used to express proteins are listed in Table 2.6.  
 




Created by  
pMW GST-EVH1-VASP 3.1 B. Boëda 
pMW GST-EVH1-Evl 3.1 B. Boëda 
pMW GST-EVH1-Mena 3.1 B. Boëda 
pMW GST 3.2 Way 
Laboratory 
CB6 GFP 3.3 Way 
Laboratory 
CB6 GFP-Nap1 3.3 X. Chen 
CB6 GFP-PIR121 3.3 X. Chen 
CB6 GFP-LIM3 Tes 3.3 B. Boëda 
pMW GST-Nap1 3.4 X. Chen 
pMW GST-PIR121 3.4 X. Chen 
pMW HIS-EVH1-Mena 3.4 B. Boëda 
pMW HIS-Grb2 3.4 I. 
Weisswange 
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pMW HIS-LIM3 Tes  3.4 B. Boëda 
pBacPAK HIS-PIR121 3.4 X. Chen 
pBacPAK GST-Nap1 3.4 X. Chen 
pMW GST-FPPPP-Zyxin 3.5 B. Boëda 
pMW GST-LIM3-Tes 3.5 B. Boëda 
pMW HIS-Nap1 3.5 X. Chen 
pMW HIS-Abi 3.5 X. Chen 
pMW GST-Abi 4.1 X. Chen 
pMW GST-Abi N-term-PR1 4.1 X. Chen 
pMW GST-Abi PR2-SH3 4.1 X. Chen 
pMW GST-Abi ∆SH3 4.1 X. Chen 
pMW GST-Abi PR2 4.1 X. Chen 
pMW GST-Abi PR1-PR2-SH3 4.1 X. Chen 
pMW GST-Abi PR1-PR2 4.1 X. Chen 
pMW GST-Abi P366G/P367G/P368G (mutant 1) 4.8 X. Chen 
pMW GST-Abi F375A (mutant 2) 4.8 X. Chen 
pMW GST-Abi P383G/P384G/P385G (mutant 3) 4.8 X. Chen 
pMW GST-Abi P366G/P367G/P368G/F375A 
(mutant 1+2) 




4.8 X. Chen 
pMW GST-Abi F375A/P383G/P384G/P385G 
(mutant 2+3) 
4.8 X. Chen 
pMW GST-Abi 
P366G/P367G/P368G/F375A/P383G/P384G/P385G 
(mutant 1+2+3, mut) 
4.8 X. Chen 




4.9 X. Chen 
pMW GST-EVH1 Ena 6.2 X. Chen 
CB6 GFP-dAbi  6.4 X. Chen 
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2.3.3 Amplification of DNA using PCR 
Polymerase chain reactions (PCR) were performed to amplify or modify genes from 
pre-existing DNA constructs or cDNA libraries.  For each PCR reaction, a forward (for) 
and a reverse (rev) primer were designed to amplify the DNA sequence of interest 
together with a suitable restriction site for sub-cloning.  A stop codon was included in 
each rev primer for sub-cloning if required.  A 100 µl PCR reaction contained 100 ng of 
DNA template, 10 pmol of each primer, 1x Taqplus Precision DNA polymerase buffer, 
5 units Taqplus Precision DNA polymerase (Stratagene) and 25 nmol dNTP mix 
(Invitrogen). The reactions were performed on an Applied Biosystems GeneAmp PCR 
machine using the conditions described below. 
96°C   4 min 
   ---------------------- 
Denaturation :  96 °C 30 sec    ⎫   
Annealing :  55 °C 30 sec    ⎬ 25 cycles 
Extension :  72 °C 1 min *    ⎭ 
   ---------------------- 
   72 °C 7 min 
   ---------------------- 
   4 °C ∞ 
CB6 GFP-dAbi 
L311A/P312G/P313G/P314G/P315G (mutant 1) 
6.4 X. Chen 
CB6 GFP-dAbi 
L374A/P375G/P376G/P377G/P378G (mutant 2) 
6.4 X. Chen 
CB6 GFP-dAbi 
L311A/P312G/P313G/P314G/P315G/ 
L374A/P375G/P376G/P377G/P378G (mutant 1+2, 
mut) 
6.4 X. Chen 
pAC GFP 6.5 Tapon Lab 




6.5 X. Chen 
pAW Ena-mCherry 6.14 X. Chen 
pMW HIS-VASP 7.3 X. Chen 
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• *Extension time: 1 min/kb of amplified product length. 
 
2.3.4 Sub-cloning 
All restriction enzymes that were used in this thesis were purchased from New England 
Biolabs (United Kingdom). Insert and vector were digested in a total volume of 25 µl 
containing 5000 units of each of the two enzymes, the adequate buffer for the 
enzymes, the DNA and BSA.  The reaction was incubated for at least 1 hr at 37 ºC. 
The reaction was then loaded on a 1% agarose gel in TBE with 0.5 µg/ml ethidium 
bromide.  The DNA was visualised using a UV lamp, bands corresponding to the 
correct size were cut out from the gel, purified with the Qiagen QIAquick gel extraction 
kit and eluted from the column in 30 µl distilled water.  A 10 µl ligation reaction was set 
up containing 100-500 ng of the digested vector DNA, an excess of purified insert 
DNA, 200 units T4 DNA ligase and 1x ligase buffer (New England Biolabs). The 
reaction was incubated for at least 1 hr at room temperature or incubated overnight at 
16 ºC before 5 µl of the ligation were transformed into 50 µl chemical competent E. coli 
(Chapter 2.3.5). Digestions of purified DNA were performed to check for correct 
insertion. 
 
2.3.5 Preparing chemical competent bacteria (Calcium chloride method) 
Chemical competent E. coli XL-10 or BL21 (DE3) Rosetta strain were prepared by 
incubating 2 ml of an overnight culture in 500 ml of LB medium. To ensure the bacteria 
where in an exponential growth phase, the culture was grown with constant shaking at 
37 ºC until an OD600 of 0.5 was reached. Subsequently, the bacterial culture was 
incubated for 30 min on ice before it was centrifuged for 12 min at 2500 rpm. The pellet 
was resuspended in 20 ml of cold RF1 buffer, incubated on ice for 15 min and 
centrifuged for 9 min at 2500 rpm. The pellet was resuspended in 7 ml cold RF2 buffer 
and the suspension was stored in 100 µl aliquots at -80ºC.  
 
RF1 Buffer 
  12.00 g  Rubidium chloride, RbCl 
    9.00 g  Manganese chloride, MnCl2 
    2.94 g  Potassium acetate 
150.00 g             Glycerol 
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The reagents were dissolved in 900 ml of distilled water and the pH was adjusted to pH 
5.8 with acetic acid, before the volume was made up to 1 L.  The buffer was 
subsequently sterile filtered through a 0.22 µm filter and stored at 4 °C. 
 
RF2 Buffer 
    2.09 g  3-(N-morpholino)propanesulfonic acid, MOPS 
    1.20 g  Rubidium chloride, RbCl 
  11.00 g  Calcium chloride, CaCl2 
150.00 g  Glycerol 
The reagents were dissolved in 900 ml of distilled water and the pH was adjusted to 
6.8 with sodium hydroxide, before the volume was made up to 1 L.  The buffer was 
subsequently sterile filtered through a 0.22 µm filter and stored at 4 °C. 
 
2.3.6 Plasmid DNA transformation of bacteria 
To transform bacteria, 5 µl of ligation reaction or 50 ng of plasmid DNA was incubated 
with 50 µl chemical competent E. coli on ice.  After 20 min, the bacteria were heat 
shocked for 30 sec at 42 ºC, before the addition of 500 µl LB medium and incubation at 
37 ºC with constant shaking for 30 min.  The bacteria culture (50 µl to 500 µl) was 
plated on LB-agar plates containing the appropriate antibiotics for the vector.  
 
2.3.7 Plasmid DNA preparation 
For plasmid DNA preparation, 5 ml and 100 ml overnight cultures from single colonies 
for mini and midi preparations were set up respectively.  The bacteria cultures were 
spun down at 3000 rpm and the pellets were processed as described in the Qiagen 
Plasmid Miniprep and Midiprep Kit instructions.  
 
2.3.8 DNA sequencing 
For sequencing reactions, oligonucleotide primers matching to sequences in the insert-
flanking regions of the vector and every 500 bp inside the insert were used.  For each 
sequencing reaction, 200 ng plasmid DNA, 3.2 pmol oligonucleotide primer and 8 µl 
BDT reaction mix (Big Dye Terminator Cycle sequencing kit) were mixed and adjusted 
to the total volume of 20 µl using distilled water.  The sequencing reactions were 
performed on an Applied Biosystems GeneAmp PCR machine.  Following 
amplification, the reaction was cleaned using the Qiagen Dye-Ex 2.0 Spin kit, and 
vacuum dried. The samples were sequenced using an Applied Biosystems DNA 
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sequencer in the sequencing facility at Cancer Research UK.  The resulting sequences 
were analysed using the DNAstar software package (Madison, USA).  
 
2.3.9 Site-Directed Mutagenesis 
Mutations in genes of interest were introduced by site-directed mutagenesis using two 
complementary synthetic primers containing the desired bases.  All primers used to 
introduce mutations in the EVH1 binding site of both human and Drosophila Abi are 
listed in Table 2.7.  For each mutagenesis, 100 ng plasmid DNA template, 125 ng of 
each oligonucleotide primer, 10 mM dNTP mix, 1x Cloned Pfu DNA polymerase 
reaction buffer and 2.5 units PfuTurbo DNA polymerase (Stratagene) were mixed and 
adjusted to the total volume of 50 µl using distilled water.  The mutated plasmids 
containing staggered nicks were generated during temperature cycling as shown 
below. 
 
95°C   30 sec 
   ---------------------- 
Denaturation :  95 °C 30 sec    ⎫   
Annealing :  55 °C 30 sec    ⎬ 18 cycles 
Extension :  68 °C 1 min *    ⎭ 
   ---------------------- 
   4 °C ∞ 
• *Extension time: 2 min/kb of plasmid length. 
 
The amplification reaction was subsequently incubated with 20 units DpnI (New 
England Biolabs) at 37 ºC for 1 hr to digest the methylated, non-mutated parental DNA 
templates.  The nicked plasmid DNA incorporating the desired mutations was then 
transformed into XL-10 E. coli (Chapter 2.3.6).   Mutations of the gene of interest were 
confirmed by sequencing DNA mini-preps of individual clones.   
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Table 2.7 Primers used to modify Abi sequence 
Mutated amino acids 
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2.4 Immunofluorescence 
2.4.1 General buffers and solutions for Immunofluorescence 
1x Cytoskeletal Buffer (CB) 
  10 mM  MES pH 6.1 
150 mM  NaCl 
    5 mM  EGTA 
    5 mM  MgCl2 
    5 mM  Glucose 
The reagents were dissolved in distilled water. 
 
Immunofluorescence (IF) Blocking Buffer 
1%                BSA  
2%                FCS 
The reagents were dissolved in 1x Cytoskeletal Buffer. 
 
Mowiol 
Mowiol (2.4 g) and glycerol (6 g) were dissolved in 6 ml distilled water. The mix was 
incubated for 2 hr at room temperature before 12 ml of 200 mM Tris-HCL (pH8.5) was 
added. The resulting solution was stirred for 10 min at 60 ºC, spun down for 5 min at 
5000 rpm and was stored in 500 µl aliquots at -20 ºC. 
 
3% Paraformaldehyde in 1x CB 
Paraformaldehyde (15 g) was added to 500 ml of pre-heated 1xCB. The solution was 
stirred under heating and 1 M NaOH tablets were added until the solution became 
clear. The solution was left to cool down to room temperature and the pH was adjusted 
to 8.8. The mix was passed through a 0.45 µm filter (Millipore) and aliquots were stored 
at -20 ºC.  
 
2.4.2 Fixation methods 
Paraformaldehyde (PFA) fixation methods were generally used to fix cells for 
immunofluorescence staining.  Cells were fixed in 3% PFA/CB for 10 min at room 
temperature and washed 3 times with PBSA and stored at 4 ºC until processed for 
immunofluorescence. 
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2.4.3 Staining and mounting  
To permeabilise cells before labelling with primary antibodies, the cover slips 
containing PFA fixed cells were incubated with a 0.1% Triton X-100/ PBSA solution for 
45 sec and washed 2 times with PBSA.  Following permeabilisation, cover slips were 
incubated for 15-30 min in IF-blocking buffer at room temperature. Cells were 
incubated with the primary antibody (diluted in IF blocking buffer) for at least 1 hr at 
room temperature (Table 2.8). After incubation with the primary antibody, the cover 
slips were washed 3 times with IF-blocking buffer and incubated for at least 30 min with 
the secondary antibody (diluted in IF-blocking buffer) at room temperature (Table 2.9).  
Phalloidin that binds to F-actin was added to the secondary antibody solution in a 
1:500 dilution where required.  During incubation, cover slips were protected from light.  
After incubation with the secondary antibody the cover slips were washed 3 times with 
IF-blocking buffer.  DNA was visualized by incubating the cover slips for at least 10 sec 
in distilled water containing 1 mg/ml 4’,6-diamidine-2-phenylidole dihydrochloride 
(DAPI) (Roche Diagnositcs, Mannheim, Germany) where required.  The cover slips 
were then washed once with distilled water and mounted on microscopy slides using 
Molviol (Calbiochem, Bad Soden, Germany) with 1 mg/ml p-phenylendiamine (Sigma).  
The prepared microscopy slides were dried at RT for at least 30 min before use.  
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Table 2.8 Primary Antibodies 
Antibody Specificity Species Dilution Origin 
α-Abi1 Abi1 and 2 Rabbit 1:1000 Dr Theresia Stradal 
α-Abi1 Abi1 Mouse 1:1000 Abcam 
α-Mena Mena Mouse 1:75 BD Transduction 
Laboratories 
α-VASP VASP Rabbit 1:1000 Dr Frank Gertler 




WAVE2 Rabbit 1:1000 Dr Theresia Stradal 
α-Nap1 (4952) Nap1 Rabbit 1:1000 Dr Theresia Stradal 
α-SCAR SCAR Guinea pig 1:1000 Dr Sven Bogdan 
α-Ena Ena Mouse 1:10 Dr Sven Bogdan 
Alexa 568-
phallodin 
Actin  1:500 Molecular Probes 
 
Table 2.9 Secondary antibodies 
Antigen Species raised in: Label Dilution Origin 
Mouse Rabbit FITC 1:500 Jackson 
ImmunoResearch 
Mouse Rabbit Texas Red 1:500 Jackson 
ImmunoResearch 
Rabbit  Donkey FITC 1:500 Jackson 
ImmunoResearch 
Rabbit  Donkey Texas Red 1:500 Jackson 
ImmunoResearch 
Guinea pig Goat Texas Red 1:500 Santa Cruz 
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2.5 Microscopy 
2.5.1 Microscopes 
2.5.1.1 Zeiss Axioplan 2 Upright 
To image fixed samples, a Zeiss Axioplan2 equipped with a Photometrics Cool Snap 
HQ cooled CCD camera, external Prior Scientific filter wheels (DAPI; FITC; Texas Red; 
Cy5) and a 63x/1.4NA Plan Apochromat objective was used. The system was 
controlled by MetaMorph software version 6.3r7 (Universal Imaging Corporation Ltd.). 
Images were analysed using MetaMorph and processed with the Adobe software 
package (Adobe Systems Incorporated, San Jose, CA, USA).  
 
2.5.1.2 Zeiss Inverted 
To image live cells, a Zeiss Axiovert 200 equipped with a Photometrics Cool Snap HQ 
cooled CCD camera, external Prior Scientific filter wheels (GFP, RFP) and a 
63x/1.4NA Oil Plan Apochromate objective was used. The system was controlled by 
MetaMorph software version 6.3r7, Universal Imaging Corporation Ltd. Movies and 
images were analysed using the MetaMorph and processed with the Adobe software 
package and Quick Time Player (Apple Computer, Incorporated).  
 
2.5.1.3 Nikon Inverted 
To image live cells in the LRI imaging facility, a Nikon ECLIPSE TE2000-E equipped 
with a Andor iXonEM + DU-888 back-illuminated EMCCD scientific camera, filter wheel 
(FITC) and a Dry 10x/0.3 Plan Fluor objective was used. The system was controlled by 
MetaMorph software version 7.7.3.0, Universal Imaging Corporation Ltd. Movies and 
images were analysed using the MetaMorph software and processed with the Adobe 
software package and Quick Time Player (Apple Computer, Incorporated).  
 
2.5.1.4 Zeiss confocal LSM 710 
To perform FRAP experiments, a Zeiss FObserver.Z1 confocal microscope equipped 
with photomultiplier spectral detector, dichroic mirrors and beam splitter (MBS 488, 
MBS 488/561), Argon laser (458nm, 488nm, 514nm), a DPSS laser (561nm), filter for 
FITC and TRITC and a 63x/1.4NA Oil DIC Plan Apochromate objective was used. The 
system was controlled by the ZEN software version 2009 (Carl Zeiss MicroImaging 
GmbH).  Movies and images were analysed using the ZEN 2009 software.  
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2.5.2 Live-cell imaging of cell migration  
Rat-2 cells stably expressing either GFP, GFP-tagged Abi or Abi mut were seeded into 
the 6 well MatTek dishes pre-coated with 10 µg/ml fibronectin (Invitrogen) at a density 
of 1x104 cells per well in complete medium lacking phenol red and grown over night.  
On the following day, the 6 well MatTek dish was transferred to the Nikon Inverted 
microscope and after 30 min, images were collected every 10 min for 20 hr in multiple 
stage positions at 37 ºC in a 5% CO2 atmosphere.  
 
2.5.3 Fluorescence Recovery After Photo-Bleaching (FRAP) 
Rat-2 cells were seeded onto fibronectin coated 3.5 cm MaTek dishes one day before 
performing FRAP analysis.  Drosophila S2 and S2R+ cells were seeded on to 
Concanavalin A (conA) (Sigma) coated 3.5 cm MaTek dishes 30 min before performing 
FRAP analysis.  To analyse the turnover rate of GFP-tagged Abi/dAbi, VASP and 
mCherry-tagged Ena at the cell plasma membrane in Rat-2 cells, S2 or S2R+ cells, the 
conditions for each FRAP assay were optimised by testing several imaging 
parameters, laser power and iteration times.  All FRAP assays were performed using a 
Zeiss LSM 710 confocal.  After the pre-seeded cells were transferred to the confocal 
microscope, cells to be imaged were first identified under low light fluorescence using 
the eyepiece.  In all cases, a region of 300x100 pixels for each cell at a higher 
magnification (digital zoom 2.0x) was recorded using a fast scan speed of 1.27 µs per 
pixel with either laser power setting of 1% for 488 nm and pinhole adjustment of 90 µm 
(GFP) or laser power setting of 2% for 561 nm and pinhole adjustment of 68 µm 
(mCherry).  A selected region within the imaging area of 90x25 pixels covering parts of 
protruding lamellipodia was bleached using either 30 iterations of the 488 nm laser at 
100% power (GFP) or 10 iterations of the 516 nm laser at 100 % (mCherry).  Five 
images in all cases were recorded before the GFP or mCherry signal was bleached.  In 
all cases, 500 images were acquired without time delay for each FRAP experiment. 
 
2.6 Analysis of microscopy data 
2.6.1 Quantification of the fluorescence intensities at the tip of 
lamellipodia 
Analysis was performed using a plug-in for ImageJ (version 1.44p) developed by Dr 
David Barry, a postdoctoral researcher in the lab.  Only non-adjoining cells were 
considered. Cells were segmented from background by grey-level thresholding of the 
dAbi-GFP signal (channel 1). Unwanted artefacts were removed using morphological 
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thresholds (minimum area and circularity). The resulting binary image was used to 
construct a Eucidean Distance Map (EDM), in which each pixel within an object was 
assigned a grey level proportional to its distance from the nearest background pixel.  
Dividing the original channel 1 image by the EDM resulted in the suppression of pixels 
distant from the cell boundary (plasma membrane), providing an estimate of dAbi 
signal strength at the cell periphery.  Dividing the signal of the immunolabeled 
endogenous Ena (Ena antibody) by the same EDM provided an estimate of Ena signal 
strength at the plasma membrane and the mean Ena:dAbi ratio was estimated.  Ten 
cells were quantified per population per timepoint.  The results of three independent 
experiments were presented. 
 
2.6.2 Single-cell tracking assay 
Cells were tracked manually using the single cell track feature of MetaMorph.  In all 
cases, the cell nucleus was tracked for 120 time points over a period of 15 hr.  No 
dividing or attaching cells were tracked.  Each day 13 cells from each cell line were 
tracked and the experiment was repeated on 3 separate days. Data that was 
generated using MetaMorph was subsequently imported into Excel (Microsoft Office 
2007).  Using Excel, the directionality, velocity and persistence of each cell over the 
tracking period was calculated.  
 
2.6.3 FRAP analysis 
The fluorescence intensity of FRAP movies was analysed using the FRAP analysis 
feature in the ZEN 2009.  A region of 88x23 pixels, which was created inside the 
bleaching area (90x25 pixels), was used to measure the recovery of the fluorescence 
intensity after photobleaching.  To subtract the background, the fluorescence intensity 
in a region of 20x20 pixels outside the cell boundary was measured.  The FRAP data 
was normalised to the first pre-bleached image and subsequently normalised to the 
background fluorescence intensity.  Kinetic modelling of normalised data was 
performed using the equation Y(T) = (Ymax – Ymin) (1-e-kt) + Ymin in the Prim 5.0 software.  
The rate of recovery k and the half time (t1/2 = -ln k) was obtained from a fitted curve. 
The maximum recovery after photobleaching (% recovery) was calculated.  Each curve 
corresponds to an average of at least 20 cells, which were acquired on 3 different 
days. 
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2.6.4 Quantification of lamellipodia formation in Drosophila haemocytes.  
GFP or GFP-tagged dAbi rescued dsRNA treated cells were seeded on ConA coated 
cover slips to allow cells to spread. Afterwards, cells were fixed, permeabilised and 
stained with phalloidin to label F-actin as described in  (Section 2.4).  Only GFP 
positive cells, were counted.  Each day 200 cells were counted and the experiment 
was repeated on 3 different days.  The cells were scored for the morphology of their 
lamellipodial structures.   
 
2.6.5 Statistical analysis of microscopy data 
Data in all graphs are presented as mean and standard error of the mean. Prism 5.0 
(GraphPad Software, CA) was used to perform standard statistical analysis of 
measured data sets. When two data sets were compared, a student’s t-test was 
performed.  If more than two data sets were compared with each other, a One Way 
ANOVA test followed by a Newman-Keuls multiple comparison test was performed.  
Statistical analysis of fitted FRAP data was performed using the extra sum-of-squares 
F test in Prism 5.0 to test whether the rate constants k differ significantly from each 
other.  All experiments were repeated at least three times on three different days.  The 
P value represents the probability of obtaining the observed values, under the 
assumption that the null hypothesis (means or k are equal) is true: the lower the P 
value, the lower the probability that the difference of the observed means or k was 
obtained by chance.  A P value of <0.05 was considered statistically significant.  
*indicates P<0.05, ** indicates P<0.01 and *** indicates P<0.001. 
 
2.7 Biochemistry 
2.7.1 Total cell lysate 
Bacteria or tissue culture cells were washed once in PBSA before preparing total cell 
lysates.  After PBSA aspiration, the appropriate amount of protein sample buffer (PSB) 
to cover the entire dish was added and cells were scraped. The lysate was then 
transferred to an microcentrifuge tube, mixed by vortexing and boiled for 10 min at 95 
ºC. The samples were stored at -20 ºC before being used in SDS-PAGE prior to 
immuno-blot analysis (Section 2.7.2).  To digest DNA in the sample before immuno-
blot analysis, 0.5 µl of 10 mg/ml Sigma D4527 deoxyribonuclease I (DNase I) was 
added where required.  
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Protein Sample Buffer (PSB) 
50%  Glycerol 
3%  SDS 
50 mM  Tris.HCl pH 6.8 
2%  β-Mercaptoethanol 
+  Solid Bromophenol Blue 
 
2.7.2 SDS-PAGE and Western blotting 
2.7.2.1 SDS-PAGE 
Pre-cast NuPAGE 4-12% Bis-Tris 1.0 mm gels (Invitrogen) were used throughout my 
studies.  Gels were loaded with at least one lane containing the SeeBluePlus2 
Prestained standard protein marker (Invitrogen) and were run using MES Running 
buffer (Invitrogen). Gels were run at 200 V for at least 35 min using Invitrogen mini gel 
tanks. Gels were run for 2-4 hr if proteins of similar size needed to be separated.  After 
the proteins were separated, gels were either transferred for immuno-blot analysis or 
stained with Coomassie solution (0.5% Coomassie Brilliant Blue, 50% methanol, 10% 
acetic acid) for 30 min, followed by destaining in high destain (50% methanol, 10% 
acetic acid) for 5 min, and then low destain (5% methanol, 10% acetic acid) for as long 
as necessary to visualise the protein bands. 
 
20x MES Running Buffer (Invitrogen) 
MES  97.6 g (1 M) 
Tris Base 60.6 g (1 M) 
SDS  10.0 g (69.3 mM) 
EDTA  3.0 g (20.5 mM) 
 
2.7.2.2 Immuno blot analysis  
After proteins were separated by size using SDS-PAGE, they were transferred onto a 
nitrocellulose membrane for immuno-blot analysis. Gels were transferred using the 
iBlotter and the iBlot gel Transfer kit from Invitrogen. After the transfer, the membrane 
was stained with Ponceau S solution to control for equal loading and successful 
transfer. Afterwards, the membrane was blocked for 30 min in blocking buffer (5% milk 
in PBSA, 0.1% Tween20 (Sigma)) and incubated with the primary antibody (in blocking 
buffer) for a period of 1 hr at room temperature to over night at 4 °C depending on the 
antibody used (Table 2.10).  The membrane was then washed 3 times in PBT (PBSA, 
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0.1% Tween20) before it was incubated in blocking buffer containing the secondary 
antibody conjugated to HRP for 30 min (Table 2.11). The membrane was then washed 
5 times in PBT before developing using ECL reagent according to manufacturer’s 
instructions (Amersham Bioscences), before being exposed on Hyperfilm-ECL 
(Amersham Biosciences) and developed using an IGP Compact automated developer 
(IPG limited).  
 
Table 2.10 Primary antibodies used for Western blot analysis 
Antibody Specificity Species Dilution Time Origin 
α-GFP (3E12) GFP monoclonal 
mouse 
1:1000 1 h  Way lab 
α-GST (G-7781) GST polyclonal 
rabbit 
1:2000 1 h Sigma 
α-HIS HIS monoclonal 
mouse 
1:2000 1 h Sigma 
α-Nap1 (4952) Nap1 polyclonal 
rabbit 






1:1000 O/N Dr Theresia 
Stradal 




1:1000 1 h Dr Theresia 
Stradal 
α-Zyxin (164D4) Zyxin monoclonal 
mouse 
1:1000 1 h Dr Matthias 
Krause 
α-dAbi dAbi polyclonal 
rabbit 
1:1000 O/N Dr Sven 
Bogdan 
α-SCAR SCAR Polyclonal 
guinea pig 
1:1000 O/N Dr Sven 
Bogdan 
α-α Tubulin α Tubulin monoclonal 
mouse 
1:5000 1 h Sigma 
Table 2.11 Secondary antibodies used for Western blot analysis 
Antigen Species  Label Dilution Origin 
Rabbit Goat HRP 1:2000 Jackson ImmunoResearch 
Mouse Goat HRP 1:5000 Jackson ImmunoResearch 
Guinea Pig Donkey HRP 1:10000 Jackson ImmunoResearch 
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2.7.3 Expression and purification of proteins in E. coli 
In thesis, the conditions of each protein produced in bacteria are listed in Table 2.12.  
 
2.7.3.1 Leaky Protein expression 
Chemically competent BL21 (DE3) Rosetta E. coli were transformed with the pMW172 
DNA vector carrying the gene of interest.  Bacteria from single colonies were used to 
inoculate 5 ml LB-ampicillin starter cultures, which were grown during the day under 
vigorous shaking at 37 °C.  Starter culture (1 ml) was then used to inoculate 1 L of LB-
ampicillin overnight cultures, which were then incubated either overnight with vigorous 
shaking at 30/37 °C or over 20 hr at 20/25 °C depending on the protein (Table 2.12). 
Bacteria were then harvested by centrifugation at 3500 rpm for 20 min at 4 °C.  The 
resulting bacterial cell pellet was snap frozen in liquid nitrogen and thawed at room 
temperature.  Afterwards, the cell pellet was resuspended in 25 ml bacterial lysis buffer 
(50 mM Tris HCl pH 8.0, 1 mM EDTA, 25% sucrose, 1x protease inhibitors (Complete 
EDTA-free protease inhibitor tablets (Roche)) at room temperature, and 3 mg lysozyme 
was added.  After 30 min incubation at room temperature, 240 µl of 1 M MgCl2, 24 µl 
MnCl2 and 10 µl of 10 mg/ml DNase I were added to the lysate and incubated at room 
temperature for another 30 min.  Subsequently, the lysate was centrifuged at 12,000 
rpm for 15 min at 4 °C. The supernatant was retained as the bacterial soluble fraction, 
which was then either snap frozen in liquid nitrogen and stored in aliquots at -20 °C or 
stored on ice at 4 °C with 1% sodium azide until they were used.    
   
2.7.3.2 Isopropyl β-D-1-thiogalactopyranoside (IPTG) induced 
Protein expression 
Chemically competent BL21 (DE3) Rosetta E. coli were transformed with the pMW172 
DNA vector carrying the gene of interest.  Fresh single colonies were used to inoculate 
a 10 ml LB-ampicillin starter culture, which was grown over night with vigorous shaking 
at 37 °C.  On the following day, the starter culture was used to inoculate 1 L of LB-
ampicillin media, which was then grown under vigorous shaking at 37 °C until the 
culture reached an OD600 of 0.6-0.7.  Cultures were incubated at 30 °C for 30 min 
before 1 mM IPTG (Sigma) was added.  After adding IPTG, cultures were grown for 2 
hr under vigorous shaking at 30 °C.  Afterwards, cells were harvested by centrifugation 
and the bacterial soluble fraction was obtained as described in Chapter 2.7.3.1. 
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Table 2.12 Expression conditions used to produce recombinant proteins in 
bacteria  
Recombinant proteins  Condition of expression  
GST-EVH1 VASP 37 °C O/N 
GST-EVH1 Evl 37 °C O/N 
GST-EVH1 Mena 37 °C O/N 
GST 37 °C O/N 
GST-Nap1 IPTG induced 
GST-PIR121 IPTG induced 
HIS-Grb2 30 °C O/N 
HIS-EVH1 Mena 37 °C O/N 
HIS-Nap1 IPTG induced 
HIS-PIR121 IPTG induced 
HIS-Abi IPTG induced 
GST-Abi 20 °C O/N 
GST-Abi N-term-PR1 30 °C O/N 
GST-Abi PR2-SH3 25 °C O/N 
GST-Abi ∆SH3 20 °C O/N 
GST-Abi PR2 20 °C O/N 
GST-Abi PR1-PR2-SH3 20 °C O/N 
GST-Abi PR1-PR2 20 °C O/N 
GST-Abi Mutant 1 20 °C O/N 
GST-Abi Mutant 2 20 °C O/N 
GST-Abi Mutant 3 20 °C O/N 
GST-Abi Mutant 1+2 20 °C O/N 
GST-Abi Mutant 1+3 20 °C O/N 
GST-Abi Mutant 2+3 20 °C O/N 
GST-Abi Mutant 1+2+3 (mut) 20 °C O/N 
pMW GST-EVH1 Ena IPTG induced 
HIS-VASP IPTG induced 
 
2.7.3.3 Purification of HIS-tagged proteins on Ni-resin 
Imidazole (1 M, pH 7.8) was added to soluble fractions to a final concentration of 50 
mM. Ni-NTA resin (Qiagen), prewashed in bacterial lysis buffer, was added to the 
soluble fraction, and incubated under constant rotation at 4 °C for at least 60 min. The 
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resin was pelleted by centrifugation at 2000 rpm, and washed 3 times in bacterial Ni 
wash buffer (50 mM Tris HCl pH 8.0, 250 mM NaCl, 0.1% Triton X-100, 50 mM 
imidazole pH 7.8).   
 
2.7.3.4 Purification of GST-tagged proteins on glutathione resin 
Glutathione sepharose resin (Amersham Biosciences), prewashed in bacterial lysis 
buffer, was added to soluble fractions, and incubated under rotation at 4 ºC for at least 
1 hr. The resin was pelleted by centrifugation at 2000 rpm, and washed 3 times in 
bacterial GST-wash buffer (150 mM NaCl, 0.1% Triton X-100, 5% glycerol in PBSA).  
 
2.7.4 Expression and purification of HIS-tagged PIR121:Nap1 protein 
complex using the Baculovirus system 
Full-length Nap1 and PIR121 were cloned into the baculovirus transfer vector 
pBacPAK-His3 (Clontech) or pBacPAK-GST (modified pBacPAK-GST (Clontech) from 
the protein expression facility at Cancer Research UK).  Expression and purification of 
HIS-tagged PIR121:Nap1 protein complex from Sf9 cells were performed by the in-
house facility at Cancer Research UK.   
 
2.7.5 In vitro EVH1 pull-downs 
The amounts of proteins in all soluble fractions used in each in vitro pull down assay 
were estimated using SDS-PAGE following by coomassie staining. In each assay, all 
samples were adjusted to contain a similar amount of GST- and HIS-tagged protein or 
protein complex, which were mixed in approximately a 1:1 ratio.  About 10% of the 
soluble fraction used in each pull-down was purified by glutathione sepharose resin or 
Ni-NTA resin and used as the input.   
 
2.7.5.1 HIS-EVH1 and bacterially produced GST-Nap1/PIR121 pull-
down assay 
Soluble bacterial fractions containing HIS-EVH1/Grb2 and GST, GST-tagged Nap1 or 
PIR121 were mixed and incubated at 4 °C for 60 min. Subsequently, pre-washed Ni-
NTA resin was added to the mixed soluble fractions, and incubated at 4 °C for 1 hr with 
rotation.  The resin was pelleted by centrifugation at 2000 rpm, washed 3 times in 
bacterial Ni wash buffer.  Samples were then boiled with PSB and subjected to SDS-
PAGE.  Afterwards, proteins were visualized by coomassie staining or immuno 
analysis.  
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2.7.5.2 GST-EVH1 and Sf9 cells produced HIS-PIR121:Nap1 pull-
down assay 
Soluble bacterial fractions containing GST/GST-EVH1 and pre-washed glutathione 
sepharose resin were incubated with rotation at 4 °C for 1 hr.  Afterwards, the resin 
was pelleted by centrifugation at 2000 rpm, and washed 3 times in bacterial GST wash 
buffer.  The resin was then incubated with the Sf9 cells produced HIS-PIR121:Nap1 
protein complex or the soluble bacterial fraction of HIS-LIM3 with rotation at 4 °C for 1 
hr.  These resins were pelleted by centrifugation at 2000 rpm, and washed 3 times in 
bacterial GST wash buffer.  Samples were then boiled with PSB and subjected to SDS-
PAGE.  Proteins were subsequently visualized by immuno-blot analysis with 
antibodies.    
 
2.7.5.3 GST-EVH1, HIS-Abi and HIS-Nap1 pull down-assays 
For GST/GST-EVH1 resin preparation, soluble bacterial fractions containing GST/GST-
EVH1 were incubated with pre-washed glutathione sepharose resin with rotation at 4 
°C for 1 hr.  For GST/GST-EVH1:HIS-Abi resin preparation, soluble bacterial fractions 
containing GST/GST-EVH1 and HIS-Abi were mixed and allowed to incubated with 
rotation at 4 °C for 1 hr.  Subsequently, pre-washed glutathione sepharose resin was 
added to the mixed soluble fractions and incubated with rotation at 4 °C for 1 hr.  All 
resins were pelleted by centrifugation at 2000 rpm, washed 3 times in bacterial GST 
wash buffer, mixed with the soluble bacterial fraction containing HIS-Nap1 and 
incubated under rotation at 4 °C for 1 hr.  Following incubation, resins were pelleted by 
centrifugation at 2000 rpm and washed 3 times in bacterial GST wash buffer.  Samples 
were boiled with PSB and then subjected to SDS-PAGE prior to be stained with 
coomassie solution.  
 
2.7.5.4 GST-EVH1 and HIS-Abi pull-down assays 
Soluble bacterial fractions containing GST/GST-EVH1 and HIS-Abi were incubated 
with rotation at 4 °C for 1 hr.  Subsequently, pre-washed glutathione sepharose resin 
was added to the mixed soluble fractions, and incubated with rotation at 4 °C for 1 hr. 
Resins were pelleted by centrifugation at 2000 rpm, and washed 3 times in bacterial 
GST wash buffer.  Samples were boiled with PSB and then subjected to SDS-PAGE 
prior to be stained with coomassie solution. 
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2.7.5.5 HIS-EVH1, GST-Abi full length and deletion mutant pull-down 
assays 
Soluble bacterial fractions containing either HIS-EVH1 or GST/GST-tagged Abi full 
length and Abi deletion mutants were mixed and incubated with rotation at 4 °C for 1 
hr. Subsequently, pre-washed Ni-NTA resin was added to soluble fractions, and 
incubated with rotation at 4 °C for 1 hr. Resin was pelleted by centrifugation at 2000 
rpm, and washed 3 times in bacterial Ni wash buffer.  Samples were boiled with PSB 
and then subjected to SDS-PAGE prior to be stained with coomassie solution. 
 
2.7.6 Pull-downs from cell lysates and protein identification by mass 
spectrometry 
Cells on a 10 or 15 cm dish were washed 2 times with PBSA at 4 °C and resuspended 
in 0.7 ml culture cell lysis buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 20 mM 
Na3VO4, 10 mM NaF, 5% glycerol, 1% Triton X-100, 1x protease inhibitors). Cells were 
disrupted by vigorous pipetting and resulting cell lysate was cleared of nuclei and 
membranes by centrifugation at 13000 rpm for 10 min at 4 °C.  Clarified cell lysates 
were the incubated with GST/GST-EVH1 resin previously washed in culture cell lysis 
buffer for 1 hr at 4 °C with rotation.  The resin was then pelleted by centrifugation at 
2000 rpm, and washed 3 times in culture cell lysis buffer. Samples were then subjected 
to SDS-PAGE and followed by coomassie staining or immuno blot analysis.  For 
protein identification, the coomassie stained gels were given to the Mass Spectrometry 
facility at Cancer Research UK.  The bands corresponding to the proteins of interest 
were then cut out and analysed using mass spectrometry. 
  
2.7.7 EVH1 binding competition assay 
For generating HIS-EVH1 affinity resin, soluble bacterial fractions containing HIS-EVH1 
domain of Mena were incubated with pre-washed Ni-NTA resin with rotation at 4 °C for 
1 hr.  For generating HIS-EVH1:GST-FPPPP and HIS-EVH1:GST-LIM3 affinity resins, 
soluble bacterial fractions containing HIS-EVH1 were mixed with the soluble fractions 
containing GST-FPPPP or GST-LIM3 and incubated with rotation at 4 °C for 1 hr.  
Subsequently, pre-washed Ni-NTA resin was added to soluble fractions, and incubated 
with rotation at 4 °C for another 1 hr.  Following incubation, all resins were pelleted by 
centrifugation at 2000 rpm, and washed 3 times in bacterial Ni wash buffer.  The 
resulting resins were then incubated with pre-prepared MVD7 cell lysates (Chapter 
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All immunoprecipitations were performed using the purified mouse monoclonal anti-
GFP antibody except one immunoprecipitation that was performed using the 
ChromoTek GFP-Trap_A, as described in the manufacture’s instructions.  Cell lysates 
that contain over-expressed GFP or GFP-tagged protein were prepared (Chapter 
2.7.6) and incubated with pre-washed Protein G resin (Pierce) with rotation at 4 °C for 
1 hr.  The resin was pelleted by centrifugation at 2000 rpm, and the cell lysates were 
subsequently transferred into a fresh tube, in which 2 µg of purified rabbit anti-GFP 
antibody was added to each pre-clarified cell lysate.  The samples were incubated with 
rotation at 4 °C for 2 hr.  Then pre-washed Protein G resin was added to the cell 
lysate/antibody mix and incubated with rotation at 4 °C for 1 hr.  The resin was pelleted 
by centrifugation at 2000 rpm, and washed 3 times in culture cell lysis buffer.  Samples 
were boiled with PSB and then subjected to SDS-PAGE.  The precipitated proteins 
were analysed by immuno blot analysis.   
 
2.7.9 Far western analysis of peptide arrays  
2.7.9.1 Purification of GST-tagged EVH1 for far western analysis 
To purify GST-tagged EVH1 domains of Mena, VASP, Evl and Ena under a more 
stringent salt and glycerol condition, NaCl and glycerol was added to soluble bacterial 
fractions to a final concentration of 500 mM NaCl and 10% glycerol.  Glutathione 
sepharose resin was prewashed in bacterial lysis buffer, was added to soluble 
fractions, and incubated under rotation at 4 °C for at least 1 hr.  Resin was pelleted and 
washed 4 times in bacterial GST wash buffer (150 mM NaCl, 0.1% Triton X-100, 5% 
glycerol in PBSA).  Bound GST-tagged EVH1 domains were eluted from beads using 4 
washes of 800 µl elution buffer (10 mM glutathione in 50 mM Tris HCl pH 8.0). The 
elution buffer containing the purified GST-tagged EVH1 was subsequently passed 
through PD-10 desalting columns according to the manufacturer’s instruction (GE 
Healthcare).  Protein concentrations were measured by spectrophotometry methods 
(Absorbance at 280 nm) using a NanoDrop spectrophotometer (Thermo Scientific). 
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2.7.9.2 Probing peptide arrays 
The peptide arrays containing overlapping peptides covering full length Abi or the 
proline rich C-terminus of Abi were generated by the peptide service at Cancer 
Research UK.  For all arrays, peptides of 20 amino acids that overlap with each other 
by 1 amino acid residue were synthesised and spotted onto a cellulose membrane.  To 
perform far western analysis, the dried peptide arrays were first moistened with 100% 
Ethanol, followed by 3 washes with PBT for 5 min each.  Subsequently, non-specific 
binding sites on the array were blocked by 1 hr or overnight incubation in blocking 
buffer (5% milk in PBSA, 0.1% Tween20).  Purified GST or GST-EVH1 was diluted to a 
concentration of 2 µg/µl in blocking buffer.  The peptide array was incubated upside 
down a parafilm in plastic box using 2-3 ml of diluted purified protein at room 
temperature for 1 hr.  The array was then washed 3 times for 10 min with blocking 
buffer followed by incubation with rabbit anti-GST primary antibody (diluted 1/10000 in 
blocking buffer) at room temperature for 1 hr.  After these 10 min washes with blocking 
buffer, the peptide array was incubated with goat anti-rabbit HRP secondary antibody 
(diluted 1/6000 in blocking buffer) at room temperature for 45 min.  After 3 washes for 5 
min with PBT, the peptide arrays were washed once with PBT containing 0.5 M NaCl to 
reduce non-specific binding. The peptide arrays containing the mutated peptides of Abi 
were probed in a similar fashion.  Peptide arrays were subsequently developed using 
the ECL reagent as described before Chapter 2.7.2.2.  
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Chapter 3. Abi mediates the interaction between 
Ena/VASP proteins and the WAVE complex 
3.1 Introduction 
Ena/VASP proteins have been found to play important roles in regulating actin 
dynamics during filopodia and lamellipodia formation.  It was previously thought that 
the EVH1 domain of Ena/VASP proteins could only interact with proteins containing 
FPPPP motifs.  However, it has been demonstrated that Tes, which lacks a FPPPP 
motif, binds to the EVH1 domain of Mena via its LIM3 domain, but does not bind VASP 
and Evl (Boeda et al., 2007).  Tes is therefore the first example of an EVH1 binding 
protein lacking a FPPPP motif that specifically regulates only one Ena/VASP family 
member.  Given these results, we speculated that other non-FPPPP containing binding 
partners and potential regulators of Ena/VASP proteins could exist.  I therefore set out 
to identify new EVH1 binding partners of Ena/VASP proteins using a combination of 
biochemical approaches and mass spectrometry.  
 
3.2 Results 
3.2.1 The EVH1 domain of Ena/VASP proteins interacts with the WAVE 
complex.  
To identify new binding partners of the EVH1 domain and potential regulators of 
Ena/VASP proteins, I made recombinant EVH1 domains of Mena, VASP and Evl with a 
GST-tag at their N-terminus.  All the GST-tagged EVH1 domains could be expressed in 
bacteria and were readily purified from the soluble fraction in high yield (Figure 3.1).   
 
I used the bacterially expressed GST-EVH1 domains of Mena, VASP and Evl as well 
as GST (control) to perform pull-down assays on HEK 293T cell lysates.  Several 
proteins were specifically retained by the GST-EVH1 domains, but not by the GST 
negative control (Figure 3.2A).  These proteins were identified by mass spectrometric 
analysis. A number of known FPPPP containing binding partners of EVH1 domains 
were found, including zyxin (Reinhard et al., 1995, Drees et al., 2000) and palladin 
(Boukhelifa et al., 2004).  We also indentified a number of novel potential EVH1 binding 
proteins, including Zap3 (240 kDa), WAVE2 (68 kDa), Nap1 (125 kDa) and PIR121 
(140 kDa) (Figure 3.2B).  
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For Zap3, a nuclear protein, no link to the actin cytoskeleton has been described.  
However, all other three potential EVH1 binding partners (WAVE2, Nap1 and PIR121) 
are part of the WAVE complex (Gautreau et al., 2004, Echarri et al., 2004, Innocenti et 
al., 2004, Leng et al., 2005).  This indicates that Ena/VASP proteins may cooperate 
with the WAVE complex to regulate actin dynamics at the leading edge.   
 
To verify the interaction between the EVH1 domain and components of the WAVE 
complex, I repeated my pull down assays using MVD7 cells, which are mouse 
embryonic fibroblasts that lack endogenous Mena/VASP and only express low levels of 
Evl (Bear et al., 2000).  By using this cell line, the competition for binding between 
bacterially produced GST-EVH1 and the EVH1 domains of endogenous Ena/VASP 
proteins is reduced.  Mass spectrometric analysis found that the GST-tagged EVH1 
domain also retained Nap1 and PIR121 from MVD7 cells (Figure 3.2C).  This assay did 
not, however, indentify any bands corresponding to WAVE2.  The EVH1 pull-down 
assay using MVD7 cells was repeated one more time under more stringent conditions.  
Nap1 and PIR121 were also found to bind the GST-EVH1 in a phosphate-based buffer 
containing 300mM NaCl and 10% glycerol (Figure 3.2D).  WAVE2 was also present 
albeit weakening in this more stringent condition.  In contrast, Zyxin was always 
detected in my pull down assays (Figure 3.2).    
 
It should be noted that Zap3 and WAVE2 were not readily detected in the pull-downs 
from MVD7 cells using a phosphate-based buffer containing 150 mM NaCl and 5% 
glycerol (Figure 3.2C).  It is possible that due to the lower band intensity of Zap3 and 
WAVE2 (Figure 3.2A), only Zyxin, Nap1 and PIR121, were found as distinct bands in 
the EVH1 pull-down compared to the control pull-downs.  The apparent difference in 
the intensity of the bands may either be due to the fact that more Nap1 and PIR121 
compared to Zap3 and WAVE2 were pulled-down by EVH1 or that Nap1 and PIR121 
have a higher affinity for the coomassie dye than Zap3 and WAVE2.  
 
However, coomassie detectable levels of WAVE2 were pulled-down by GST-EVH1 
from MVD7 cell lysates under more stringent conditions (Figure 3.2D).  Additionally, 
C77080, a FPPPP motif-containing protein, was pulled down by GST-EVH1 that was 
not found in the other conditions (Figure 3.2D).  These two findings can be explained 
by the reduced unspecific binding to GST and GST-EVH1 (compare Figure 3.2D to 
3.2C) under the more stringent conditions.  When comparing GST-EVH1 to GST alone, 
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bands corresponding to WAVE2 and C77080 may have been masked by other 
unspecific bands in the less stringent conditions.  Given Nap1, PIR121 and WAVE2 are 
binding to GST-EVH1 under the more stringent conditions strengthens the idea that the 
WAVE complex is a bona fide interaction partner of the EVH1 domain of Ena/VASP 
proteins. 
  
In my pull-down assays, five novel potential binding partners of the EVH1 domain were 
identified: Zap3 (240 kDa), WAVE2 (68 kDa), Nap1 (125 kDa), PIR121 (140 kDa) and 
C77080 (120 kDa).  Zap3 contains multiple FPPPP motifs and is thought to serve as a 
scaffold protein for type 1 serine/threonine protein phosphatases (PP1s) and several 
RNA binding proteins within the nucleolus (Armstrong et al., 2004).  C77080 also 
contains FPPPP motifs.  Neither the cellular localisation nor its functions are known.  
The other three proteins belong to the WAVE complex, and Nap1 and PIR121 have 
been always detected in my pull down assays.  Given the function of Ena/VASP 
proteins and the WAVE complex in regulating the actin cytoskeleton at the leading 
edge, I therefore decided to verify if the non-FPPPP containing proteins Nap1/PIR121 
and the EVH1 domains of Ena/VASP proteins interact.  
 
In order to confirm the mass spectrometric results for Nap1 and PIR121, I performed 
pull-down assays using HEK 293T cells overexpressing N-terminally GFP-tagged Nap1 
or PIR121, and the bacterially produced GST-EVH1 domain of Mena. HEK 293T cells 
overexpressing GFP alone or the GFP-LIM3 domain of Tes (Boeda et al., 2007) were 
used as negative and positive controls respectively.  Western blot analysis with a GFP 
antibody revealed that the GST-EVH1 domain of Mena but not GST alone retained 
GFP-tagged Nap1 and PIR121 from cell lysates that were overexpressed separately or 
co-overexpressed (Figure 3.3).  Together, these results suggest that Nap1 and 
PIR121, which both lack a classical FPPPP motif, may provide a link between 
Ena/VASP proteins and the WAVE complex. 
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Figure 3.1 Purification of recombinant GST- EVH1 domains of Ena/VASP 
proteins. 
A. Schematic representation of Ena/VASP proteins.  The N-terminal EVH1 domain 
(green) and the C-terminal EVH2 domain (blue) are separated by the middle proline 
rich region (pink).  Numbers indicate the first and last residue of each domain.  B. 
Coomassie stained gel illustrating the successful production and purification of soluble 
GST-EVH1 domains of Mena, VASP and Evl in bacteria.   
  111 
 
 
Figure 3.2 The non-FPPPP containing proteins Nap1 and PIR121 are potential 
binding partners of Ena/VASP proteins.  
A. Coomassie stained gel showing pull-downs from HEK 293T cell lysates using GST-
EVH1 domains.  The protein bands that are indicated by small black arrowheads were 
sent for mass spectrometric analysis.  Identified proteins are indicated with numbers. 
Pull-downs were performed in a PBS buffer containing 150 mM NaCl and 5% glycerol. 
B. Table of proteins from A that were identified by mass spectrometric analysis.  
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C. Coomassie stained gel showing pull-downs from MVD7 cell lysates using the GST-
EVH1 domain of Ena/VASP proteins.  Pull downs were performed in a PBS buffer 
containing 150 mM NaCl and 5% glycerol. Coloured asterisks indicate protein bands 
that were identified by mass spectrometric analysis.   
D. Coomassie stained gel of GST-EVH1 pull-down from MVD7 cell lysates using more 
stringent conditions (PBS buffer containing 300 mM NaCl and 10% glycerol). Nap1 (red 
asterisk), PIR121 (black asterisk), WAVE2 (yellow asterisk), Zyxin (green asterisk) and 
C77080 (blue asterisk) were identified by mass spectrometric analysis.  In all panels, 
the large black arrowheads indicate GST or the GST-EVH1 domain of Ena/VASP 
proteins.  4% of the cell lysate used in each pull down was used as the input. 
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Figure 3.3 The EVH1 domain of Mena retains GFP-Nap1 and GFP-PIR121 from 
HEK 293T cell lysates. 
Immunoblot analysis of pull-downs using GST-EVH1 domain of Mena (right panel) or 
GST alone (left panel) incubated with HEK 293T cell lysates containing overexpressed 
GFP-Nap1 and GFP-PIR121.  GFP alone and GFP-LIM3 domain of Tes were used as 
controls.  The input (I) and bound (B) samples with the respective GFP-tagged proteins 
are indicated.  The Ponceau S staining shows equivalent amounts of GST and GST-
EVH1 domain of Mena were present on the resin.  
  
3.2.2 Nap1/PIR121 do not interact directly with the EVH1 domain of Mena 
To test if the interactions between the EVH1 domain and Nap1/PIR121 are direct, I 
carried out an in vitro pull-down assay using recombinant proteins.  I expressed and 
purified full-length Nap1 and PIR121 with either a GST- or HIS-tag at their N-terminus 
from E. coli.  The expression of these proteins in bacteria was problematic, presumably 
at least in part due to the size of the proteins.  However, after testing different E. coli 
strains and expressing under different conditions, I did obtain small amounts of soluble 
full length Nap1 and PIR121 by performing IPTG induced protein expression in E. coli 
BL21 (DE3) Rosetta strain.  Although full length Nap1 and PIR121 with either a GST- 
or HIS-tag were soluble, a lot of breakdown products of the full-length proteins were 
observed (data only shows the GST-tagged Nap1 and PIR121 in figure 3.4 A).  In the 
end, I decided to use N-terminally GST-tagged Nap1 and PIR121 instead of the HIS-
tagged versions for the following experiments as they had better expression.  
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In the in vitro pull-down assays, HIS-EVH1 domain of Mena or HIS-Grb2 (as negative 
control) was bound to the resin and GST-Nap1/PIR121, GST (as negative control) or 
GST-LIM3 domain of Tes (as positive control) was added.  The coomassie stained gel 
revealed that GST-LIM3, but not GST binds directly to HIS-EVH1 as expected.  
However, no convincing binding of HIS-EVH1 to GST-Nap1 or GST-PIR121 was 
detected (Figure 3.4A).  This suggests that the interaction between Nap1/PIR121 and 
the EVH1 domain of Mena is indirect.  In order to confirm this result, I performed 
western blot analysis on the same samples.  Also using specific antibodies no 
interaction between GST-Nap1 or GST-PIR121 and the HIS-EVH1 domain of Mena 
was detected (Figure 3.4B).  However, I detected binding of a fragment of PIR121 to 
the EVH1 domain (Figure 3.4B).  The nature of this fragment, which may be an 
artefact, is unknown.  However, EVH1 pull-down assays on HEK 293T cell lysates 
overexpressing GFP-PIR121 deletion mutant (residue 1-536) showed that GST-EVH1 
was able to retain this GFP-PIR121 deletion mutant from cell lysates (data not shown).  
Based on these observations, it suggests that PIR121 may actually contain an atypical 
EVH1 binding site in its N-terminus, which is hidden in the full-length protein.  However, 
subsequent in vitro binding assays with the N-terminal mutant of PIR121 (residue 1-
536) produced in bacteria confirmed that this was not the case, as no binding to the 
EVH1 domain of Mena was detected using western blot analysis with GST antibody 
(data not shown).    
 
Given the fact that obtaining soluble recombinant HIS or GST-tagged Nap1 and 
PIR121 from bacteria was problematic, I repeated the in vitro pull-down assays using a 
Nap1 and HIS-tagged PIR121 protein complex that was purified from insect cells by 
the protein expression facility at Cancer Research UK (Figure 3.4C). Although no 
breakdown products were observed, the purified protein complex was unstable as it 
rapidly precipitated after purification (data not shown).  Consequently, the complex had 
to be used in the in vitro EVH1 pull-down assays on the same day when it was purified.  
In this pull-down assay, GST alone and HIS-LIM3 domain of Tes were used as 
controls.  Western blot analysis with a HIS-tag antibody showed no binding of the HIS-
tagged Nap1/PIR121 complex to the GST-EVH1 domain of Mena (Figure 3.4D).  This 
data is in line with the results from the in vitro pull-down assays using bacterially 
produced Nap1 and PIR121.  Although the quality of recombinant Nap1 and PIR121 
used in the in vitro pull-down assays were not great, overall, the results suggest that 
both, Nap1 and PIR121 do not bind directly to the EVH1 domain of Ena/VASP proteins.   
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Figure 3.4 Nap1 and PIR121 do not bind directly to the EVH1 domain of Mena.  
A. Coomassie-stained gel of in vitro pull-downs using HIS-EVH1 domain of Mena and 
GST-Nap1/GST-PIR121.  HIS-EVH1 domain of Mena and HIS-Grb2 (control) were pre-
incubated with resin.  GST-Nap1, GST-PIR121, GST alone or GST-LIM3 was added to 
the resin.  GST-Nap1 and GST-PIR121 (indicated by small arrowheads) do not interact 
with the HIS-EVH1 domain of Mena or HIS-Grb2.  Asterisks indicate bands 
corresponding to bacterial proteins that are present in all HIS-EVH1 fractions.  Note 
that this band is not specific for GST-Nap1 or GST-PIR121, since it can also be 
observed in the GST and GST-LIM3 lanes.  B. The results shown in A were confirmed 
by western blot analysis.  The input and HIS-tagged proteins, which were pre-
incubated with resin, are indicated at the top of the panels.  GST and GST-tagged 
proteins are indicated on the left of the panels.  Antibodies are indicated on the right of 
the panels.  PIR121 breakdown product that can bind the EVH1 domain of Mena is 
indicated.  C. Coomassie stained gel of purified recombinant HIS-tagged Nap1/PIR121 
protein complex produced in insect cells.  D. Western blot analysis of in vitro pull-
downs using HIS-tagged Nap1/PIR121 protein complex produced in insect cells.  As 
bacterially produced Nap1 and PIR121, the insect cell produced proteins do not bind 
the EVH1 domain of Mena.  The input and GST-tagged proteins, which were pre-
incubated with resin, are indicated at the top of the panels.  HIS-tagged Nap1/PIR121 
and HIS-tagged LIM3 domain of Tes (control) are indicated on the left of the panels.  
Anti-HIS antibody is indicated on the right of the panels.  The Ponceau S stain shows 
equivalent amounts of GST and the GST-EVH1 domain of Mena was present on the 
resin. 
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3.2.3 Abi mediates the interaction between the EVH1 domain and the 
WAVE complex 
My analysis reveals that Nap1 and PIR121 do not directly interact with the EVH1 
domain of Mena.  However, the pull-down of three subunits of the WAVE complex 
(Nap1, PIR121 and WAVE2) by the EVH1 domain suggests that the interaction may be 
mediated by another component of the WAVE complex.  A potential candidate is Abi.  
Previous biochemical studies have demonstrated that Abi binds directly to the EVH1 
domains of Mena and VASP through its C-terminal proline rich region (Tani et al., 
2003, Dittrich et al., 2010).  However, none of these studies have mapped the EVH1 
binding site in Abi, as Abi does not contain classical FPPPP motifs.   
 
Curiously, Abi was not detected by coomassie staining in GST-EVH1 pull-down assays 
(Figure 3.2).  However, the stability of the WAVE complex and the 1:1:1:1:1 
stoichiometry of its components suggested that Abi should have been retained if 
Ena/VASP proteins bind to the WAVE complex (Eden et al., 2002).  To test if Abi was 
present in my previous pull downs assays, I performed western blot analysis using 
antibodies that recognise individual WAVE complex components.  Using these 
antibodies, additional to Nap1 and PIR121 that were detected by mass spectrometry, I 
also found that Abi was associated with the EVH1 domain of Mena (Figure 3.5B).  
Since the interaction between coomassie dyes and proteins are dependent on a variety 
of factors such as the overall composition of a protein and it is known that the 
coomassie staining of Abi is less efficient than other components of the WAVE 
complex (personal communication with Dr Michael Rosen), it is likely that the amount 
of Abi that was pulled down could only be detected by western blot analysis, but not by 
coomassie staining.  
 
To test if the WAVE components bind to the same site on EVH1 as the FPPPP-
containing proteins and Tes, I pre-incubated the EVH1 domain with the FPPPP region 
of zyxin (human zyxin polyproline region, residues 61-141) or the LIM3 domain of Tes 
(Boeda et al., 2007).  The results showed that the interaction between EVH1 and the 
components of the WAVE complex as well as Zyxin were inhibited by GST-FPPPP and 
GST-LIM3 (Figure 3.5A, B).  This suggests that the components of the WAVE complex, 
Zyxin and Tes all compete for the same binding site on the EVH1 domain of Ena/VASP 
protein.   
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Since Nap1 and PIR121 do not directly bind to the EVH1 domain, I set up an in vitro 
pull-down assay to examine if Abi acts as a bridging protein to mediate the interaction 
between the WAVE complex and Ena/VASP proteins.  There are three mammalian Abi 
isoforms Abi1, Abi2 and Abi3 (Hirao et al., 2006).  As all three isoforms share similar 
domain organisation and associate with the WAVE complex.  I only used the human 
Abi1 isoform, which I designated as Abi.  Full-length soluble recombinant Abi was 
produced in bacteria with an N-terminal HIS-tag (Figure 3.5C).  Pull-down assays using 
bacterially produced proteins revealed that the GST-EVH1 domain of Mena but not 
GST alone interacts directly with HIS-Abi.  Moreover, Nap1, which does not interact 
directly with EVH1, but is known to interact directly with Abi (Yamamoto et al., 2001), 
can bind the Abi-EVH1 complex (Figure 3.5D).  Together, my data indicate that Abi 
acts as the link between Mena and the rest of the WAVE complex. 
 
The sequences of the EVH1 domains of Ena/VASP proteins are very similar, although 
not totally identical (Figure 3.6A).  Given Tes only binds Mena and not VASP and Evl 
(Boeda et al., 2007), I wanted to investigate if Abi, is a specific binding partner of Mena 
or if it also binds to VASP or Evl.  To address this question, I performed an in vitro pull-
down assay using bacterially produced GST-EVH1 domains of Mena, VASP and Evl 
together with HIS-Abi.  GST was used as a negative control.  The coomassie stained 
gel revealed direct interactions between Abi and the GST-tagged EVH1 domains of all 
three mammalian Ena/VASP isoforms but not GST (Figure 3.6B).  These results 
indicate that Abi is not a specific Mena interactor.  This is consistent with the previous 
pull-down assays demonstrating that Nap1 and PIR121 were retained from cell lysates 
by the EVH1 domains of all three mammalian Ena/VASP proteins (Figure 3.2). 
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Figure 3.5 Abi binds directly to the EVH1 domain.  
A. Schematic representation of the competitive binding assay that is shown in B.  B. 
Western blot analysis of GST-EVH1 pull-downs shows that endogenous Abi is only 
retained from MVD7 cell lysates together with Nap1, PIR121 and Zyxin (control) by the 
EVH1 resin not by the resins that were pre-incubated with the EVH1:FPPPP or 
EVH1:LIM3 complexes.  The input and pull-downs are indicated at the top of the 
panels.  The Ponceau S panel shows proteins that are on the resins.  C. Coomassie 
stained gel shows the bacterially produced HIS-Abi.  D. Coomassie stained gel of in 
vitro pull-down assays demonstrating that Nap1 can only interact with the EVH1 
domain of Mena in the presence of Abi.  Resins were pre-incubated with either GST 
(control) or GST-EVH1.  The pre-bound resins were then incubated with either HIS-Abi 
or HIS-Nap1.  The GST-EVH1:HIS-Abi bound resins were incubated with HIS-Nap1.  
The presences of HIS-tagged proteins are indicated at the top of the gel.  The large 
arrowheads indicate the bands representing HIS-Nap1, HIS-Abi as well as the GST-
EVH1 domain of Mena and GST respectively.  




Figure 3.6 Abi does not bind specifically to Mena. 
A. Sequence alignment of the EVH1 domains of human Mena, VASP and Evl.  
Conserved residues are highlighted in yellow.  Gaps are indicated by -.  The three 
conserved aromatic residues that are essential for FPPPP binding are indicated in red.  
B. The table lists the sequence identity and divergence between the EVH1 sequences 
of human Mena, VASP and Evl.  ClustalW2-Multiple Sequence Alignment (EMBL-EBL) 
was used to generated both A and B.  C. A coomassie stained gel of an in vitro pull-
down assay demonstrating that Abi interacts directly with the EVH1 domains of Mena, 
VASP and Evl.  HIS-Abi, GST, and GST-tagged proteins are indicated at the top of the 
gel.  Large black arrowheads indicate the protein bands corresponding to HIS-Abi, 
GST and the different GST-EVH1 domains.  
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3.3 Summary 
Using EVH1 pull-down assays combined with mass spectrometry, I identified the 
WAVE complex components Nap1 and PIR121 as potential binding partners for the 
EVH1 domain of Ena/VASP proteins.  However, data from in vitro pull-down assays 
showed that this interaction is indirect and actually dependent on Abi, another 
component of the WAVE complex, which also lacks a classical FPPPP motif.  My data 
is consistent with published data, which demonstrated a direct interaction between Abi 
and Ena/VASP proteins (Dittrich et al., 2010, Tani et al., 2003).  Moreover, in contrast 
to Tes, which only binds Mena, Abi can interact with all three mammalian Ena/VASP 
proteins in vitro. These results suggest that Abi may act as a linker to mediate an 
interaction between Ena/VASP proteins and the rest of the WAVE complex. 
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Chapter 4. Identification of the EVH1 binding site in 
Abi 
4.1 Introduction 
My data suggests Abi, which is an integral component of the WAVE complex interacts 
directly with the EVH1 domain of Ena/VASP proteins in vitro.  Both, the WAVE complex 
and Ena/VASP proteins are key regulators of actin dynamics at the leading edge 
during cell migration.  I wondered if uncoupling the interaction of Ena/VASP proteins 
from the WAVE complex would therefore affect the actin-based motility of the cell.  In 
order to study the physiological significance of the Abi-EVH1 interaction in vivo, I aimed 
to make a mutant Abi that could not bind the EVH1 domain of Ena/VASP proteins but 
could still incorporate into the WAVE complex.  The first stage of this goal required the 
identification of the EVH1 binding site in Abi.   
 
4.2 Results 
4.2.1 The C-terminal proline rich region of Abi binds the EVH1 domain of 
Ena/VASP proteins 
To identify the EVH1 binding site in Abi, I generated a series of deletion mutants.  The 
same boundaries for the deletion mutants were selected as in previous work that 
partially mapped the EVH1 binding region in Abi (Tani et al., 2003) (Figure 4.1A).  N-
terminal GST-tagged Abi deletion mutants were expressed and purified from bacteria 
(Figure 4.1B, C, D).  In contrast to the expression of GST-Abi-N-term-PR1, which was 
not detected by western blot analysis with GST antibody, other GST-tagged Abi 
deletion mutants were expressed and soluble, although their expression levels were 
somewhat variable (Figure 4.1B, C, D).  Most of the recombinant GST-tagged Abi 
deletion mutants, however, were generally less stable than full length Abi as 
precipitation of Abi deletion mutants was often observed (data not shown).  These 
recombinant Abi deletion mutants, together with full length Abi were used in EVH1 in 
vitro pull-down assays with GST alone as a control.  The results demonstrated that the 
HIS-EVH1 domain of Mena bound full length Abi and only the GST-tagged Abi deletion 
mutants containing the proline rich region (PR1+PR2 or PR2) (Figure 4.2).  These 
results suggest the EVH1 binding region of Abi may also involve a proline rich motif.  
 
The problem of producing stable recombinant Abi deletion mutants in significant 
qualities in bacteria led to difficulties in narrowing down the essential region for EVH1 
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binding within the proline rich regions of Abi.  Interestingly, far western approaches 
using the EVH1 domain on peptide arrays were successful used to initially identify the 
FPPPP motif in ActA from Listeria as the binding site for the EVH1 domain of 
Ena/VASP proteins (Niebuhr et al., 1997).  Given this I decided to use this approach to 
try to identify the EVH1 binding site in Abi.  A peptide array containing a series of 
overlapping peptides of 20 amino acids in length that covered the full length of Abi was 
generated by the peptide service facility at Cancer Research UK (Figure 4.3A).  The 
overlapping peptides were spaced one amino acid residue apart.  The peptide array 
was probed with bacterially produced GST-EVH1 domain of Mena.  The interaction 
between the GST-EVH1 domain of Mena and binding peptides was subsequently 
detected by GST antibodies, followed by secondary antibodies and ECL detection 
(Figure 4.3B).  As shown in Figure 4.4A, the black spots represent peptides that bound 
to the GST-EVH1 domain of Mena.  These peptides covered only the PR2 region, but 
not the PR1 region of Abi.  To confirm this data, I repeated the far western analysis 
using the GST-EVH1 domain of Mena and GST alone (control) on a peptide array 
consisting of a series of overlapping 20 residue peptides corresponding to the residues 
320-415 of Abi, which contains both PR1 and PR2 regions.  Again, the overlapping 
peptides in this peptide array were spaced one amino acid apart.  The same peptides, 
which were shown to bind EVH1 in the previous experiment, were detected by probing 
with the GST-EVH1 domain of Mena but not GST (Figure 4.4B). Discontinuous 
detections within the overlapping peptides in the potential EVH1 binding site of Abi 
were observed in both experiments  (Figure 4.4C).  These gaps in signal could be due 
to errors or defects that occurred during peptide synthesis.  Taken together, the far 
western analyses of both peptide arrays indicate that Abi interacts with the EVH1 
domain of Ena/VASP proteins through residues 352-394 in its PR2 region.  The results 
obtained from these far western experiments are consistent with my data from the in 
vitro pull-down assays as well as the previously published data from yeast two-hybrid 
screening (Tani et al., 2003). 
 
Curiously, it has been shown that an extended WIP sequence (residue 454-459 and 
475-478) and a central polyproline rich motif are essential for binding to the WH1 
domain of WASP family proteins (Peterson et al., 2007, Zettl and Way, 2002, Volkman 
et al., 2002).  Given the binding site in Abi I identified appears to cover 43 amino acid 
residues, it may be that Abi binds the EVH1 domain of Ena/VASP proteins in a similar 
fashion to the WIP and WASP family interaction 
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The EVH1 domains of all three mammalian Ena/VASP proteins are highly conserved 
(Figure 3.6A, B).  In order to test if Abi binds to the EVH1 domains of VASP and Evl in 
a similar fashion to that of the EVH1 domain of Mena, I performed far western analysis 
using the GST-EVH1 domains of Mena, VASP, and Evl on individual peptide arrays 
consisting of overlapping 20 residue peptides covering the residues 320-415 of Abi.  
Although similar peptide binding patterns were observed for the three different GST-
EVH1 domains, these peptide-binding patterns were not identical (Figure 4.5).  The 
difference in peptide binding patterns for different GST-EVH1 domains may reflect 
variation in peptide binding affinities.   My results suggest that the EVH1 domains of all 
three mammalian Ena/VASP proteins interact with Abi in a similar fashion.  
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Figure 4.1 Generation deletion mutants of Abi. 
A. Schematic representation of Abi and the deletion mutants that were used to map the 
EVH1 binding site. The PR1 and PR2 regions (pink) and SH3 domain (blue) are 
indicated.  The corresponding name of each deletion mutant is shown on the left.  B. 
Coomassie-stained gel of soluble fractions of GST-tagged Abi and Abi deletion 
mutants produced in bacteria indicates that except for GST-tagged PR2-SH3 and PR1-
PR2-SH3 (red arrows) no other recombinant proteins could be clearly detected.  C. 
Coomassie-stained gel of GST-tagged Abi and Abi deletion mutants purified from the 
soluble fraction on glutathione beads (red arrows).  D. Western blot analysis confirms 
the bands indicated by red arrows in C (except GST-Abi-N-term-PR1) are GST-tagged 
Abi and its deletion mutants (red arrows).  GST-Abi-N-term-PR1, which was not 
detected by GST antibody, is indicated by red asterisk.  
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Figure 4.2 The proline rich region of Abi is essential for EVH1 binding. 
Coomassie stained gels of pull-down assays using the indicated GST-tagged Abi 
deletion mutants and GST with HIS-EVH1 domain of Mena as a resin.  Only the GST-
tagged Abi mutants containing both PR1 and PR2 regions bound strongly to the EVH1 
domain of Mena.  The input (I) and bound (B) samples of the respective GST-tagged 
inputs are indicated at the top of the gel.  Red small arrowheads indicate the bands 
representing GST-tagged Abi mutants.  Black arrowheads at the side of the gels 
indicate the bands representing GST, GST-Abi and HIS-EVH1 domain of Mena (resin).  
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Figure 4.3 Schematic representation of the far western approach used to map the 
EVH1 binding site in Abi.  
A. Overlapping peptides corresponding to the amino acid sequence of Abi were 
synthesised on a cellulose membrane.  Each peptide consists of 20 residues displaced 
by one residue starting with amino acids 1-20 of Abi at position 1 on the array and 
ending with amino acids 457-476 at position 457.  B. The peptide array was probed 
with GST-EVH1 domain of Mena.  The potential interactions between the peptides and 
the EVH1 domain were subsequently detected by immunoblot using anti-GST (blue), 
followed by antibody conjugated to HRP (orange).   
  128 
 
 
Figure 4.4 Residues 352-394 of Abi bind the EVH1 domain of Mena.  
A.  Far western analysis on a peptide array of the overlapping peptides that cover the 
full length of Abi.  The black spots identify the peptides that interact with the GST-
EVH1 domain of Mena.  The spots that cover the proline rich region (residues 352-394) 
of Abi are highlighted in the red box B. Far western analyses of peptide arrays 
consisting of overlapping peptides covering residues 320-415 of Abi.  The black spots 
represent the peptides that bound the GST-EVH1 domain of Mena. No black spots 
were observed on the peptide array that had been probed with GST.  Red boxes in 
both arrays indicate the positions of the peptides that cover the proline rich region of 
Abi (residues 352-394).  C. Schematic representation of the peptides of Abi that bind 
the EVH1 domain of Mena.  The sequence of the EVH1 binding site in Abi is indicated 
in red.  Each line represents a peptide of 20 amino acids, which partially covers the 
EVH1 binding site in Abi.  The intensities of the lines from darkest (black) to lightest 
(light grey) reflect the binding efficiencies of the EVH1 domain to the different peptides 
from strongest to weakest. 
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Figure 4.5 The EVH1 domains of Mena, VASP and Evl bind the same region of 
Abi.  
A. Far western analysis with GST-EVH1 domains of Mena, VASP and Evl on peptide 
arrays consisting of overlapping peptides covering residues 320-415 of Abi. The 
peptide arrays were probed with either GST or the purified GST-tagged EVH1 domain 
of different Ena/VASP proteins.  Similar peptides were found to interact with all three 
EVH1 domains, but not GST alone.  Red arrowheads indicate the examples of non-
identical peptide binding patterns.  Green arrowheads indicate the first and the last 
peptide in each array that are listed in B.  B. A List of peptides that interact with the 
EVH1 domain of Mena, VASP or Evl.  The intensity of the spots were scored with “- “ 
and/or “+”.  The peptides with the strongest intensities are highlighted in black.    
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4.2.2 Identification of key residues in Abi required for EVH1 binding 
My data has shown that the PR2 region of Abi (residues 352-394) contains the EVH1 
binding site of Ena/VASP proteins.  To make an Abi mutant that cannot bind EVH1 with 
minimal disruption, I needed to identify key residues that are required for mediating this 
interaction within this region of Abi.   
  
Given that the length of peptide that can be synthesised on peptide array is limiting, 
generation of a peptide that spans residues 352-394 of Abi is problematic.  Therefore, 
based on my far western results, I picked three peptides, which bound strongly to the 
GST-EVH1 domain of Mena and covered residues 352-394 of Abi, and used them for 
mutational analysis (Figure 4.6A).  Each residue of the three peptides was mutated into 
the 20 different possible amino acids combinations and spotted onto a peptide array.  
Far western analysis was performed using the GST-EVH1 domain of Mena and the 
binding subsequently detected by anti-GST as described previously (Figure 4.3).  The 
results revealed that the interactions between the peptides and the GST-EVH1 domain 
of Mena was significantly reduced when the proline residues 366-368 and 383-385 as 
well as phenylalanine 375 of Abi were substituted to the majority of other amino acids 
(Figure 4.6B).  These results suggest that the two sets of proline residues as well as 
the single phenylalanine residue within the EVH1 binding site of Abi are important for 
the Abi-EVH1 interaction.   
 
However, it is noticeable that mutating the proline residues 366-368 of Abi in the first 
peptide dramatically reduced binding, whereas mutating the same proline residues in 
the second peptide had no effect on EVH1 binding (Figure 4.6B).  Similarly, in contrast 
to the effects of mutating the phenylalanine 375 of Abi in the second peptide on EVH1 
binding, no effect on EVH1 binding was observed when this phenylalanine residue of 
Abi in the third peptide was mutated (Figure 4.6B).  It is possible that these residues 
become less essential for the entire peptide to interact with the EVH1 domain when 
they are placed at the end of the peptide.   
 
Additional effects of mutating proline 369 and the following two aspartic acids of Abi in 
the first peptide but not the second peptide were observed (Figure 4.6B).  This could 
be explained by the fact that errors or defects may occur during peptide synthesis, as 
potential errors in peptide synthesis were observed in previous experiments (Figure 
4.4).  
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To confirm that the proline and phenylalanine residues in Abi identified by mutational 
analysis are important for EVH1 binding, I substituted proline 366, 367, 368, 383, 384 
and 385 with glycine residues and phenylalanine 375 with alanine (Figure 4.7A).  I then 
examined whether these substitutions disrupted the interaction between Abi peptides 
and the EVH1 domain of Ena/VASP proteins using the far western approach.  The data 
demonstrated that, in contrast to the wild type peptides, the mutated peptides were no 
longer able to bind to the EVH1 domain of any of the three Ena/VASP proteins (Figure 
4.7B).  The amino acid substitutions I designed are clearly sufficient to disrupt the 
interaction between the EVH1 domain of Ena/VASP proteins and linear peptides.  
However, these substitutions may not be sufficient to disrupt the interaction between 
the EVH1 domain and full length Abi.  Therefore, it is essential to examine the effects 
of changing these residues in Abi on EVH1 binding in the context of the full length 
protein.  To address this question, I expressed and purified full length Abi containing 
P366G, P367G and P368G substitutions (mutant 1), F375A substitution (mutant 2), 
P383G, P384G and P385G substitutions (mutant 3), mutant 1+2, mutant 1+3, mutant 
2+3 or mutant 1+2+3 with a GST tag at their N terminus (Figure 4.8A).  These 
bacterially produced mutant Abi proteins, together with the wild type Abi, were used in 
in vitro pull-down assays.  The coomassie stained gel revealed that each mutant in 
isolation was not sufficient to block the binding between Abi and EVH1 (Figure 4.8B).  
However, when any two mutants were combined, the binding of Abi to the EVH1 
domain was reduced.  The combinations of mutant 2 with either mutant 1 or mutant 3 
partially affected the interaction between Abi and EVH1 to a similar level.  In contrast, 
the interaction between Abi and EVH1 domain was significantly disrupted when mutant 
1 and 3 were combined.  The effects of mutant 1+3 on EVH1 binding are almost the 
same as the effects of combining all three mutants on EVH1 binding.  Based on these 
observations, it suggests that all three mutants are required to block the binding of Abi 
to the EVH1 domain of Mena, although mutant 1 and 3 appear to play major role in 
disrupting this interaction.  To ensure the maximum disruption of the binding between 
Abi and EVH1 for future experiments, the mutant Abi carrying all three mutants 
(P366/367/368G, F375A and P383/384/385G) (Abi mut) was used in future 
experiments.  
 






Figure 4.6 Identification of the 
essential residues in Abi for EVH1 
binding. 
A. Schematic representation of three 
overlapping peptides covering the 
EVH1 binding site in Abi that bound 
strongly to the GST-tagged EVH1 
domain of Mena.  B. Far western 
analysis of EVH1 binding on the three 
peptides shown in A.  Residues in the 
peptides were substituted each in turn 
to 20 different amino acids (columns) 
and examined for their ability to 
interact with the EVH1 domain of 
Mena.  Each of the positions in the 
array corresponded to the peptides 
that were synthesised with single 
amino acid substitutions.  The 
intensities of the spots reflect the ability 
of each mutated peptide to bind the 
EVH1 domain of Mena.  For each blot, 
the residues, which have been affected 
most on their capacities for binding 
EVH1 after substitutions, are 
highlighted in red boxes.  Proline 366-
368 of Abi in peptide 2 and 
phenylalanine 375 of Abi in peptide 3 
are indicated by red arrowheads.  
Residues 369-371 of Abi are indicated 
by red asterisks.  
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Figure 4.7 The amino acids substitutions in Abi peptides disrupt their interaction 
with the EVH1 domain of Mena. 
A. Schematic representation of the strategy for blocking the interaction between Abi 
and EVH1.  The key residues that are important to mediate the Abi-EVH1 interactions 
are highlighted in yellow.  These residues were replaced with either glycine or alanine 
(black) to generate a mutant Abi that is deficient in EVH1 binding.  B. Far western 
analyses on the peptide arrays that contain either the wild type (top panel) or the 
mutated overlapping peptides (bottom panel) covering residues 320-415 of Abi.   Each 
set of peptide arrays was probed with either GST or GST-EVH1 domain of the different 
Ena/VASP proteins.  In contrast to the wild type peptides, the mutated peptides lost 
their ability to interact with EVH1 domains.  GST and the GST-tagged recombinant 
proteins that were used as probes are indicated on the left of the arrays.  
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Figure 4.8 Abi mutant 1+2+3 is deficient in EVH1 binding. 
A. Schematic representation of 3 different sets of amino acid substitutions that were 
introduced into the bacterially produced GST-full length Abi.  The three sets of amino 
acid substitutions are referred to mutant 1, 2 and 3.  B.  Coomassie stained gel of HIS-
EVH1 pull-downs reveals that the combinations of double or triple mutants had a larger 
impact on EVH1 binding than the single substitution mutants.  Input and HIS-tagged 
EVH1 pull-down are indicated at the top of the gels.  GST and GST-tagged Abi and Abi 
mutants are indicated at the bottom of the gels. The bands corresponding to GST, 
GST-tagged Abi or its mutants, and the HIS-EVH1 domain of Mena are indicated by 
arrowheads on each side of the gels.  
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4.2.3 Abi mut is incorporated into the WAVE complex but cannot bind 
Mena 
To ensure the amino acids substitutions I created in Abi mut do not affect the ability of 
the protein to incorporate with the WAVE complex, I performed immunoprecipitation 
experiments using anti-GFP on HEK 293T cells over-expressing GFP-Abi or GFP-Abi 
mut.  As shown in Figure 4.9, GFP-Abi but not GFP-Abi mut or GFP interacted with 
Mena.  Both, GFP-Abi and GFP-Abi mut, however, pulled-down the endogenous 
PIR121 from cell lysates.  This suggests the amino acids substitutions I created in Abi 
mut only disrupt its interaction with EVH1 domains and not its capacity to associate 




Figure 4.9 Abi mut incorporates into the WAVE complex but cannot associate 
with Mena. 
Abi and Abi mut with an N-terminal GFP tag were over-expressed in HEK 293T cells.  
The GFP-tagged proteins were immunoprecipitated from cell lysates using a mouse 
monoclonal antibody against GFP.  The precipitated proteins were analysed by 
western blotting with antibodies against Mena and PIR121.  To estimate the amounts 
of over-expressed proteins, 4% of each lysate was used as the input (I).  
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4.3 Summary 
Work presented in this chapter was aimed at generating a mutant Abi that cannot bind 
Ena/VASP proteins but can still associate with the other components of the WAVE 
complex.  A far western approach was used to identify key residues, which when 
mutated, are sufficient to disrupt the interaction of Abi with EVH1.  I found that the 
EVH1 binding site is in the PR2 region of Abi by performing in vitro pull-down assays 
using recombinant proteins as well as the far western analysis on peptide arrays.  
Moreover, the amino acid substitutions that disrupt the EVH1 interaction do not affect 
the interaction between Abi and PIR121.  This mutant Abi can therefore be used in cell 
based assays to study the physiological importance of the interaction between 
Ena/VASP proteins and the WAVE complex.   
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Chapter 5. Is the interaction between Ena/VASP 




To study the physiological role of the interaction between Ena/VASP proteins and the 
WAVE complex in lamellipodia formation during cell migration, I used Rat-2 cells as the 
model system, as they have been extensively used to study the role of Ena/VASP 
proteins in lamellipodia formation and cell migration (Bear et al., 2000, Bear et al., 
2002, Krause et al., 2004, Cai et al., 2007, Cai et al., 2008).  Since Rat-2 cells are very 
difficult to transfect transiently, I generated a series of stable Rat-2 cell lines expressing 
GFP/RFP-tagged proteins using a Lentivirus system (Figure 5.1).  Using these stable 
Rat-2 cell lines, I tested if the cellular localisation of the WAVE complex is dependent 
on Ena/VASP proteins.  I also examined the effect of uncoupling Ena/VASP from the 
WAVE complex on the rate of cell migration and the turnover of each protein at the 
leading edge.  
 
5.2 Results 
5.2.1 The localisation of the WAVE complex is independent of Ena/VASP 
proteins 
I wondered whether Ena/VASP proteins play a role in recruiting the WAVE complex to 
the leading edge, as they co-localise at the plasma membrane of migrating cells 
(Boeda et al., 2007, Nozumi et al., 2003).  In order to address this question, I 
performed immunofluorescence analysis of stable Rat-2 cell lines that express either 
RFP-APPPP-mito or RFP-FPPPP-mito.  FPPPP-mito, which is derived from the ActA 
protein of Listeria, contains four FPPPP EVH1 interaction motifs and a mitochondria-
targeting domain at its C-terminus (Bear et al., 2000).  FPPPP-mito, when 
overexpressed in cells, depletes Ena/VASP proteins from the leading edge and focal 
adhesions (Disanza et al., 2006, Bear et al., 2000, Bear et al., 2002, Gates et al., 2009, 
Tucker et al., 2011, Evans et al., 2007).  APPPP-mito, which has phenylalanine to 
alanine substitution in each of the four FPPPP can no longer interact with EVH1 and 
provides a negative control (Figure 5.2).  These two constructs have been widely used 
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to sequester Ena/VASP proteins form their normal cellular locations to mitochondria 
(Bear et al., 2000, Bear et al., 2002, Gates et al., 2009, Tucker et al., 2011).   
 
Stable Rat-2 cells that express either RFP-tagged APPPP-mito or FPPPP-mito were 
established using a Lentivirus system (Figure 5.1) (Chapter 2).  The RFP-positive cells 
were sorted using fluorescence based activated cell sorting (FACS) (Figure 5.3). 
Uninfected Rat-2 cells were used as the RFP-negative control to set the gating 
parameters to ensure only RFP positive cells are collected (Figure 5.3A).  Expression 
of RFP-FPPPP-mito and RFP-APPPP-mito in the FACS sorted Rat-2 cells, (from here 
called Rat-2-RFP-FP and Rat-2-RFP-AP cells respectively), was confirmed by western 
blot analysis with an antibody against RFP (Figure 5.3B).  
 
Using Rat-2-RFP-FP and Rat-2-RFP-AP cells, I examined the role of the EVH1 domain 
in recruiting the WAVE complex to the plasma membrane by immunofluorescence 
analysis using antibodies against endogenous VASP and Abi.  An antibody that 
recognises endogenous Paxillin, a focal adhesion protein, was used as a control.  As 
shown in Figure 5.4, Paxillin and Abi were present at their normal cellular localisations 
of focal adhesions and the plasma membrane respectively, in both Rat-2-RFP-AP and 
Rat-2-RFP-FP cells.  In contrast, VASP was dramatically re-localised to mitochondria 
in Rat-2-RFP-FP cells.  This result indicates that the FPPPP-mito construct effectively 
recruits VASP and presumably Mena and Evl from focal adhesions and the plasma 
membrane to the surface of mitochondria.  However, the sequestration of VASP to 
mitochondria did not affect the cellular localisation of Abi, suggesting that the 
localisation of the WAVE complex at the plasma membrane is not dependent on 
Ena/VASP proteins.   
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Figure 5.1 Schematic representation of Lentivirus–mediated generation of stable 
Rat-2 cell lines. 
Lentivirus expression vectors pL.L 3.7 or pLVX-Puro/Hygro that contain a GFP/RFP-
tagged protein of interest (green) and the three packaging vectors: pRRE (gag-pol 
plasmid) (blue), pREV (RNA export protein) (brown), pVSV-G (virus envelope) (purple) 
were co-transfected into HEK 293T cells using a calcium phosphate method.  
Lentivirus particles encoding the GFP/RFP-tagged protein of interest are released into 
the supernatant media.  This viral-supernatant is then collected after two days, filtered 
and can then be used to infect Rat-2 cells. The lentivirus-infected cells that express 
GFP/RFP-tagged proteins were selected by FACS (Chapter 2.2.4.2) or by antibiotic 
selection (Chapter 2.2.4.3).  





Figure 5.2 Schematic representation of sequestration of Ena/VASP proteins to 
mitochondria.  
A. Schematic illustration of FPPPP-mito and APPPP-mito (control) constructs.  
FPPPP-mito, which is derived from the ActA protein of Listeria, contains four FPPPP 
EVH1 interaction motifs (purple) and a mitochondria-targeting domain (yellow) at its C-
terminus.  Adapted from (Bear et al., 2000) with the permission of Elsevier.  B.  
Schematic representation of depleting Ena/VASP proteins from the plasma membrane 
where the WAVE complex is localised by targeting them to mitochondria using RFP-
FPPPP-mito.  
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Figure 5.3 FACS sort to establish Rat-2-RFP-FP and Rat-2-RFP-AP cell lines.  
A. Bivariate dot plot of control Rat-2 cells were used to set up the gating parameters to 
select RFP-positive cells.  The cells in the pink boxes correspond to the cells that 
showed a strong RFP fluorescence signal.  For Rat-2-RFP-AP 22.9% and for Rat-2-
RFP-FP 33% of the cells were sorted as RFP-positive.  B. Immunoblot analysis 
showing that RFP-tagged proteins were expressed at the predicted size in each cell 
line. The control and RFP-positive cell lines are indicated at the top and antibodies are 
indicated on the right of the panels. Tubulin levels were used as loading control. 
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Figure 5.4 Sequestration of Ena/VASP proteins to mitochondria does not deplete 
Abi from the plasma membrane.   
A. Immunofluorescence images showing the localisations of VASP, Paxillin and Abi in 
Rat-2 control cells.  B. Overexpression of RFP-AP does not affect the normal cellular 
localisation of VASP, Paxillin and Abi in Rat-2 cells.  C.VASP, but not Paxillin or Abi is 
depleted from its normal cellular localisation by overexpressing RFP-FP in Rat-2 cells. 
Red arrowheads indicate the leading edge of cells.  Yellow arrowheads indicate 
mitochondria of cells.  The primary antibodies are indicated on the left of the panels.  
Scale bar represents 10µm. 
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5.2.2 The physiological significance of Abi-EVH1 interaction during cell 
migration 
Ena/VASP proteins and the WAVE complex are key players in the regulation of the 
actin cytoskeleton during cell migration (Chapter 1).  I therefore examined the effect of 
disrupting the binding of Abi to EVH1 on cell migration using the Abi mutant deficient in 
EVH1 binding. 
 
I generated Rat-2 cells stably expressing GFP, GFP-Abi or GFP-Abi mut using the 
lentivirus system.  GFP-positive cells were subsequently sorted using FACS (Figure 
5.5A).  Western blot analysis demonstrated that the expression of GFP-Abi and GFP-
Abi mut was much lower than GFP alone (Figure 5.5B).  Moreover, the expression 
level of GFP-Abi or GFP-Abi mut decreased rapidly at early cell passages compared 
with GFP alone, which remained stable (data not shown).  These observations suggest 
that over-expression of GFP-Abi is poorly tolerated in Rat-2 cells.  Dictyostelium cells 
lacking Abi exhibited a serious defect in cytokinesis (Pollitt and Insall, 2008).  This 
suggests that in addition to the role of the WAVE complex in regulating actin 
cytoskeleton during cell migration, the activity of the WAVE complex is required for 
cytokinesis.  Thus, alterations in the expression level of Abi may cause cell stress or 
inhibit cell division and survival.  If GFP-Abi expressing Rat-2 cells are unable to 
properly undergo cytokinesis, then cells expressing higher levels of GFP-Abi may 
either undergo apoptosis or attempt to survive by down regulating the expression of 
GFP-Abi.  All these possibilities could contribute to the poor expression of GFP-Abi 
constructs in Rat-2 cells as well as the rapid loss of signal in the stable Rat-2 cells 
lines.  To over come the problem of losing GFP/RFP-tagged Abi expression at early 
cell passages, all the GFP/RFP-positive cells were amplified and further sorted at least 
two more rounds by FACS.  Only the data from the last FACS sort for each of the Rat-2 
stable cell lines expressing GFP/RFP-tagged Abi is shown.  
 
To ensure the over-expressed GFP-Abi and Abi mut can still co-localise with other 
components of the WAVE complex at the plasma membrane in Rat-2 cells, I performed 
immunofluorescence analysis using antibodies against endogenous Abi, Nap1 and 
WAVE.  This immunofluorescence analysis demonstrated that GFP-Abi and GFP-Abi 
mut but not GFP alone, co-localise with endogenous Nap1 and WAVE, suggesting that 
the overexpressed GFP-tagged proteins retain their capacity to interact with the rest of 
the WAVE complex (Figure 5.6A).  This suggestion was confirmed by performing 
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immunoprecipitation using anti-GFP and antibodies against endogenous PIR121 
(Figure 5.6B).  My data demonstrate that exogenously expressed GFP-Abi and its 
mutant is incorporated into the WAVE complex and localises to the plasma membrane 
in my stable Rat-2 cell lines.    
 
Using these stable Rat-2 cell lines, I performed single cell-tracking assays using time-
lapse imaging to examine whether there are any differences in the migration of cells 
that expressing GFP-Abi or GFP-Abi mut.  The parental Rat-2 cells and GFP-
expressing cells were used as controls in these experiments.  The data from the single 
cell-tracking assays, in which 30 cells were tracked, demonstrate that the GFP-Abi mut 
expressing cells migrate at a slightly higher velocity than the GFP-Abi expressing cells 
(Figure 5.7B).  However, the difference between the two cell populations was not 
statistically significant (Figure 5.7B).  Additionally, no differences in directionality or 
persistency during migration were observed (Figure 5.7A,C).  My analysis reveals that 
there is no obvious alteration in migration of Rat-2 cells when GFP-Abi mut is 
overexpressed as compared to wild type Abi. 
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Figure 5.5 FACS sort to establish GFP, GFP-Abi and GFP-Abi mut Rat-2 cell lines.   
A. Bivariate dot plot showing GFP-positive cells (inside the red box) in each cell 
population that were collected.  More cells expressing GFP alone were collected than 
cells expressing either GFP-Abi or GFP-Abi mut.  Control Rat-2 cells were used to set 
up the gating parameters to select GFP-positive cells only (data not shown).  B. 
Immunoblot analysis showing that GFP-tagged and endogenous Abi were expressed 
at the predicted size in each cell line.  The control and GFP-positive cell lines are 
indicated at the top of the panels and the antibodies are indicated on the right of the 
panels.  Tubulin levels were used as loading control. 
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Figure 5.6 GFP-Abi  is incorporated into the WAVE complex in Rat-2 cells.  
A. Immunofluorescence analysis demonstrating that GFP-Abi and GFP-Abi mut, but 
not GFP, are recruited to the leading edge of Rat-2 cells, where they co-localise with 
endogenous Nap1 and WAVE.  Scale bar represents 10 µm.  B. Immunoprecipitation 
analysis reveals that endogenous PIR121 can be retained by GFP-Abi and GFP-Abi 
mut, but not GFP from Rat-2 cell lysates.  4% of each lysate was used as input.   
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Figure 5.7 Uncoupling Ena/VASP proteins from the WAVE complex does not 
effect cell migration.  
A.  Representative centroid plots showing the trajectory of Rat-2 cells with and without 
expression of GFP, GFP-Abi and GFP-Abi mut over 15 hr.  Scale unit is µm.  B. 
Analysis of migration speeds of the four cell lines from A. A One Way ANOVA test was 
performed and the P value was found to be <0.01.  C. Quantitative analysis of the 
migration persistence of the four cell lines.  A One Way ANOVA test was performed 
and the P value was found to be <0.05.  In B and C, a Newman-Keuls multiple 
comparison test was performed for paired comparisons after the One Way ANOVA test 
found means to be significantly different.  *indicates P<0.05; **indicates P<0.01;  ns 
indicates no significance.  The data presented in this figure was collected from 3 
independent experiments, in which 30 cells from each group were tracked.  Bars 
represent the mean +/- SEM.  n =  30.  
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5.2.3 Ena/VASP proteins stabilise the WAVE complex at the plasma 
membrane 
My data suggest that Abi-EVH1 interactions neither affect the cellular localisation of the 
WAVE complex nor play a role in regulating the rate of cell migration.  To test if 
Ena/VASP proteins affect the dynamics of the WAVE complex at the leading edge, I 
performed fluorescence recovery after photobleaching (FRAP) analysis using my 
stable Rat-2 cells lines (Figure 5.5).  
 
FRAP is an optical technique that was first established in 1985 and has been used 
successfully to study the turnover of proteins in the leading edge of migrating cells (Lai 
et al., 2008, Wang, 1985).  FRAP is based on selectively photobleaching fluorescently 
tagged-proteins within a selected region in a live cell and then measuring the 
reappearance of fluorescently tagged-proteins into the selected region.   The rate, at 
which non-photobleached fluorescently tagged-proteins reappear within the 
photobleached region, reflects the turnover or exchange rate of the protein in this 
region of the cell (Figure 5.8).  FRAP is therefore a powerful tool to study the dynamics 
of proteins in living cells.  The key for performing a successful FRAP assay is to 
acquire as many time points as possible after rapid photobleaching while avoiding 
photobleaching damage that affects the cell.  To achieve optimal conditions to analyse 
the turnover rate of GFP-Abi at the leading edge of Rat-2 cells, several imaging 
parameters and photobleaching parameters (laser power and times of iteration) were 
tested with the assistance from the light microscopy facility at Cancer Research UK 
(Chapter 2.5.4).   
 
As shown in Figure 5.9, both, GFP-Abi and GFP-Abi mut fully recovered to ~100% 
after photobleaching within 20 seconds, suggesting these proteins are highly dynamic 
and turnover in a time scale of seconds.  Interestingly, the red curve that represents 
the turnover rate of GFP-Abi mut is shifted slightly to the left compared to the curve 
corresponding to GFP-Abi.  This suggests the Abi mut turns over faster than Abi.  
Importantly, the difference in the turnover rates between GFP-Abi and GFP-Abi mut is 
statistically significant (Figure 5.9B).  My FRAP results suggest that the WAVE 
complex becomes more dynamic after being uncoupled from Ena/VASP proteins at the 
plasma membrane.  
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To further study the effects of uncoupling Ena/VASP proteins on the dynamics of the 
WAVE complex at the cell plasma membrane, I also performed FRAP analysis using 
Rat-2 cell lines that express GFP-Abi with either RFP-AP or RFP-FP.  My aim was to 
determine the turnover rates of GFP-Abi at the plasma membrane using FRAP in the 
presence or absence of Ena/VASP.  To generate these new cell lines, I expressed 
GFP-Abi in the Rat-2-RFP-FP and Rat-2-RFP-AP cell lines that I established earlier 
(Figure 5.3).  The GFP-positive Rat-2 cells stably expressing RFP-tagged proteins 
were subsequently sorted using FACS (Figure 5.10A).  Moreover, the expression of the 
GFP and RFP-tagged proteins in these new Rat-2 cell lines was confirmed by western 
blot analysis using antibodies against GFP and RFP (Figure 5.10B).   
 
FRAP analysis using my Rat-2 cell lines stably expressing GFP-Abi with either RFP-FP 
or RFP-AP revealed that the turnover rate of GFP-Abi at the plasma membrane was 
not affected by the presence of Ena/VASP proteins at the plasma membrane (the black 
and red curves overlap; Figure 5.11).  This result was unexpected, as I found that 
uncoupling Ena/VASP proteins from Abi reduced the turnover rate of Abi at the plasma 
membrane.  Depletion of Ena/VASP proteins from the plasma membrane is therefore 
expected to have a similar or greater effect on the turnover rate of Abi.  However, 
sequestration of Ena/VASP proteins from their normal cellular localisations to the 
surface of mitochondria will not only disrupt their interaction with Abi, but will also 
disrupt interactions with other proteins at both focal adhesion and the plasma 
membrane.  Loss of Ena/VASP proteins will also affect actin dynamics at the leading 
edge (Bear et al., 2000, Bear et al., 2002, Tucker et al., 2011).  I can only assume that 
the global effects of depleting Ena/VASP proteins from their normal cellular 
localisations may mask or cancel out the effect of disrupting the interaction between 
Ena/VASP proteins and Abi on the dynamics of the WAVE complex at the plasma 
membrane.   
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Figure 5.8 Analysis of GFP-Abi dynamics at the plasma membrane using FRAP.  
A. Movie stills showing the recovery over time of GFP-Abi after photobleaching in the 
selected area (red box).  Time points after photobleaching are indicated at the top of 
the panels.  Scale bar represents 2µm.  B. Schematic of normalised data collected 
during an idealised FRAP experiment.  The fluorescence intensity in the photobleached 
area (Y-axis) is plotted over time (X-axis).  The steeper the curve, the faster the 
recovery, which means the protein is more dynamic.  Imax represents the fluorescence 
intensity when the signal reaches a plateau phase after recovery.  I1/2 represents the 
fluorescence intensity reaches half of the final recovered intensity.  Imin represents the 
remaining fluorescence intensity after photobleaching.  t0 represents the first time point 
after photobleaching.  t1/2 represents the time point when the fluorescence intensity 
reaches half of the final recovered intensity.  C. The rate constant of recovery (k) was 
calculated using the non-linear regression curve-fitting formula in the Prism software. 
t1/2 was calculated from the value of k.   
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Figure 5.9 Ena/VASP proteins stabilise the WAVE complex at the plasma 
membrane.  
A. The graph illustrates the recovery rates of GFP-Abi (black) and GFP-Abi mut (red) 
at the plasma membrane after photobleaching.  Intensity values of the GFP-tagged 
proteins were normalised to the pre-bleached intensity values.  Linear curves 
correspond to best fits of averaged data obtained from 30 data sets. Bars represent the 
SEM.  n =  30.  B. The table lists the values derived from 30 fitted recovery curves 
together with the SEM for the percentage, rate constant and half-time of recovery of 
GFP-tagged Abi as well as Abi mut in Rat-2 cells. *** indicates P<0.001. 
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Figure 5.10 FACS sort to establish RFP-AP/GFP-Abi and RFP-FP/GFP-Abi Rat-2 
cell lines.  
A. Bivariate dot plot showing control Rat-2 cells that were used to set up the gating 
parameters to select GFP-positive cells.  The cells in the bottom pink box represent the 
background fluorescence of GFP negative cells and 99.9% of cells are in this range.  
Only cells which showed a strong fluorescence signal (top pink box) were sorted.  For 
RFP-AP/GFP-Abi 36.8% and for RFP-FP/GFP-Abi 28.6% of the cells were sorted as 
GFP-positive.  B. Immunoblot analysis revealing that the GFP and RFP-tagged 
proteins were expressed at the predicted size in each cell line.  The bands that are 
indicated by red asterisks are likely to be RFP-tagged proteins, as the GFP antibody 
may also weakly recognise RFP.  The different cell lines are indicated at the top of the 
panels.  GFP/RFP-tagged proteins and antibodies are indicated on the right of the 
panels.  Tubulin levels were used as loading control.  
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Figure 5.11 Loss of Ena/VASP proteins from the leading edge does not affect the 
dynamics of Abi.  
A. The graph illustrating the recovery rate of GFP-Abi at the plasma membrane after 
photobleaching in cells expressing either RFP-AP (black) or RFP-FP (red).  Intensity 
values of the GFP-Abi were normalised to the pre-bleached intensity value.  Linear 
curves corresponded to best fits of averaged data.  Bars represent the SEM and n =  
20.  B. The table lists the values derived from 20 fitted recovery curves together with 
the SEM, for the percentage, rate constant and half time of recovery of GFP-Abi in the 
presence of the indicated RFP-tagged protein.  
  155 
 
5.2.4 The WAVE complex may help stabilise Ena/VASP proteins at the 
plasma membrane 
I next wanted to ask if the WAVE complex plays a role in regulating the dynamics of 
Ena/VASP proteins at the plasma membrane.  In order to address this question, I 
generated stable Rat-2 cell lines that co-express GFP-VASP with either Abi-RFP or Abi 
mut-RFP.  For these lines I used lentivirus system, in which the expression vectors 
(pLVX-Puromycin and pLVX-IRES-Hygromycin) also contain an antibiotic resistant 
cassette to allow for antibiotic selection of cells expressing my protein of interest 
(Chapter 2.2.4.3).  In contrast to the stable expression of GFP-VASP, I found that 
expression of Abi-RFP and Abi mut-RFP in Rat-2 cells rapidly decreased with three 
days despite continuous selection with antibiotics (data not shown).  This observation 
is consistent with my previous observations on the stability of GFP-Abi expression in 
Rat-2 cells and again suggest that overexpression of Abi is poorly tolerated.  To 
overcome this problem, GFP and RFP-positive cells were again re-selected using 
FACS after antibiotic selection and cell amplification (Figure 5.12A).  Due to the limited 
numbers of cells, co-expression of GFP-VASP and Abi-RFP in Rat-2 cells is illustrated 
by fluorescence microscopy rather than western blot analysis (Figure 5.12B).   
 
FRAP analysis using these stable cell lines demonstrated that there was a small but 
significant reduction in the turnover rate of the GFP-VASP in the presence of Abi mut-
RFP compared to Abi-RFP (Figure 5.13).  My FRAP data suggests that an interaction 
with the WAVE complex increases the dynamics of GFP-VASP at the plasma 
membrane.  By contrast, my previous FRAP data indicates Ena/VASP proteins 
stabilise the WAVE complex at the plasma membrane (Figure 5.9).  Taken together, 
my data suggests that Ena/VASP proteins and the WAVE complex might regulate the 
dynamics of each other at the plasma membrane.  
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Figure 5.12 FACS sort to establish Abi-RFP/GFP-VASP and Abi mut-RFP/GFP-
VASP Rat-2 cell lines.  
A. Bivariate dot plot showing control Rat-2 cells that were used to set up the gating 
parameters to select RFP and GFP-positive cells.  The cells in the bottom pink box 
represent the background fluorescence of RFP negative cells and 98.9% of cells are in 
this range.  Only cells which showed a strong signal for both RFP and GFP (top pink 
box) were sorted.  For Abi-RFP/GFP-VASP 1.6% and for Abi mut-RFP/GFP-VASP 
1.97% of the cells were sorted as RFP and GFP-positive.  B. The GFP and RFP-
positive cells were fixed and analysed by fluorescence microscopy.  GFP-VASP and 
Abi-RFP localised at their predicated cellular localisations.  Cell lines are indicated on 
the side of the panels.  The fluorescence channels that were used are indicated on the 
top of the panels.  Scale bar represents 10 µm. 
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Figure 5.13 The WAVE complex regulates the turnover of Ena/VASP proteins at 
the plasma membrane.  
A. The graph illustrating the recovery rate of GFP-VASP at the plasma membrane after 
photobleaching in cells expressing either Abi-RFP (black) or Abi mut-RFP (red).  
Intensity values of the GFP-VASP were normalised to the pre-bleached intensity value.  
Linear curves corresponded to best fits of averaged data.  Bars represent the SEM and 
n = 20.  B.  The table lists the values derived from 20 fitted recovery curves together 
with the SEM, for the percentage, rate constant and half time of recovery of GFP-VASP 
in the presence of the indicated RFP-tagged protein.  *** indicates P<0.001 
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5.2.5 Knockdown of endogenous Abi proteins in Rat-2 cells is 
problematic  
My FRAP analysis established that the GFP-Abi mut is more dynamic at the leading 
edge compared with GFP-Abi (Figure 5.9).  In contrast, GFP-VASP is less dynamic 
when it was co-expressed with the Abi mut-RFP.  However, single cell tracking assays 
showed that the overexpression of the GFP-Abi mut did not lead to a major difference 
in the rate of cell migration.  It may be that the absence of a migration phenotype for 
the GFP or RFP-tagged Abi mut is masked by the presence of endogenous Abi.  I 
therefore aimed to repeat all my previous experiments using my Rat-2 cell lines that 
lack endogenous Abi.   
 
To deplete endogenous Abi in Rat-2 cells, I needed to know how many Abi isoforms 
are present in this cell line, as mammals express three Abi isoforms (Hirao et al., 
2006).  To address this question, I performed quantitative real-time polymerase chain 
reaction (qRT-PCR).  The results revealed that Rat-2 cells expressed all three Abi 
isoforms (Figure 5.14A).  The amount of Abi1 mRNA was almost 3.5 times more than 
that of Abi3.  The Abi 2 mRNA was more than double that of Abi3.  While mRNA levels 
do not immediately predict protein levels, it is likely that Abi1 represents the most 
abundant isoform in Rat-2 cells.  Importantly, all three Abi isoforms are known to 
interact with Mena and WAVE (Hirao et al., 2006).  Therefore, in order to obtain a 
clearer phenotype of overexpressed GFP or RFP-tagged Abi mut, RNAi knockdown of 
all three endogenous Abi isoforms in Rat-2 cells was required. 
 
Small interfering RNA (siRNA) oligonucleotides, which do not target GFP or RFP 
tagged human Abi and Abi mut, were used to knockdown each Abi isoform in Rat-2 
cells.  The efficiency of each siRNA oligonucleotide to deplete the different Abi 
isoforms was examined in Rat-2 cells.  The best siRNA oligonucleotide for each Abi 
isoform would then be combined to generate a siRNA pool, which could be used to 
simultaneously knockdown all three Abi isoforms in the GFP or RFP-tagged Abi 
expressing Rat-2 cells.  Due to a lack of antibodies that recognise the three different 
Abi isoforms, qRT-PCR was performed to determine the changes in mRNA level of 
each of isoform in Rat-2 cells.  The mRNA level of β-actin was used as the internal 
control.  Even after many attempts, I found no statistically significant decrease in the 
mRNA level of any Abi isoform when cells were treated with the appropriate siRNA 
(Figure 5.14).  Given this and the lack of suitable antibodies to detect all three Abi 
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isoforms, I abandoned the knockdown of endogenous Abi isoforms in Rat-2 cells using 




Figure 5.14 siRNA depletion of 3 Abi isoforms in Rat-2 cells.  
A. The qRT-PCR reveals the mRNA levels of three Abi isoforms in Rat-2 cells, which 
were normalised to the mRNA level of β-actin.  B-D. The qRT-PCR analyses show that 
the normalised mRNA expressions of three Abi isoforms in Rat-2 cells when the cells 
were treated with different siRNA oligonucleotides that target specific Abi isoforms.  
The mRNA levels of Abi isoforms in cells that were treated with non-targeting siRNA 
oligonucleotides were used as control.  Rat-2 Abi isoforms are indicated in each bar 
chart.  siRNA oligonucleotides used are indicated at the bottom of each bar chart.  
Bars represent the SEM.  n = 3. 
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5.3 Summary 
In order to study the physiological importance of the interaction between Ena/VASP 
proteins and the WAVE complex in regulating the actin cytoskeleton during cell 
migration, I generated a series of stable Rat-2 cell lines expressing GFP or RFP-
tagged proteins using a lentivirus system.  Immunofluorescence analysis revealed that 
Ena/VASP proteins did not drive plasma membrane targeting of the WAVE complex.  
Moreover, time-lapse live cell imaging did not show any significant effects of over-
expressing GFP-Abi mut on the migration of Rat-2 cells.  FRAP analysis, however, 
demonstrated that uncoupling Abi from EVH1 increased the dynamics of the WAVE 
complex but decreased the dynamics of Ena/VASP proteins at the plasma membrane.  
This suggests a negative feedback loop might be involved in regulating the dynamics 
of the two groups of proteins at the plasma memberane.  To try and obtain a clearer 
phenotype from overexpressing Abi mut in Rat-2 cell, it is likely that depletion of the 
endogenous Abi isoforms will be required.  However, RNAi knockdown of the all three 
endogenous Abi isoforms in Rat-2 cells proved unsuccessful.  I therefore decided to 
investigate the physiological significance of Abi-EVH1 interaction in regulation of actin 
cytoskeleton using a different model system, which is more amenable to RNAi 
techniques and only expresses one Abi isoform.  
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Chapter 6. Characterisation of the interaction 
between Ena and the WAVE complex in Drosophila 
haemocytes 
6.1 Introduction 
Given that depletion of the three Abi isoforms in Rat-2 cells is problematic (Figure 5.14) 
and antibodies that recognise specific Abi isoforms are currently unavailable, I decided 
to investigate the interplay between Ena/VASP proteins and the WAVE complex using 
Drosophila S2 and S2R+ cells.  S2 cell lines were originally derived from an embryonic 
macrophage-like lineage in Drosophila (Schneider, 1972).  The S2R+ cell line, which is 
positive for the Wingless (Wg) receptor, was subsequently identified and characterised 
(Yanagawa et al., 1998).  This is an easier cellular system to study the potential role of 
this interaction as Drosophila only express one Abi isoform (dAbi) and one Ena 
(Drosophila homologue of Mena).  Moreover, both, Drosophila S2 and S2R+ cells have 
been widely used to study lamellipodial dynamics (LeClaire et al., 2008, Biyasheva et 
al., 2004, Jovceva et al., 2007, Iwasa and Mullins, 2007, Kim et al., 2011).  Although 
the EVH1 domain of Ena/VASP proteins is highly conserved from fly to human, 
Drosophila Abi and human Abi (hAbi) have significantly less sequence similarity 
(Figure 6.1).  Given the differences between the proline rich regions in human and 
Drosophila Abi, it is difficult to predict the location of the EVH1 binding site in dAbi 
based on the location of the EVH1 binding site in hAbi.  Therefore, to generate a 
mutant dAbi that is deficient in EVH1 binding, I used similar biochemical approaches to 
those used to generate the hAbi mutant (Chapter 4).  This dAbi mutant was then used 
to study the physiological importance of the dAbi-EVH1 interaction in Drosophila S2 
and S2R+ cells that had been depleted of endogenous dAbi using dsRNA.   
 
6.2 Results 
6.2.1 Generation of a mutant dAbi that is deficient in EVH1 binding 
Given that the far western analysis of peptide arrays was successfully used to identify 
the EVH1 binding site in hAbi, the same approach was used to map the EVH1 binding 
site in dAbi.  A peptide array was generated by the peptide service facility at Cancer 
Research UK, which contained a series of overlapping peptides 20 amino acid 
residues in length, and covering the full length of dAbi.  The GST-EVH1 domain of Ena 
from Drosophila was expressed and purified in bacteria and used as a probe.  Potential 
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interactions between peptides and the EVH1 domain were subsequently detected by 
GST antibodies as previously described (Figure 4.3B).  As shown in Figure 6.2A, two 
regions in the C-terminal half of dAbi which both contain a single LPPPP motif were 
detected by GST antibodies.  This suggests that these two LPPPP-containing regions 
of dAbi may be responsible for EVH1 binding.  This data was confirmed by repeating 
the far western analysis on peptide arrays covering only the C-terminus of dAbi 
(residues 291-429), which includes the two potential EVH1 binding sites.  In addition to 
using GST-EVH1 of Ena as a probe, purified GST alone was used as a negative 
control probe in this second assay.  The results from this second experiment 
highlighted the same peptides that were detected in the previous array (Figure 6.2A).  
These peptides were detected only by GST-EVH1 and not GST (Figure 6.2B).  Similar 
to my results from previous far western analyses (Figure 4.4), discontinuous detections 
of overlapping peptides was also observed with dAbi (Figure 6.2A, B).  This may be 
due to errors or the efficiency of peptide synthesis.  Taken together, my results suggest 
that residues 301-322 and 362-387 of dAbi are potential sites for EVH1 binding (Figure 
6.2 C). 
 
Given that the length of peptide that can be synthesised on a peptide array is limiting, 
generation of a peptide that covers the entire EVH1 binding site of dAbi is problematic.  
Therefore, to identify residues within the EVH1 binding sites of dAbi that are essential 
for EVH1 binding, I selected two dAbi peptides that bound strongly to the EVH1 domain 
of Ena (Figure 6.3A).  Each amino acid position in the two peptides was sequentially 
mutated into the possible 20 different amino acids and spotted on to a peptide array.  
The peptide arrays with the mutated peptides were probed with GST-EVH1 of Ena and 
binding subsequently detected using GST antibodies.  As shown in Figure 6.3B, 
substituting any of the residues in the LPPPP motifs for alternative amino acids 
significantly disrupted binding between the peptides and the EVH1 domain. These 
results suggest that these two LPPPP motifs are key residues for mediating the 
interaction between dAbi and EVH1.   
 
Additionally, mutating the proline immediately after the LPPPP motif or mutating any of 
the last three amino acids in peptide 1 dramatically reduced binding (Figure 6.3B).  In 
contrast, mutating the proline at the position after the LPPPP motif in peptide 2 had 
minimal effects on EVH1 binding.  The different effects of mutating the proline 
immediately after the LPPPP motif on EVH1 binding between peptide 1 and 2 may be 
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due to the different sequences that are present downstream of this proline residue in 
these two peptides.  For peptide 1, it should be noted that all the spots for the last two 
aspartic acids (last two rows) appear to be weaker (Figure 6.3B).  This can be seen in 
the intensity of the spots where the aspartic acids remain unchanged, when compared 
to other spots representing unchanged residues.  Therefore, it is likely that the 
decrease in binding seen when mutating any of these residues may be due to errors 
during peptide synthesis.  However, it is curious that changing downstream acidic 
residues in both human and Drosophila Abi does seem to have an effect on EVH1 
binding.  
 
Identification of the two LPPPP motifs as being involved in EVH1 binding is consistent 
with previous studies that demonstrate FPPPP motifs as the classical binding motif for 
the EVH1 domain of Ena/VASP proteins (Niebuhr et al., 1997, Ball et al., 2000, Carl et 
al., 1999).  Therefore, I hypothesised that the interaction between dAbi and the EVH1 
domain of Ena is mediated by the two LPPPP motifs in dAbi.  To test my hypothesis, I 
generated mutant dAbi, in which the first, second or both LPPPP motifs were 
substituted with “AGGGG” (Figure 6.4A).  I then used these mutants to examine their 
effects on the dAbi-EVH1 interaction.  Initially, I tried to perform in vitro pull-down 
assays with bacterially produced proteins.  However, production of recombinant dAbi in 
bacteria proved unsuccessful, as no expression of dAbi with either GST or HIS tag in 
E. coli was observed (data not shown).  I therefore performed pull-down assays on 
lysates from HEK 293T cells overexpressing dAbi containing the different mutations 
tagged at their N-terminus with GFP using the bacterially produced GST-EVH1 domain 
of Ena.  Cell lysates with expressed GFP and GFP-dAbi were used as negative and 
positive controls respectively.  Western blot analysis with a GFP antibody revealed that 
the GST-EVH1 domain of Ena but not GST alone retained GFP-dAbi but not GFP from 
cell lysates.  In contrast, the GST-EVH1 domain of Ena only partially retained GFP-
dAbi containing mutant 1 and was unable to retain dAbi containing either mutant 2 or 
both mutants (Figure 6.4B).  These results suggest that both of the mutants affect 
binding of dAbi to the EVH1 domain of Ena, although mutating the second LPPPP 
motif at position 374-378 gives the greatest effect. To ensure a complete absence of 
interaction between dAbi and EVH1, a mutant dAbi that carries both sets of amino 
acids substitutions (L311A/P312G/P313G/P314G/P315G/ and 
L374A/P375G/P376G/P377G/P378G) is referred to as dAbi mut and used in future 
experiments. 
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To ensure overexpressed GFP-tagged dAbi and dAbi mut could still co-localise with 
other components of the WAVE complex at the plasma membrane, I performed 
immunofluorescence analysis using antibodies against endogenous SCAR (Drosophila 
homologue of WAVE) on S2 cells expressing GFP, dAbi-GFP or dAbi mut-GFP.  DAbi-
GFP and dAbi mut-GFP but not GFP alone co-localised with endogenous SCAR 
(Figure 6.5A).  This suggests that overexpressed dAbi-GFP and dAbi mut-GFP retain 
their capacity to interact with rest of the WAVE complex.  This suggestion was 
confirmed through immunoprecipitation using anti-GFP and antibodies against 
endogenous SCAR (Figure 6.5B).  The same experiments were repeated using S2R+ 
cells.  Results from experiments using S2R+ cells are consistent with those from S2 
cells (Figure 6.6).  Taken together, my data indicate that exogenously expressed dAbi-
GFP and dAbi mut-GFP are properly incorporated into the WAVE complex in S2 cells 
and S2R+ cells.   
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Figure 6.1 Sequence conservation of Drosophila and human Abi and the EVH1 
domain of Mena/Ena. 
A. Alignment of the sequence of human Abi (hAbi) and Drosophila (dAbi). Conserved 
amino acids are highlighted in yellow.  B. Alignment of the EVH1 sequences of human 
Mena and Drosophila Ena.  Conserved amino acids are highlighted in yellow.  The 
conserved aromatic residues binding FPPPP ligands are indicated in red.  C. The 
divergence and identity between the sequences of human Abi and Drosophila Abi.  D. 
The divergence and identity between the EVH1 sequences of human Mena and 
Drosophila Ena.  Figure was generated using ClustalW2-Multiple Sequence Alignment 
(EMBL-EBL).     
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Figure 6.2 Residues 301-322 and 362-387 of dAbi can bind the EVH1 domain of 
Ena.  
A.  Far western analysis of a peptide array that contains overlapping peptides covering 
full length dAbi.  Black spots highlight an interaction between a peptide and the GST-
EVH1 domain of Ena.  The spots that cover residues 301-322 and 362-387 in the 
proline rich region of dAbi are highlighted by red boxes.  B. Far western analyses of 
peptide arrays that contain overlapping peptides covering residues 291-429 of dAbi.  
Black sports represent peptides that bound the GST-EVH1 domain of Ena.  No black 
spots were observed in the peptide array that was probed with GST.  Red boxes in 
both arrays indicate the positions of the peptides that cover residues 301-322 and 362-
387 of dAbi.  Red arrowheads indicate non-specific binding peptides.  C. Schematic 
representation of the peptides of dAbi that bind the EVH1 domain of Ena.  The 
sequence of the EVH1 binding sites in dAbi is indicated in red.  Each line represents a 
peptide of 20 amino acids, which partially covers the EVH1 binding site in dAbi.  The 
colours of the lines from darkest (black) to lightest (light grey) reflect the binding 
intensities observed in the peptide arrays. 
 




Figure 6.3 Identification of the residues in dAbi required for EVH1 binding. 
A. Schematic representation of two peptides from dAbi that bound strongly to the GST-
EVH1 domain of Ena.  B. Residues in the two selected peptides were substituted in 
turn to the 20 different amino acids and examined for their interaction with the EVH1 
domain of Ena. The intensities of the spots represent the comparative binding affinities 
of each mutated peptide to the EVH1 domain of Ena.  The residues, which have largely 
lost the capacity to bind EVH1, are highlighted in red boxes.  Red arrowheads indicate 
other residues that have also been also affected after substitution, although this may 
be due to problems in peptide synthesis.  
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Figure 6.4 Mutation of LPPPP motifs in dAbi disrupts EVH1 binding. 
A. Schematic representation of dAbi and LPPPP motif substitutions.  The LPPPP 
motifs that mediate EVH1 interactions are highlighted in yellow.  These residues were 
substituted to either glycine or alanine (black) to generate the indicated dAbi mutants.  
B. Immunoblot analysis of pull-downs using the GST-EVH1 domain of Ena (right panel) 
or GST alone (left panel) incubated with cell lysates containing GFP, GFP-tagged dAbi 
or dAbi mutants 1, 2 or 1+2.  The input (I) and bound (B) samples with their respective 
GFP-tagged proteins are indicated.  The Ponceau S stain shows equivalent amounts of 
GST and GST-EVH1 domain of Ena were present on the resin.  
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Figure 6.5 dAbi-GFP is incorporated into the WAVE complex in S2 cells.  
A. Immunofluorescence analysis demonstrating that dAbi-GFP, dAbi mut-GFP but not 
GFP, are recruited to the plasma membrane of S2 cells, where they co-localise with 
endogenous SCAR.  Scale bar represents 10µm.  B. Immunoprecipitation analysis 
revealing that endogenous SCAR associates with dAbi-GFP, dAbi mut-GFP but not 
GFP in S2 cell lysates.  4% of each lysate was used as input.   
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Figure 6.6 dAbi-GFP is incorporated into the WAVE complex in S2R+cells.  
A. Immunofluorescence analysis demonstrating that dAbi-GFP, dAbi mut-GFP but not 
GFP, are recruited to the plasma membrane of S2R+ cells, where they co-localise with 
endogenous SCAR.  Scale bar represents 10µm.  B. immunoprecipitation analysis 
revealing that endogenous SCAR associates with dAbi-GFP, dAbi mut-GFP but not 
GFP in S2R+cell lysates.  4% of each lysate was used as input.   
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6.2.2 S2 and S2R+ cells lacking dAbi have defects in lamellipodia 
formation 
Large double stranded RNA (dsRNA) has been successfully used to suppress gene 
expression in Drosophila haemocytes (Clemens et al., 2000, Kiger et al., 2003, Liu et 
al., 2009b).  To inhibit the expression of endogenous dAbi in S2 and S2R+ cells, I 
generated dsRNAs that targeted either the opening reading frame of dAbi (ORF) or the 
3 prime untranslated region of dAbi (3’UTR) (Chapter 2.2.3.2).  The ORF dsRNA, 
which is able to target both exogenous dAbi-GFP and endogenous dAbi, was used as 
a control to avoid unexpected off-target effects.  In contrast, the 3’UTR dsRNA, which 
can only target dAbi and not dAbi-GFP, was used to reduce expression of endogenous 
dAbi in S2 and S2R+ cells (Figure 6.7).  In addition, dsRNA that suppresses Drosophila 
β-galactosidase (LacZ) expression was also generated and used as negative control 
(Chapter 2.2.3.2).   
 
To verify the knockdown efficiency in S2 cells, I performed western blot analysis using 
an antibody that recognises endogenous dAbi on cell lysates derived from either non-
transfected S2 cells or S2 cells expressing dAbi-GFP.  LacZ dsRNA treated cells and 
non-dsRNA treated cells (mock) were used as controls.  Western blot analysis 
revealed that the ORF dsRNA knocked down both the expression of endogenous dAbi 
and dAbi-GFP effectively.  In contrast, the 3’UTR dsRNA only reduced expression of 
the endogenous dAbi (Figure 6.8A).  Furthermore, qRT-PCR analysis also confirmed 
that both, ORF and 3’UTR dsRNA but not LacZ dsRNA are able to reduce the mRNA 
levels of the endogenous dAbi (Figure 6.8B).  My results show that the 3’UTR dsRNA I 
generated can suppress the expression of endogenous dAbi but not that of dAbi-GFP 
in S2 cells. 
 
To examine the phenotype of S2 cells lacking endogenous dAbi, I stained cells with 
phalloidin, which labels actin filaments.  In contrast to LacZ dsRNA treated cells, which 
exhibited normal lamellipodia, both, the ORF and 3’UTR dsRNA transfected cells 
showed severe defects in lamellipodia formation and had spikey morphologies (Figure 
6.8C).  This appearance is consistent with previous results (Huang et al., 2007) and 
confirms that dAbi plays a central role in lamellipodia formation in S2 cells.  
 
Using similar approaches, the knockdown efficiency of dAbi in S2R+ cells and the 
resulting phenotype were examined.  As observed in S2 cells, the expression levels of 
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endogenous dAbi and exogenously expressed dAbi-GFP were both reduced 
significantly by treating the S2R+ cells with the ORF dsRNA (Figure 6.9A, B).  In 
addition, the 3’UTR dsRNA was only able to knock down endogenous dAbi (Figure 
6.9A, B).  Moreover, S2R+ cells lacking endogenous dAbi exhibited similar defects in 
lamellipodia formation as observed in ORF/3’UTR treated S2 cells (Figure 6.9C). 
 
Given my results, I was now ready to study the significance of the interaction between 
Ena and the WAVE complex in S2 and S2R+ cells lacking endogenous dAbi using my 
dAbi mutant that is deficient in EVH1 binding. 
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Figure 6.7 Schematic representation of dsRNA targeting the ORF or 3’UTR of 
dAbi. 
Individual DNA fragments corresponding to the ORF or the 3’UTR of dAbi were 
amplified from a Drosophila cDNA library by using PCR.  Each primer used in the PCR 
contains a 5 prime T7 RNA polymerase-binding site followed by sequences for the 
targeted gene (not shown).  The resulting DNA fragments were used as templates for 
ssRNA synthesis using a transcription T7 kit.  The ssRNAs were annealed to generate 
the dsRNA (Chapter 2.2.3.2). The dsRNA, which recognises the ORF of dAbi (red), 
targets both dAbi-GFP and endogenous dAbi.  The dsRNA, which recognises the 
3’UTR of dAbi (purple), only targets endogenous dAbi.  
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Figure 6.8 Knockdown of endogenous dAbi in S2 cells using dsRNA. 
A. Immunoblot analysis of dAbi and dAbi-GFP expression in S2 cells treated with the 
indicated dsRNA (top of blot).  DsRNA and cell lysates derived from untransfected cells 
or cells expressing dAbi-GFP are indicated.  B. qRT-PCR analysis showing the 
normalised mRNA levels of dAbi in S2 cells when they are treated with dsRNA that 
targets either the ORF or the 3’UTR of dAbi.  The mRNA level of dAbi in LacZ dsRNA 
treated S2 cells was used as control.  dsRNA are indicated at the bottom of the bar 
chart.  Error bars represent the SEM and n = 3.  C. Immunofluorescent images of S2 
cells that were treated with dsRNA targeting LacZ, the ORF or the 3’UTR of dAbi 
plated on con-A and stained with phalloidin.  Loss of endogenous dAbi leads to a loss 
of lamellipodia and a spikey appearance.  dsRNA are indicated below the panels.   
Scale bar represents 10 µm.  
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Figure 6.9 Knockdown of endogenous dAbi in S2R+ cells using dsRNA. 
A. Immunoblot analysis of dAbi and dAbi-GFP expression in S2R+ cells treated with the 
indicated dsRNA (top of blot).  DsRNA and cell lysates derived from untransfected cells 
or cells expressing dAbi-GFP are indicated on the top of the panels.  B. qRT-PCR 
analysis showing the normalised mRNA levels of dAbi in S2R+ cells when they are 
treated with dsRNA that targets either the ORF or the 3’UTR of dAbi.  The mRNA level 
of dAbi in LacZ dsRNA treated S2R+ cells was used as control.  dsRNA are indicated at 
the bottom of the bar chart.  Error bars represent the SEM and n =3.  C. 
Immunofluorescent images of S2R+ cells that were treated with dsRNA targeting LacZ, 
the ORF or the 3’UTR of dAbi plated on con-A and stained with phalloidin.  Loss of 
endogenous dAbi leads to a loss of lamellipodia and spikey appearance.  dsRNA are 
indicated below the panels.   Scale bar represents10µm.  
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6.2.3 Uncoupling Ena from the WAVE complex does not affect 
lamellipodia formation 
My previous results show that dAbi (WAVE complex) is essential for lamellipodia 
formation.  I now wondered whether the interaction of dAbi with Ena plays a role in 
regulating lamellipodia formation.  To address this question, I treated S2 cells with four 
different knockdown/re-expression strategies.  I overexpressed GFP in S2 cells that 
had been pre-treated with either LacZ or 3’UTR dsRNA.  Alternatively I overexpressed 
GFP-tagged dAbi or dAbi mut in S2 cells that had been pre-treated with 3’UTR dsRNA.  
After two days, I then performed immunofluorescence analysis and GFP-positive cells 
in each group were scored based on their morphology.  As shown in Figure 6.10A, 
approximately 80% of the LacZ dsRNA-treated cells that express GFP exhibited 
normal lamellipodia, whereas only 25% of the 3’UTR dsRNA treated cells that express 
GFP had lamellipodia.  Lamellipodia formation is rescued by expression of dAbi-GFP in 
3’UTR dsRNA treated cells.  Expression of dAbi mut-GFP also rescues lamellipodia 
formation to almost the same extent as the wild type protein.  Similar results were 
obtained in the experiments using S2R+ cells (Figure 6.10B).  These experiments 
demonstrate that the dAbi mut-GFP is as efficient as the wild type in rescuing the 
defect in lamellipodia formation in both, S2 and S2R+ cells that lack endogenous dAbi.  
Taken together the results suggest that the interaction between Ena and dAbi is not 
required for lamellipodia formation.   
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Figure 6.10 dAbi-GFP and dAbi mut-GFP can rescue lamellipodia formation in S2 
and S2R+ cells lacking endogenous dAbi.  
A. Quantification of the ability of GFP-tagged dAbi or dAbi mut to rescue lamellipodia 
formation in S2 cells lacking endogenous dAbi.  The phenotypes of lamellipodial 
structures were quantified based on the image standards shown in the left panel.  
Treatments used are indicated at the bottom of the graphs.  B. The experiment 
described in A was repeated using S2R+ cells.  In both cases, error bars represent the 
SEM and n = 600. Scale bar represents 10µm. 
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6.2.4 The localisation of Ena at the plasma membrane is independent of 
dAbi 
It is known that the localisation of Ena/VASP proteins at the plasma membrane is 
mediated by the direct interactions between their EVH1 domains and the FPPPP-
containing MRL family proteins such as lamellipodin (Krause et al., 2004, Michael et 
al., 2010).  I wanted to ask if the WAVE complex cooperates with MRL proteins to drive 
the cellular localisation of Ena/VASP proteins to the plasma membrane.  To address 
this question, I perfomed rescue experiments in which 3’UTR-treated S2 cells were 
transfected with either dAbi-GFP or dAbi mut-GFP.  Using these cells, I performed 
immunofluorescence analysis with an antibody that recognises endogenous Ena.  Both 
overexpressed dAbi-GFP and dAbi mut-GFP were found to co-localise with 
endogenous Ena at the plasma membrane in S2 cells (Figure 6.11A).  Quantification of 
the fluorescence intensity of Ena in cells that either express dAbi-GFP or dAbi mut-
GFP revealed that there was no significant difference in the amount of Ena at the 
plasma membrane (Figure 6.11B) (Chapter 2.6.1).  This result suggests that 
localisation of Ena at the plasma membrane is not dependent on the WAVE complex.  
Unfortunately, I was unable to repeat this experiment in S2R+ cells, as the Ena 
antibody does not detect endogenous Ena in these cells (data not shown).  Together 
with my previous results in migrating Rat-2 cells (Figure 5.4), this suggests that 
recruitment of Ena/VASP proteins and the WAVE complex at the plasma membrane is 
not mediated by an Abi-EVH1 interaction.  
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Figure 6.11 Uncoupling of Ena from dAbi does not affect the localisation of Ena 
at the plasma membrane. 
A. Immunofluorescence images showing the localisation of endogenous Ena together 
with GFP-tagged dAbi or dAbi mut in S2 cells.  Ena antibody is indicated on the top of 
the panels and GFP-tagged proteins are indicated on the left of the panels.  Scale bar 
represents 10µm.  B. Quantification of the fluorescence intensity of Ena at the plasma 
membrane in S2 cells expressing either GFP-tagged dAbi or dAbi mut.  A student’s t-
test was performed.  ns indicates no significance.  Error bars represent the SEM.  n = 
30.   
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6.2.5 dAbi-EVH1 interaction regulates the dynamics of the WAVE 
complex at the plamsma membrane  
The results from previous FRAP analyses using the stable Rat-2 cell lines suggest that 
uncoupling Ena/VASP proteins from the WAVE complex increases the dynamics of the 
WAVE complex but not the former at the leading edge of migrating cells (Figure 5.9 
and 5.13). However, the stable Rat-2 cell lines that were used in these FRAP 
experiments had endogenous Abi, which could partially mask any phenotype of the 
overexpressed GFP-Abi mut.  Therefore I wanted to examine the effects of the dAbi-
EVH1 interaction on the dynamics of both Ena and the WAVE complex at the plasma 
membrane in S2 and S2R+ cells lacking endogenous dAbi.   
 
To test the effects of abrogating the interaction between dAbi and Ena on the dynamics 
of the WAVE complex at the plasma membrane, I performed FRAP analysis on 3’UTR 
dsRNA-treated S2 and S2R+ cells that express either dAbi-GFP or dAbi mut-GFP.  
After photobleaching, the dAbi mut-GFP recovered faster than the dAbi-GFP at the 
plasma membrane in both S2 and S2R+ cells lacking endogenous dAbi (Figure 6.12A 
and 6.13A).  Furthermore, statistical analysis revealed that the difference in the 
turnover rates of dAbi-GFP and dAbi mut-GFP is significant (Figure 6.12B and 6.13B).  
These results are consistent with my previous FRAP results in Rat-2 cells (Figure 5.9).  
Together, this suggests that the WAVE complex is more dynamic if it does not interact 
with Ena/VASP proteins.  Notably, the turnover rate of dAbi mut-GFP is almost 30% 
higher than that of dAbi-GFP in S2 cells lacking endogenous dAbi (Figure 6.12B).  In 
contrast, there was only approximately 20% difference in the turnover rates between 
GFP-Abi and GFP-Abi mut in Rat-2 cells containing the endogenous Abi (Figure 5.9B).  
These differences may be due to the presence or absence of endogenous dAbi.  My 
observations from the FRAP analyses using both, mammalian and insect cells suggest 
that Ena/VASP proteins play a role in helping to stabilise the WAVE complex at the 
plasma membrane.   
 
To test if uncoupling Ena from the WAVE complex also affects the dynamnics of Ena at 
the plasma membrane, I performed FRAP analysis using S2 cells co-overexpressing 
Ena-mCherry with either GFP-tagged dAbi or dAbi mut in the absence of the 
endogenous dAbi.  As shown in Figure 6.14A, the black curve that represents the 
recovery rate of Ena in the dAbi-GFP background overlapped with the red curve that 
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corresponds to the recovery rate in the dAbi mut-GFP expressing cells.  The statistical 
analysis showed that there was no difference in the turnover rate of Ena-mCherry 
when co-overexpressed with dAbi or its mutant (Figure 6.14B).  The results suggest 
that the dynamics of Ena at the plasma membrane is not dependent on the WAVE 
complex.  The overexpression of Ena-mCherry in S2R+ cells was problematic (data not 
shown).  The low expression level of Ena-mCherry led to difficulties in performing 
FRAP analysis.  Therefore, the interplay between Ena and the WAVE complex in 
regulating the dynamics of Ena at the plasma membrane could not be studied in S2R+ 
cells.   
 
The results from the FRAP analysis using stable Rat-2 cell lines suggest that the 
WAVE complex regulates the dynamics of VASP at the plasma membrane (Figure 
5.13), whereas the results from the FRAP analysis using S2 cells suggest that the 
dynamics of Ena at the plasma membrane is not affected by the WAVE complex 
(Figure 6.14).  It is not clear why different results were obtained from the two 
experiments.  I am sure that this is at least in part due to the problems of 
overexpressing Abi-RFP in Rat-2 cells.  The difficulties in overexpressing Abi-RFP in 
Rat-2 cells led to limited numbers of RFP positive cells that could be analysed using 
FRAP (n=20).  The results from the FRAP analysis using Rat-2 stable are therefore 
likely to be less reliable due to the limited sample size as well as the inconsistent 
expression and aggregation problem of Abi-RFP and Abi mut-RFP.  In contrast, the 
expression level of dAbi-GFP in transiently transfected S2 cells was always relatively 
high (data not shown).  More cells were also measured in the FRAP analysis of S2 
cells (n=45).  Furthermore, the phenotype of the overexpressed dAbi mut-GFP in S2 
cells was fully uncovered through knocking down endogenous dAbi.  Thus, I feel a firm 
conclusion can be better drawn from the FRAP analysis of S2 cells.   
 
Taken together, my data from FRAP analyses using different model systems suggests 
that the interaction between Ena/VASP proteins and the WAVE complex is essential 
for stabilising the WAVE complex at the plasma membrane, although the dynamics of 
Ena at the plasma membrane does not appear to be affected by the WAVE complex.  
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Figure 6.12 Ena stabilises the WAVE complex at the plasma membrane in S2 
cells.  
A. The graph illustrates the recovery rates of dAbi-GFP (black) and dAbi mut-GFP 
(red) at the plasma membrane in the absence of endogenous dAbi after 
photobleaching.  Intensity values of the GFP-tagged proteins were normalised to a pre-
bleach image.  Linear curves correspond to best fits of averaged data.  Error bars 
represent the SEM and n = 30.  B. The table lists values derived from the 30 fitted 
recovery curves together with the SEM for the percentage, rate constant and half time 
of recovery of dAbi-GFP and dAbi mut-GFP in S2 cells. *** indicates P<0.001. 
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Figure 6.13 Ena stabilises the WAVE complex at the plasma membrane in S2R+ 
cells.  
A. The graph illustrates the recovery rates of dAbi-GFP (black) and dAbi mut-GFP 
(red) at the plasma membrane in the absence of endogenous dAbi after 
photobleaching.  Intensity values of the GFP-tagged proteins were normalised to a pre-
bleach image.  Linear curves correspond to best fits of averaged data.  Error bars 
represent the SEM and n = 30.  B. The table lists values derived from the 30 fitted 
recovery curves together with the SEM for the percentage, rate constant and half time 
of recovery of dAbi-GFP and dAbi mut-GFP in S2R+ cells. *** indicates P<0.001. 
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Figure 6.14 The WAVE complex does not help stabilise Ena at the plasma 
membrane in S2 cells.  
A. The graph illustrates the fluorescence recovery rate after photobleaching of Ena-
mCherry at the plasma membrane of S2 cells co-overexpressing either dAbi-GFP 
(black) or dAbi mut-GFP (red) but lacking endogenous dAbi.  Intensity values of the 
mCherry-Ena were normalised to a pre-bleach image.  Linear curves corresponded to 
best fits of averaged data.  Error bars represent the SEM and n = 45.  B. The table lists 
the values derived from the 45 fitted recovery curves together with the SEM for the 
percentage, rate constant and half time of recovery of Ena-mCherry when it was co-
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6.3 Summary 
Drosophila S2 and S2R+ cells, which have a single dAbi and Ena isoform, were used 
as model systems to further investigate the significance of the Abi-EVH1 interaction in 
regulating actin dynamics.  As the proline rich regions of hAbi are not conserved with 
those in dAbi, I identified the Ena EVH1 binding site in dAbi and generated a dAbi 
mutant that is deficient in EVH1 binding using the biochemical approaches I 
established earlier.  Moreover, western blot analysis together with qRT-PCR analysis 
revealed that the expression of endogenous dAbi but not dAbi-GFP in S2 and S2R+ 
cells could be knocked down efficiently by dsRNA targeting the 3’UTR of dAbi.  Cells 
lacking endogenous dAbi exhibited several defects in lamellipodia formation, although 
overexpressing either dAbi-GFP or dAbi mut-GFP could rescue this defective 
phenotype.  Furthermore, immunofluorescence analysis revealed that the localisation 
of Ena at the plasma membrane was independent of the WAVE complex.  Consistent 
with the results from the FRAP analysis using Rat-2 cells, FRAP experiments using 
both, S2 and S2R+ cells demonstrated that Ena helps stabilise the WAVE complex at 
the plasma membrane.  However, in contrast to previous results Rat-2 cells, I found 
that in S2 cells, the WAVE complex does not regulate the dynamics of Ena at the 
plasma membrane.  
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Chapter 7. Discussion 
Work presented in my thesis was aimed at identifying new non-FPPPP containing 
binding partners of the EVH1 domain of Ena/VASP proteins.  Using a combination of 
biochemical approaches together with mass spectrometry, I initially identified the 
WAVE complex subunits Nap1 and PIR121, which both lack FPPPP motifs, as 
potential binding partners of the EVH1 domain of Ena/VASP proteins.  However, 
subsequent in vitro binding assays showed that neither Nap1, nor PIR121 could 
interact with the EVH1 domain.  Instead I found Abi, another component of the WAVE 
complex binds directly to the EVH1 domain of Ena/VASP proteins.  I was then able to 
identify the EVH1 binding site in both human and Drosophila Abi.  By expressing an 
Abi mutant deficient in EVH1 binding I was able to demonstrate that Ena/VASP 
proteins help stabilise the WAVE complex at the tip of lamellipodia in mammalian and 
Drosophila cells.  My work has shown that Ena/VASP proteins are directly coupled to 
the WAVE complex, suggesting that they may regulate actin dynamics at the plasma 
membrane in a more coordinated fashion than previously thought.  
 
7.1 The biochemistry of the Abi-EVH1 interaction 
7.1.1 Human Abi is a non-classical EVH1 binding partner  
The FPPPP motif in ActA from Listeria was the first binding site for the EVH1 domain of 
Ena/VASP proteins to be identified (Niebuhr et al., 1997).  Subsequent studies solved 
the structure of the EVH1 domains of Mena or Evl in complex with a short FPPPP-
containing peptide derived from ActA (Prehoda et al., 1999, Fedorov et al., 1999).  As 
shown in Figure 7.1 A and B, a triad of three highly conserved aromatic residues in the 
EVH1 domain provides a V-shaped binding surface for the poly-proline core of the 
FPPPP ligand.  The essential left-handed poly-proline type II helix required for FPPPP 
peptide binding will be disrupted if any proline is exchanged for another amino acid.  In 
addition to the poly-proline core, a hydrophobic residue (F/W/Y/L) flanking the proline 
core docks into a pocket outside of the aromatic triad of the EVH1 domain.  Data from 
far western approaches on peptide arrays suggests that the phenylalanine in the 
FPPPP motif can be replaced by leucine, tryptophan or tyrosine (Ball et al., 2000).  
However, most of the EVH1 binding partners of Ena/VASP proteins actually contain 
phenylalanine in their FPPPP motif (Figure 7.1 C).  Moreover, the binding capacity of 
the LPPPP motif in lamellipodin has not been tested in the context of the full length 
protein.  It is thought that the interaction between this hydrophobic residue and the 
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EVH1 domain determines the directionality of FPPPP binding (Fedorov et al., 1999).  
Based on the structure of the EVH1:FPPPP complex, it is clear that all five residues in 
the FPPPP motif are required for EVH1 binding.  However, human Abi, which lacks the 
classical FPPPP motif, is still able to interact directly with the EVH1 domain of 
Ena/VASP proteins (Figure 3.5).  This immediately raises questions about the 
molecular details of the interaction between human Abi and the EVH1 domain. 
 
The results from my pull-down and far western assays demonstrated that the EVH1 
domain interacts with the second proline rich region (PR2) of Abi.  PR2 can be further 
divided into two subregions consisting of prolines 366-368 and 383-385.  Both these 
proline regions were found to be important for EVH1 binding (Figure 4.8).  Although the 
EVH1 binding sites in Abi mostly consist of prolines, they lack a hydrophobic residue 
that is essential for the interaction of FPPPP ligands with the EVH1 domain (Figure 
7.1D).  Instead, another proline can be found.  Given the importance of the 
hydrophobic residue within the FPPPP motif in EVH1 binding (Fedorov et al., 1999, 
Prehoda et al., 1999, Peterson and Volkman, 2009), it is not immediately clear how the 
interaction between Abi and EVH1 is achieved.  However, examination of the structure 
of EVH1 domains bound to their FPPPP peptides reveals that the phenylalanine does 
not form any hydrophobic contacts with the EVH1 domain.  The binding cleft of 
phenylalanine residue could also easily accommodate a proline residue.  In the 
absence of additional structural information using longer FPPPP peptides, it is hard to 
tell exactly why the phenylalanine is essential.  However, one possible reason could be 
that the phenylalanine satisfies constraints imposed on this position by the residues 
upstream of the FPPPP motif that are lacking in all solved structures (Peterson and 
Volkman, 2009).  Presumably, these upstream residues can be wrapped around the 
EVH1 domain as observed for the WH1 binding motif in WIP (Volkman et al., 2002, 
Zettl and Way, 2002, Peterson et al., 2007).  Consistent with this suggestion, the EVH1 
binding motif in Abi involves three separate motifs (prolines 366-368, phenylalanine 
357 and prolines 383-385) in residues 352-394 of Abi (Figure 4.6).  It is possible that 
the Abi interaction also involves an extended surface that wraps around the EVH1 
domain in a similar fashion as observed in the interaction between WIP and the WH1 
domain of N-WASP.   
   
The idea that a proline can replace the hydrophobic residue of FPPPP motifs is further 
substantiated by the observation that several acidic residues follow both proline rich 
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subregions (Figure 7.1D).  It has been shown that a cluster of negatively charged 
residues immediately downstream of the poly-proline core increases the binding affinity 
of FPPPP containing peptides for the EVH1 domain (Prehoda et al., 1999, Ball et al., 
2000, Peterson and Volkman, 2009).  Moreover, in binding assays, Abi was shown to 
compete with FPPPP containing peptides for binding to the EVH1 domain (Figure 3.5A, 
B).  
 
My data show that human Abi contains two separate EVH1 binding motifs that appear 
to be equal (Figure 4.8).  However, the structure of EVH1:FPPPP complexes suggests 
that only one FPPPP-motif can be packed into the binding pocket of the EVH1 domain 
(Fedorov et al., 1999, Prehoda et al., 1999).  At least two models of binding between 
human Abi and the EVH1 domain are plausible.  It is possible that both proline rich 
subregions are equivalent to the FPPPP-motif and compete with each other to interact 
with the EVH1 domain in a “classical” fashion.  However, it may be that only one 
proline rich subregion of Abi is equivalent to the classic FPPPP-motif and the other 
subregion binds to the EVH1 domain at a different site as observed for the WH1 
binding protein WIP (Peterson and Volkman, 2009).  Additionally, it cannot be excluded 
that Abi may associate with more than one EVH1 domain using both of its proline rich 
subregions to form an EVH1:Abi:EVH1 trimer.   
 
To determine which binding model is correct and whether a proline residue can replace 
the phenylalanine residue in the FPPPP-motif, future work should focus on determining 
the structure of the EVH1 domain and the binding regions of human Abi.  Since 
sufficient amounts of recombinant EVH1 domain and the binding regions of human Abi 
can be produced in bacteria or as peptides, it is hoped that crystallisation trials can be 
started in the near future.  Moreover, future experiments using biochemical assays 
such as gel filtration chromatography will shed light on the stoichiometric ratio between 
Abi and EVH1 when they are in a complex.  
 
In addition to Abi1, mammals contain two additional Abi isoforms: Abi2 and Abi3 
(Chapter 1).  Similar to the overall sequence identity between the three isoforms, the 
second proline rich region of Abi1 and 2 are more similar to each other, whereas the 
second proline rich region of Abi3 shares less similarity with the second proline rich 
regions of the other two Abi isoforms (Figure 7.1 E). The residues that are essential for 
EVH1 binding in Abi1 (proline 366-368, 383-385 and phenylalanine 357) can be found 
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in Abi2.  Similar to Abi1, in Abi2, acidic residues that are also important for EVH1 
binding follow both of the two proline rich subregions.  In Abi3, the prolines that 
correspond to the prolines in Abi1 that are essential for EVH1 binding can be found, 
however the phenylalanine is missing.  Also, in contrast to the second proline rich 
region of Abi1 and Abi2, Abi3 contains two LPPPP motifs.  This suggests that Abi3 
may bind to the EVH1 domain of Ena/VASP proteins in a classical way.  Overall, 
although Abi2 and Abi3 differ from Abi1, it is possible that they both bind to the EVH1 
domain of Ena/VASP proteins.  From the sequence alignment alone, no obvious 
binding specificity can be deduced. 
 
7.1.2 Drosophila Abi is a classical EVH1 binding partner 
In contrast to human Abi, which lacks the classical FPPPP-motif, dAbi contains two 
distinct LPPPP-motifs in its C-terminal half (Figure 6.1).  All published data on EVH1 
binding has only identified a single functional LPPPP interaction motif in lamellipodin 
(Krause et al., 2004) (Figure 7.1C).  The assumption that leucine replaces 
phenylalanine is largely based on far western analysis of peptide arrays, which may not 
fully reflect the native situation in the full length protein (Ball et al., 2000).  Sequence 
alignments reveal that the second LPPPP motif of dAbi is highly conserved and 
equivalent to the first proline rich subregion of human Abi (Figure 7.1F).  This 
conservation suggests that these residues in human and Drosophila are likely to be 
functionally equivalent.  Indeed, my pull down assays revealed that the second LPPPP 
motif in dAbi appears to be more important in mediating EVH1 binding than the first 
LPPPP motif, which is not conserved in human (Figure 6.4).  
 
As for the human Abi:EVH1 complex, the molecular basis for the interaction as well as 
the stoichiometric ratio between the two proteins needs to be resolved.  The EVH1 
domain of Ena can be produced in bacteria, however, the production of full-length 
recombinant dAbi proved to be unsuccessful (data not shown).  Future work to address 
these outstanding questions could attempt to produce dAbi deletion mutants that 
contain the EVH1 binding site in bacteria or as peptides instead of producing full-length 
Abi.   
 
7.1.3 The interaction of Abi-EVH1 in vivo 
In immunoprecipitation assays using HEK 293T cells I showed that endogenous Mena 
could be retained by GFP-Abi but not by GFP-Abi mut from cell lysates (Figure 4.9).  
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These results suggest that the overexpressed GFP-Abi interacts with Mena in vivo and 
that the mutation disrupted the interaction between GFP-Abi and the EVH1 domain of 
Mena in HEK 293T cells.  To confirm that GFP-Abi binds the EVH1 domain of 
Ena/VASP proteins in the model systems that I used to study the physiological 
importance of the interaction between Ena/VASP proteins and the WAVE complex, the 
same immunoprecipitation assay was repeated using Rat-2 and Drosophila S2/S2R+ 
cells.  However, the antibodies against Mena or Ena could not detect the respective 
endogenous protein in these two cell lines (data not shown).  To overcome this 
problem, the immunoprecipitation assay could be carried out using over-expressed 
tagged Abi and Ena/VASP proteins in Rat-2 and Drosophila S2/S2R+ cells.  Moreover, 
the interaction between Abi and Ena/VASP proteins in Rat-2 and Drosophila S2/S2R+ 
cells could be examined by fluorescence resonance energy transfer (FRET).  CFP-
Abi/dAbi and YFP-Mena/Ena could be co-overexpressed in Rat-2 and Drosophila 
S2/S2R+ cells.  If both proteins interacted in vivo at the leading edge, the excitation of 
the CFP fluorophore should lead to the emission of light from the YFP fluorophore.  
 
In addition, to test if endogenous components of the WAVE complex interact with 
Ena/VASP proteins in vivo, co-immunoprecipitation assays could be performed in the 
future using antibodies that recognise endogenous Abi (or other components of the 
WAVE complex).  The precipitated protein could be subsequently detected using 
western blot analysis with antibodies that recognise endogenous Ena/VASP proteins.  
Alternatively, the co-immunoprecipitation assays could be performed using antibodies 
that recognise endogenous Ena/VASP proteins to pull down endogenous components 
of the WAVE complex. 
 
It has been shown that both, Abi and Mena are substrates of the tyrosine kinase Abl 
(Tani et al., 2003, Huang et al., 2007).  Abl can phosphorylate Mena on Tyr296 (Tani et 
al., 2003).  In contrast, multiple tyrosine residues in Abi can be phosphorylated by Abl 
(Huang et al., 2007).  Although the tyrosine phosphorylation sites in Mena and Abi are 
not at the Abi-EVH1 binding surface, it is possible that the phosphorylation state of Abi 
and Mena is affecting their binding to each other.  Therefore, phospho-deficient 
mutants of both, Abi and Mena could be generated, or Abl could be co-overexpressed. 
Under these conditions, biochemical assays could be performed to investigate whether 
Abl-mediated phosphorylation influences the interaction between Abi and Mena.  
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Figure 7.1 Human Abi may interact with the EVH1 domain of Ena/VASP proteins 
in a classical way. 
A. Ribbon diagram illustrating the EVH1 domain of Mena (green) and the FPPPP 
peptide of Listeria ActA (purple).  The triad of conserved aromatic residues in EVH1 
that provide the pocket for binding the poly-proline core of the FPPPP-motif binding are 
shown in dark green.  B. Schematic representation of the interaction that is shown in A.  
C. Alignment of FPPPP motifs of known EVH1 binding partners of Ena/VASP proteins.  
D. Alignment of two FPPPP containing motifs with the two proline rich subregions of 
human Abi.  E. Alignment of the second proline rich region of all three human Abi 
isoforms.  F. Alignment of the first proline rich subregion in human Abi with the second 
LPPPP motif in Drosophila Abi.  In D, E and F, residues that were found to be key for 
EVH1 binding in human and Drosophila Abi are indicated in red.  Acidic residues C-
terminal to the polyproline core are underlined.  A and B was taken from (Prehoda et 
al., 1999) with the permission of Elsevier.  
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7.2 Biology of the Abi-EVH1 interaction 
7.2.1 Ena/VASP proteins stabilise the WAVE complex at the plasma 
membrane 
Depletion of Ena/VASP proteins from the plasma membrane by overexpressing 
FPPPP-Mito in Rat-2 cells did not affect the localisation of Abi at the plasma 
membrane (Figure 5.4).  Moreover, uncoupling of dAbi from Ena in S2 cells lacking 
endogenous dAbi had no effect on the localisation of Ena at the plasma membrane 
(Figure 6.11).  Taken together, these results suggest that the localisation of Ena/VASP 
and the WAVE complex are independent of each other.  Consistent with this, 
Ena/VASP proteins are recruited to the plasma membrane by binding to MRL family 
proteins (Lafuente et al., 2004, Krause et al., 2004, Michael et al., 2010, Quinn et al., 
2006), whereas the WAVE complex is recruited to the plasma membrane through the 
action of Rac, membrane lipids and membrane-associated proteins such as IRSp53 
(Takahashi and Suzuki, 2010, Suetsugu et al., 2006, Mattila et al., 2007, Oikawa et al., 
2004, Miki et al., 1998, Steffen et al., 2004, Koronakis et al., 2011).  
 
Although Ena/VASP proteins and Abi do not require each other for their localisation, 
my FRAP analysis in both Rat-2 and S2 cells, reveals that the Abi-EVH1 interaction 
appears to regulate the dynamics of Abi at the plasma membrane (Figures 5.9, 6.12 
and 6.13).  In contrast, my FRAP analysis in S2 cells showed no significant effects on 
the turnover of Ena at the plasma membrane when the interaction between dAbi and 
Ena was disrupted (Figure 6.14).  These data suggest that the dynamics of Ena/VASP 
proteins at the plasma membrane is likely to be largely dependent on MRL family 
proteins.  
 
Interestingly, the differences between the turnover rate of Abi and Abi mut in stable 
Rat-2 cell lines in the presence of endogenous Abi is smaller than the difference that 
was observed in S2 cells lacking endogenous dAbi (Figure 5.9 and 6.12).  This may be 
explained by the ability of Abi to oligomerise (Fan et al., 2003, Echarri et al., 2004).  I 
envisage that endogenous Abi that associates with Abi mut will effectively mask the 
binding deficiency in Abi mut.  This idea also does not rule out that there is a direct 
competition between endogenous Abi and Abi mut to incorporate into the WAVE 
complex.  In both cases, the difference between the turnover rate of Abi and Abi mut in 
Rat-2 cells would be expected to be reduced, which is what my data shows.    
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In addition, I also found that the turnover rate of Abi is slower than that of VASP at the 
plasma membrane in both stable Rat-2 cell lines and S2 cells (Figure 5.9, 5.13, 6.12 
and 6.14).  These differences suggest that in the cell lines I used, Abi and Ena/VASP 
are not turning over as one complex.  However, a previous study suggested that Abi 
and VASP might form a complex at the plasma membrane as they had similar turnover 
rates (Lai et al., 2008).  The discrepancies between my results and Lai et al. (2008) 
may be explained by the fact that in mouse melanoma (B16-F1) cells Abi and VASP 
are turned over as a complex, or that by chance they show a similar turnover rate in 
that cell line.  
 
Using immunofluorescence analysis and immunoprecipitation, I have shown that the 
GFP-tagged human and Drosophila versions of Abi and Abi mut I generated are 
incorporated into the rest of the WAVE complex (Figure 5.6 and 6.5 and 6.6).  
Therefore, it is plausible that the dynamics of Abi could be coupled to the dynamics of 
the WAVE complex and that Ena/VASP proteins not only regulate the dynamics of Abi, 
but the whole WAVE complex.  However, it has been shown that the turnover rate of 
Abi at the plasma membrane is different from the turnover rate of other components of 
the WAVE complex (Lai et al., 2008) and furthermore, Abi is found to interact with other 
proteins that localise at the plasma membrane, such as N-WASP (Liebau et al., 2011, 
Innocenti et al., 2005).  Therefore, Abi may be turned over independent of the WAVE 
complex.  The direct effects of overexpressing Abi mut in cells on the dynamics of 
other WAVE complex components at the plasma membrane has not yet been 
examined.  Therefore, future analysis of the dynamics of other WAVE complex 
components in cells expressing either Abi or Abi mut will confirm the effect of 
Ena/VASP proteins on the dynamics of the WAVE complex at the plasma membrane.  
 
It is unclear whether the increased dynamics of the WAVE complex will affect the rate 
of actin polymerisation at the plasma membrane.  Ina Weisswange, a former PhD 
student in the laboratory showed that the stability of the N-WASP, another class I NPFs 
affects the length of actin tails and the speed of actin based motility of vaccina virus 
(Weisswange et al., 2009).  Based on this, it is not unreasonable to think that the 
stability of the WAVE complex may also affect actin polymerisation at the plasma 
membrane.  How the dynamics of the WAVE complex influences the rate and extent of 
Arp2/3 complex dependent actin polymerisation is an important area for future work, 
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since it clearly has a strong bearing on the fundamental mechanisms underlying the 
regulation of cell migration.  The interaction between Abi and EVH1 that I have 
described could provide an important fine turning mechanism to control actin 
dependent motility. 
 
7.2.2 Is the Abi-EVH1 interaction involved in actin-based protrusions?  
Depletion of WAVE and other components of the WAVE complex leads to severe 
defects in lamellipodia formation (Suetsugu et al., 2003, Yamazaki et al., 2005, 
Yamazaki et al., 2003, D'Ambrosio and Vale, 2010).  In contrast, the removal of 
Ena/VASP proteins from the plasma membrane only affects the rate of lamellipodial 
protrusion and not their formation (Bear et al., 2000, Bear et al., 2002, Tucker et al., 
2011).  Nevertheless, the regulation of lamellipodia formation by the WAVE complex 
may still involve the binding of Abi to Ena/VASP proteins.  However, this interaction is 
not essential as the dAbi mut I generated can fully restore defects in lamellipodia 
formation in S2 cells lacking endogenous dAbi (Figure 6.10).  My results indicate that 
the direct interaction between Ena/VASP proteins and the WAVE complex is not 
required for lamellipodia formation.  Overexpression of WAVE, however, is known to 
negatively affect spontaneous lamellipodial protrusions (Hahne et al., 2001).  Since 
Ena/VASP proteins regulate the rate of lamellipodial protrusions, it is possible that their 
direct interaction with the WAVE complex contributes to the regulation of lamellipodial 
protrusions.  Future work will focus on determining if the rate of lamellipodial protrusion 
is dependent on the interaction between dAbi and EVH1 in Drosophila haemocytes, as 
these cells exhibit extensive membrane protrusions in tissue culture (Tucker et al., 
2011) (Dr Sven Bogdan personal communication).    
 
In addition to the role of Ena/VASP proteins in regulating lamellipodial protrusions, 
Ena/VASP proteins contribute to the formation of filopodia (Mattila and Lappalainen, 
2008).  It has been shown that filopodia can arise in existing lamellipodia at the leading 
edge of migrating cells (Svitkina et al., 2003).  However, the molecular mechanism 
underlying the lamellipodia to filopodia transition is still not clear.  Since Ena/VASP 
proteins and the WAVE complex primarily regulate filopodia and lamellipodia formation 
respectively, it is possible that the interaction between Ena/VASP proteins and the 
WAVE complex is also involved in the lamellipodia to filopodia transition.  
Unfortunately, S2 and S2R+ cells do not produce filopodia.  Thus, a cell line needs to 
be identified that ideally contains a single Abi isoform, which is amenable for 
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knockdown using RNAi and has filopodial protrusions at the leading edge.  A recent 
study using embryonic Drosophila primary neurons showed that the Arp2/3 complex 
cooperates with Ena to regulate filopodia formation (Goncalves-Pimentel et al., 2011).  
This co-operation may be via the WAVE complex.  Future work could use embryonic 
Drosophila primary neurons as the model to study the dAbi-EVH1 interaction.   
 
Ena/VASP proteins have emerged as important regulators of cancer cell metastasis 
and tumour invasion (Wang et al., 2004, Wang et al., 2007, Philippar et al., 2008, Han 
et al., 2008, Roussos et al., 2011, Gertler and Condeelis, 2011).  Actin rich 
invadopodia are able to degrade ECM to promote cancer cell invasion (Buccione et al., 
2009).  Recent findings have suggested that Ena/VASP proteins and the WAVE 
complex are both required for invadopodia formation during tumour cell invasion 
(Philippar et al., 2008, Kikuchi and Takahashi, 2008).  The direct interaction between 
Ena/VASP proteins and the WAVE complex may also be also involved in invadopodia 
stability during tumour cell invasion.   Using the reagents I have developed, it would be 
possible to examine whether the Abi-EVH1 interaction promotes invadopodia formation 
and tumour cell invasion.  Depending on the results from these experiments, further 
studies could be extended into mouse models of tumour invasion and metastasis. 
 
7.2.3 Is the Abi-EVH1 interaction involved in actin-based cell motility?  
Loss- and gain-of-function experiments have shown that Ena/VASP proteins regulate 
the speed of cell migration, although whether they enhance or decrease migration 
speed remains controversial (Chapter 1).  Moreover, the WAVE complex provides the 
driving force for cell migration by activating Arp2/3 complex dependent actin 
polymerisation at the leading edge (Chapter 1).  Considering that both Ena/VASP 
proteins and the WAVE complex are key regulators of actin-based cell motility, it is 
possible that their interaction will also regulate the speed of cell migration.  This idea is 
based on the fact that Ena/VASP proteins stabilise Abi at the leading edge.  However, 
single cell-tracking assays showed no difference in velocity, directionality and 
persistency during random cell migration between Rat-2 cells expressing Abi and Abi 
mut (Figure 5.7A).  As discussed earlier, however, the endogenous Abi isoforms could 
not be knocked down by RNAi and thus may mask the phenotype of Abi mut in Rat-2 
cells in these single cell-tracking assays (Figure 5.14).  Changing to Drosophila 
haemocytes to study cell migration in vitro is also not possible, as they do not migrate 
in culture (Tucker et al., 2011). 
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To study the significance of the direct interaction between Ena/VASP proteins and the 
WAVE complex in regulating cell migration we therefore started a collaboration with Dr 
Sven Bogdan at the University of Münster, Germany.  The group of Dr Sven Bogdan 
studies photoreceptor guidance in Drosophila larvae as a model system to examine the 
role WASP and WAVE family proteins in neuronal migration (Gohl et al., 2010) (Figure 
7.2). They found that abi null mutants have over shooting axon projections in the 
photoreceptor (unpublished data).  Currently they are examining the role of the Abi-
EVH1 interaction in neuronal migration by performing rescue experiments in abi null 
mutants using my dAbi mutant that is deficient in EVH1 binding.   
 
My dAbi binding mutant can also be used to test the significance of the Abi-EVH1 
interaction in cell migration in other Drosophila models.  For example cell migration can 
be studied in Drosophila embryos (Evans and Wood, 2011).  Embryonic haemocytes 
that do not migrate in vitro are actually highly motile in vivo (Tucker et al., 2011).  A 
recent study demonstrated that Ena increases the rate of haemocyte migration in 
Drosophila embryos (Tucker et al., 2011).  In addition, Ena has also been found to 
promote border cell migration in Drosophila egg chambers during oogenesis (Gates et 
al., 2009). These systems can easily be used to test if the interaction between Ena and 
dAbi plays a role in regulating cell migration in vivo.   
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Figure 7.2 Schematic representation of photoreceptor connectivity in Drosophila 
larvae. 
A compound eye of Drosophila consists of about 750 ommatidia, each of which 
possesses eight photoreceptor neurons (R-cells) that are uniquely identifiable.  During 
development, these R-cells extend axons to target different areas of the fly brain.  This 
neuronal targeting process provides a model system for studying cell migration as it 
occurs in very specific and organised fashion.  Taken from (Tayler and Garrity, 2003) 
with the permission of Elsevier. 
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7.2.4 Can VASP activate the ability of the WAVE complex to stimulate 
Arp2/3 complex dependent actin nucleation? 
FRAP analyses revealed that Ena/VASP proteins stabilise the WAVE complex at the 
plasma membrane.  The next question was whether Ena/VASP proteins are able to 
directly activate the WAVE complex to induce Arp2/3 dependent actin polymerisation.  
To address this question, we have collaborated with the group of Dr Michael Rosen 
(University of Texas Southwestern Medical Center, Dallas, USA).  Dr Baoyu Chen, a 
post-doctoral scientist in the Rosen laboratory performed WAVE complex dependent in 
vitro actin polymerisation assays in the presence or absence of VASP and/or its EVH1 
domain that I produced and purified from bacteria.    
 
These experiments are ongoing, although preliminary data reveal that in contrast to the 
EVH1 domain alone, full length VASP dramatically enhances the ability of the WAVE 
complex to stimulate the actin nucleating activity of the Arp2/3 complex (Figure 7.3A).  
This stimulation requires a direct interaction with the WAVE complex, as it does not 
occur in the absence of the proline rich region of Abi.  Since Ena/VASP proteins can 
undergo tetramerisation via a coiled coil region at their C terminus (Bachmann et al., 
1999, Zimmermann et al., 2002), it may be that clustering of four VASP proteins is 
required for the activation of the WAVE complex as the EVH1 domain has no effect 
(Figure 7.3A).  Further mutational analysis using VASP that is unable to undergo 
tetramerisation will reveal whether tetramerisation is required for activating the WAVE 
complex.  VASP on its own is also able to trigger actin polymerisation at a 
concentration of 50 nM.  These observations agree with studies indicating that 
Ena/VASP proteins are capable of promoting the elongation of actin filaments 
(Breitsprecher et al., 2011, Breitsprecher et al., 2008).  
 
The small GTPase Rac is the best-studied activator of the WAVE complex in vitro 
(Chen et al., 2010, Ismail et al., 2009, Lebensohn and Kirschner, 2009).  In vitro actin 
polymerisation assays using Rac that is persistently bound to a non-hydrolysable GTP 
analogue revealed that Rac and VASP can activate the WAVE complex independently 
(Figure 7.3B).  Moreover, VASP and Rac have an additive effect on actin 
polymerisation.  These in vitro data strongly suggest that the Abi-EVH1 interaction I 
have described will have an impact on the rate of cell migration.  
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The fact that VASP activates the WAVE complex by a direct interaction raises 
important mechanistic questions about how this action occurs.  Since the release of the 
C-terminal meander-VCA region of WAVE from PIR121 leads to the activation of the 
Arp2/3 complex (Chen et al., 2010, Ismail et al., 2009), it is possible that binding of Abi 
to EVH1 influences the binding interface between PIR121 and the C-terminus of 
WAVE.  However, any conformational change induced in the WAVE complex must be 
different from the change that is induced by Rac, as the effects of VASP and Rac on 
activating the WAVE complex are additive.  It has been shown that the dimerisation of 
VCA domains dramatically increases their affinity for Arp2/3 complex and the maximal 
Arp2/3 complex activation is thought to involve more than one VCA domain (Padrick et 
al., 2008, Padrick et al., 2011, Ti et al., 2011).  It is therefore possible that the 
activation of WAVE complex is a consequence of clustering of WAVE complexes, as 
the VASP tetramer but not the monomeric EVH1 domain activates Arp2/3 dependent 
actin polymerisation.  Unfortunately, the PR2 region of Abi is not present in the 
structure of the WAVE complex (Chen et al., 2010).  Therefore, future experiments are 
required to uncover the underlying mechanism of the VASP mediated WAVE complex 
activation.  
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Figure 7.3 VASP activates the WAVE complex and enhances the effect of Rac on 
activating the WAVE complex in vitro.  
A. In vitro pyrene actin polymerisation assay showing the affect of both, the EVH1 
domain alone and full length VASP on activating the WAVE complex. B. In vitro pyrene 
actin polymerisation assays showing the effects of VASP and Rac on the ability of the 
WAVE complex to stimulate Arp2/3 dependent actin polymerisation.  In all cases, the 
fluorescence indicates the amount of newly formed F-actin and was plotted against the 
time in seconds.  A steeper curve represents a higher rate of actin polymerisation. 
Different combinations of proteins in each are indicated with different colours.  
Concentrations of proteins are indicated next to their respective curves.  WRC 
represents the WAVE regulatory complex.  ∆Abi represents a mutant Abi lacking the C-
terminal region that contains the EVH1 binding site.  
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7.3 Working model for the role of the Abi-EVH1 interaction in 
cell migration 
I have shown that Ena/VASP proteins can stabilise the WAVE complex at the plasma 
membrane in vivo and potentially activate the WAVE complex in vitro.  Figure 7.4 
shows a new model for the cooperation between Ena/VASP proteins and the WAVE 
complex in regulating actin-based membrane protrusions.  The recruitment of 
Ena/VASP proteins and the WAVE complex are regulated by their respective signalling 
pathways.  Once at the membrane, the EVH1 domain of Ena/VASP proteins binds 
directly to the WAVE complex via the PR2 region of Abi.  This interaction helps 
stabilise the WAVE complex at the plasma membrane and enhances its ability to 
activate Arp2/3 dependent actin polymerisation.  The interaction with Ena/VASP 
proteins also enhances the effect of Rac on activating the WAVE complex.  Overall, 
this interaction helps regulate the coordination of actin polymerisation at the plasma 
membrane (Figure 7.4).   
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Figure 7.4 Hypothetical scheme of the consequences of the Abi-EVH1 
interaction.  
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